Original Article
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
N Engl J Med 2007; 356:115-124January 11, 2007
- Abstract
Background
Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted.
Methods
We enrolled 750 patients with previously untreated, metastatic renal-cell carcinoma in a multicenter, randomized, phase 3 trial to receive either repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) or interferon alfa (at a dose of 9 MU given subcutaneously three times weekly). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, patient-reported outcomes, and safety.
Results
The median progression-free survival was significantly longer in the sunitinib group (11 months) than in the interferon alfa group (5 months), corresponding to a hazard ratio of 0.42 (95% confidence interval, 0.32 to 0.54; P<0.001). Sunitinib was also associated with a higher objective response rate than was interferon alfa (31% vs. 6%, P<0.001). The proportion of patients with grade 3 or 4 treatment-related fatigue was significantly higher in the group treated with interferon alfa, whereas diarrhea was more frequent in the sunitinib group (P<0.05). Patients in the sunitinib group reported a significantly better quality of life than did patients in the interferon alfa group (P<0.001).
Conclusions
Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa (ClinicalTrials.gov numbers, NCT00098657 and NCT00083889).
Media in This Article
Figure 1
Patient Enrollment and Outcomes.Figure 2
Kaplan–Meier Estimates of Progression-free Survival (Independent Central Review).Article Activity
- Article
Renal-cell carcinoma is the most common cancer of the kidney.1 Up to 30% of patients with renal-cell carcinoma present with metastatic disease,2,3 and recurrence develops in approximately 40% of patients treated for a localized tumor.2,4 Since renal-cell carcinoma is highly resistant to chemotherapy, interleukin-2 or interferon alfa is widely used as first-line treatment of metastatic disease. Response rates with these cytokines are low (5 to 20%), and median overall survival is approximately 12 months.5-9
Alternative treatments have been lacking for renal-cell carcinoma that is resistant to cytokines. In two recent uncontrolled trials, sunitinib malate, an antiangiogenic agent, showed clinical activity in patients who had undergone previous cytokine therapy.10,11 In a pooled analysis of these phase 2 studies of sunitinib, the objective response rate was 42%.11 This rate exceeds the rates reported for cytokines as first-line treatment of metastatic disease.5,7,9
Sunitinib is an orally administered inhibitor of tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).12-14 These receptor tyrosine kinases play a key role in the pathogenesis of clear-cell carcinoma, the predominant type of renal-cell carcinoma, through involvement of the von Hippel–Lindau (VHL) gene. VHL is inactivated in up to 80% of sporadic cases of clear-cell carcinoma by deletion, mutation, or methylation. This tumor-suppressor gene encodes a protein that is involved in the regulation of the production of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and a number of other hypoxia-inducible proteins. Inactivation of the VHL gene causes overexpression of these agonists of VEGFR and PDGFR, and the resulting persistent stimulation of the receptors may promote tumor angiogenesis, tumor growth, and metastasis.15-18 Yang et al.19 demonstrated that bevacizumab, an anti-VEGF antibody, has efficacy in renal-cell carcinoma. All these considerations make the receptors for VEGF and PDGF rational targets in the treatment of clear-cell renal-cell carcinoma.
We report on the results of a randomized, phase 3 trial of sunitinib, as compared with interferon alfa, as first-line treatment of metastatic renal-cell carcinoma. We selected interferon alfa as a comparator because it is widely used as standard treatment for metastatic renal-cell carcinoma. The response rates, median progression-free survival, and overall survival with first-line interferon alfa treatment have been characterized from the extensive use of this drug as a comparator in previous phase 3 trials.20
Methods
Patients
The study population consisted of patients who were at least 18 years of age and had metastatic renal-cell carcinoma with a clear-cell histologic component, confirmed by the participating centers. Patients who had not received previous treatment with systemic therapy for renal-cell carcinoma were enrolled in the study. Other key eligibility criteria included the presence of measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate hematologic, coagulation, hepatic, renal, and cardiac function. Patients were ineligible if they had brain metastases, uncontrolled hypertension, or clinically significant cardiovascular events or disease during the preceding 12 months. All patients gave written informed consent.
Study Design
The study was an international, multicenter, randomized, phase 3 trial of sunitinib (Sutent [also called SU11248], Pfizer), as compared with interferon alfa. Randomization was stratified according to baseline levels of lactate dehydrogenase (>1.5 vs. ≤1.5 times the upper limit of the normal range), ECOG performance status (0 vs. 1), and previous nephrectomy (yes vs. no). Patients were randomly assigned in a 1:1 ratio to receive either sunitinib or interferon alfa. Random permuted blocks of four were used to attain balance within strata.
Sunitinib was administered orally at a dose of 50 mg once daily, taken without regard to meals, in 6-week cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment. Sunitinib was provided by Pfizer, the sponsor of the trial. Commercially available interferon alfa-2a (Roferon-A, Roche) was used in this study and was provided by Pfizer. Interferon alfa was given as a subcutaneous injection three times per week on nonconsecutive days at 3 MU per dose during the first week, 6 MU per dose the second week, and 9 MU per dose thereafter. A reduction in the dose of sunitinib (to 37.5 mg and then to 25 mg daily) or of interferon alfa (to 6 MU and then to 3 MU three times per week) was allowed for the management of adverse events, depending on the type and severity of adverse events, according to a nomogram specified in the protocol. Treatment in both groups was continued until the occurrence of disease progression, unacceptable adverse events, or withdrawal of consent.
The study was approved by the institutional review board or ethics committee at each participating center and was conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines.
Efficacy, Safety, and Quality of Life
The primary end point of the study was progression-free survival, defined as the time from randomization to the first documentation of objective disease progression or to death from any cause, whichever occurred first. Secondary end points included the objective response rate, overall survival, patient-reported outcomes, and safety.
We assessed the tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST).21 We performed tumor assessments with the use of imaging studies at baseline, at day 28 of cycles 1 through 4, and every two cycles thereafter until the end of treatment. We also used such assessments to confirm a response (at least 4 weeks after initial documentation) and whenever disease progression was suspected. The response was assessed by RadPharm, an independent third-party radiology group (independent central review), and by treating physicians (investigators' assessments). The third-party radiologists were unaware of assignments to study groups. Safety was assessed at regular intervals by documentation of adverse events, physical examination, radiography, and multigated acquisition scanning. Laboratory assessments (hematologic and serum chemical measurements) were performed throughout the study by a central laboratory. Adverse events were graded with the use of the Common Terminology Criteria for Adverse Events of the National Cancer Institute, version 3.0.
Health-related quality of life was assessed with the use of the Functional Assessment of Cancer Therapy — General (FACT-G) and FACT–Kidney Symptom Index (FKSI) questionnaires,22,23 which were administered before randomization, on days 1 and 28 of each cycle, and at the end of treatment.
Statistical Analysis
Retrospective studies have shown that the median progression-free survival was 4.7 months for nearly 500 patients with advanced renal-cell carcinoma who received interferon alfa as first-line therapy.20 For our study, we determined that 471 events (disease progression or death from any cause) would be required for 90% power to detect a clinically relevant increase in progression-free survival from 4.7 to 6.2 months in patients treated with sunitinib, with the use of a two-sided, unstratified log-rank test with an overall significance level of 0.05. With a 1:1 randomization of assignment to study groups, we estimated that we would need to enroll 690 patients to observe 471 events.
The primary end point was analyzed in all patients assigned to a study group, according to the intention-to-treat principle. A blinded central review of radiologic images was used to assess the primary end point and the objective response rate. Safety analyses were performed on the basis of the treatment actually received. Time-to-event analyses were performed with the use of the Kaplan–Meier method. We explored the potential influences of the baseline characteristics of the patients — such as age, sex, and known risk factors20,24 — on progression-free survival with the use of a stratified log-rank test25 and a Cox regression model.26 The proportion of patients who had an objective tumor response in each treatment group was compared by the Pearson chi-square method. For the analyses of health-related quality-of life data, we used repeated-measures mixed-effects models to test overall differences between the two treatment groups.27,28 All reported P values are two-sided and were not adjusted for multiple testing.
The cutoff date for data for the planned interim analysis was November 15, 2005. We planned for three scheduled analyses; this report provides the results of the second analysis. The nominal significance level for the interim analysis was determined with the use of the Lan–DeMets procedure with an O'Brien–Fleming stopping rule.29 After the interim analysis had been performed and discussed with the data and safety monitoring committee, patients in the interferon alfa group with progressive disease were allowed to cross over to the sunitinib group.
The academic authors and the sponsor were jointly responsible for the trial design and the development of the protocol. Data were collected by means of case-report forms and were analyzed by the sponsor. The decision to publish the trial data and final decisions with regard to the content of the manuscript were made by the academic principal investigator in consultation with the other authors. All authors had access to the primary data and take responsibility for the veracity and completeness of the data reported.
Results
Patients
Between August 2004 and October 2005, 750 patients were enrolled at 101 centers in Australia, Brazil, Canada, Europe, and the United States, with 375 patients in each treatment group (Figure 1Figure 1
Patient Enrollment and Outcomes.). All 375 patients in the sunitinib group received at least one dose of the study drug. Fifteen patients (4%) in the interferon alfa group withdrew consent before starting treatment; the remaining 360 patients received at least one dose of interferon alfa. The treatment groups were balanced with respect to baseline demographic and disease characteristics (Table 1Table 1
Baseline Demographic and Clinical Characteristics.).Treatment Duration
At the time of analysis, the median duration of treatment was 6 months (range, 1 to 15) in the sunitinib group and 4 months (range, 1 to 13) in the interferon alfa group. Treatment was ongoing among 248 patients in the sunitinib group (66%) and 126 patients in the interferon alfa group (34%). Reasons for discontinuing treatment were progressive disease (in 25% of the patients in the sunitinib group and 45% in the interferon alfa group, P<0.001), adverse events (8% and 13%, respectively; P=0.05), withdrawal of consent (1% and 8%, respectively; P<0.001), and protocol violation (<1% in each group).
Adverse Events
Most general adverse events of all grades occurred more frequently in the sunitinib group than in the interferon alfa group (Table 2Table 2
Adverse Events and Selected Laboratory Abnormalities.). The proportion of patients with grade 3 or 4 adverse events was relatively low in both groups. Treatment-related grade 3 or 4 fatigue was significantly higher among patients in the interferon alfa group than in the sunitinib group (12% vs. 7%, P<0.05). Patients in the sunitinib group, as compared with those in the interferon alfa group, had higher rates of grade 3 diarrhea (5% vs. no cases), vomiting (4% vs. 1%), hypertension (8% vs. 1%), and the hand–foot syndrome (5% vs. no cases, P<0.05 for all comparisons).The incidence of a grade 3 decline in the left ventricular ejection fraction was similar in the sunitinib group and the interferon alfa group (2% and 1%, respectively). In the sunitinib group, this decline was not associated with clinical sequelae and was reversible after a modification of the dose or discontinuation of treatment. No grade 4 events were reported in this category.
As expected, adverse events that are typically associated with interferon alfa — such as pyrexia, chills, myalgia, and influenza-like symptoms — were all reported more frequently in the interferon alfa group than in the sunitinib group, but the symptoms were generally mild to moderate in severity.
Grade 3 or 4 leukopenia, neutropenia, and thrombocytopenia occurred more often in the sunitinib group than in the interferon alfa group (P<0.05 for all comparisons). Grade 3 or 4 neutropenia was observed in 12% of patients in the sunitinib group and in 7% of those in the interferon alfa group; the condition was associated with fever in two patients receiving sunitinib. Grade 3 lymphopenia occurred with greater frequency in patients treated with interferon alfa (P<0.05).
A total of 38% of patients in the sunitinib group and 32% in the interferon alfa group had a dose interruption because of adverse events, whereas 32% and 21%, respectively, had a dose reduction.
Efficacy
Objective Response Rate
Sunitinib treatment was associated with a higher objective response rate than was interferon alfa, as assessed by blinded central review of imaging studies: 31% in the sunitinib group (95% confidence interval [CI], 26 to 36) and 6% in the interferon alfa group (95% CI, 4 to 9; P<0.001) (Table 3Table 3
Best Tumor Response.). The results of investigator assessment were similar (37% and 9%, respectively; P<0.001).Progression-free and Overall Survival
Median progression-free survival (as assessed by central review of imaging studies) was 11 months in the sunitinib group (95% CI, 10 to 12) and 5 months in the interferon-alfa group (95% CI, 4 to 6), corresponding to a hazard ratio of 0.42 (95% CI, 0.32 to 0.54; P<0.001) (Figure 2Figure 2
Kaplan–Meier Estimates of Progression-free Survival (Independent Central Review).). The results were similar in the analyses using the investigators' assessments: 11 months (95% CI, 8 to 14) and 4 months (95% CI, 4 to 5), respectively, with a hazard ratio of 0.42 (95% CI, 0.33 to 0.52; P<0.001).At the time of the analysis, median overall survival had not been reached in either group; 13% of patients in the sunitinib group and 17% in the interferon alfa group had died. Although there was a trend toward improved survival with sunitinib (hazard ratio for death, 0.65; 95% CI, 0.45 to 0.94; P=0.02), the comparison did not meet the prespecified level of significance for this interim analysis. A final survival analysis will be reported when the data become mature.
Outcome According to Risk Factors
We analyzed the influence of baseline clinical features and previously identified prognostic factors20 on the treatment effect with the use of a Cox proportional-hazards model, controlling for each factor at a time. The benefit of sunitinib over interferon alfa was observed across all subgroups of patients (Figure 3Figure 3
Progression-free Survival in Subgroups, According to Baseline Factors (Independent Central Review).).Patients were grouped according to prognostic risk category on the basis of Memorial Sloan-Kettering Cancer Center (MSKCC) criteria.20 The three prognostic risk categories (favorable, intermediate, and poor) were assigned on the basis of the baseline clinical features (Table 1). In all three prognostic risk groups, the median progression-free survival was longer for patients treated with sunitinib than for those treated with interferon alfa. In patients with favorable risk features, the median progression-free survival had not been reached at the time of the analysis for 143 patients in the sunitinib group, as compared with a median survival of 8 months for 121 patients in the interferon alfa group (hazard ratio for disease progression, 0.37; 95% CI, 0.21 to 0.64). In the intermediate-risk group, respective median values for 209 patients in the sunitinib group and 212 patients in the interferon alfa group were 11 months and 4 months, with a hazard ratio in the sunitinib group of 0.39 (95% CI, 0.28 to 0.54). In the poor-risk group, the respective median values for 23 patients in the sunitinib group and 25 patients in the interferon alfa group were 4 months and 1 month, with a hazard ratio of 0.53 (95% CI, 0.23 to 1.23). These results highlight the efficacy of sunitinib, as compared with interferon alfa, regardless of the patients' baseline features or prognostic factors.
Quality of Life
Health-related quality of life was significantly better in the sunitinib group than in the interferon alfa group (P<0.001), as reported by patients in post-baseline assessments with the use of both FACT-G and FKSI questionnaires (see Table 1 of the Supplementary Appendix, available with the full text of this article at www.nejm.org). The higher scores (indicating better quality of life) in the sunitinib group for kidney cancer–related symptoms and overall quality of life were clinically meaningful, on the basis of established guidelines.22,23,30
Discussion
This randomized, phase 3 trial shows that previously untreated patients with metastatic renal-cell carcinoma who received sunitinib had longer progression-free survival than did patients who received interferon alfa. Median progression-free survival in the sunitinib group (11 months) was 6 months longer than that in the interferon alfa group (5 months). This improvement was greater than the expected improvement that we used for calculating the number of patients needed for the trial, thereby meeting the trial's primary end point in the interim analysis.
This trial also demonstrates a higher objective response rate and better patient-reported outcomes in the sunitinib group than in the interferon alfa group. Response rates in the range of 30 to 40% have been observed in three trials of sunitinib as first-line and second-line therapy.10,11 These rates are substantially higher than the rates reported for other cytokines or chemotherapeutic agents.31 The consistently higher scores for patient-reported outcomes in the sunitinib group indicated an improved sense of well-being, which is influenced by factors related to the adverse-event profile and efficacy of sunitinib. Hypertension, the hand–foot syndrome, vomiting, and diarrhea were observed with sunitinib treatment, as reported previously.10,11 The proportion of grade 3 or 4 adverse events with sunitinib ranged from 1 to 13% for all categories (Table 2). Most sunitinib-related adverse events were ameliorated by interruption or modification of the dose; treatment was discontinued in less than 10% of patients because of adverse events.
The group of patients in our trial consisted of a relatively unselected population of patients with metastatic clear-cell renal-cell carcinoma. The median age and sex distributions were typical for this type of cancer, and patients with coexisting conditions (e.g., hypertension and diabetes) were allowed to enter the study as long as such conditions were controlled medically. Moreover, when we examined the outcome according to known prognostic factors and risk groups, the benefit of sunitinib extended across all clinical prognostic subgroups studied, although the number of patients in the poor-risk group was small.
Cytokine treatment has been standard therapy for metastatic renal-cell carcinoma for the past 20 years. Interferon alfa monotherapy has been associated with an improvement in survival among patients with advanced renal-cell carcinoma, as compared with a variety of controls.32-34 However, previous trials have not shown the superiority of one cytokine treatment (interferon alfa or interleukin-2) over another.8,35 Interferon alfa was chosen as the comparator for this trial on the basis of these data and the widespread use of this agent, which is the least toxic of the available cytokine treatments. In 1992, the Food and Drug Administration approved the use of high-dose interleukin-2 for the treatment of renal-cell carcinoma on the basis of phase 2 data, which showed prolonged complete remission in approximately 7% of treated patients.9,36 The use of high-dose interleukin-2 has been limited because of significant cardiorespiratory adverse events.32,37 The question of the relative merits of high-dose interleukin-2 and sunitinib for patients who are eligible for high-dose interleukin-2 treatment has not been settled, since the two agents have been shown to be beneficial according to different end points. Additional data on the durability of the response to sunitinib and the long-term outcome may further clarify the survival benefit associated with each treatment.
Renal-cell carcinoma of the clear-cell type overexpresses many cellular receptors related to angiogenesis and the maintenance of the tumor microvascular environment. Sunitinib is one of several agents (including sorafenib and bevacizumab) that target the activity of angiogenic growth factors and show favorable results in clinical trials involving patients with metastatic clear-cell renal-cell carcinoma. The data from these trials9,38 indicate that inhibition of angiogenesis is a promising strategy for the treatment of clear-cell renal-cell carcinoma. Further studies are warranted to assess the relationships among the response to sunitinib, genetic abnormalities, and the expression of angiogenic growth factors in metastatic renal-cell carcinoma.
Supported by Pfizer.
Dr. Motzer reports receiving research grants from Pfizer and Genentech, consulting fees from Wyeth, and lecture fees from Bayer Pharmaceuticals; Dr. Hutson, consulting and lecture fees from Pfizer, Bayer Pharmaceuticals, and Onyx Pharmaceuticals; Dr. Michaelson, consulting fees from Pfizer and Wyeth Pharmaceuticals and lecture fees from Pfizer; Dr. Bukowski, research grants from Pfizer, Bayer Pharmaceuticals, Genentech, Genzyme, and Bristol-Myers Squibb and consulting and lecture fees from Pfizer, Bayer Pharmaceuticals, Onyx Pharmaceuticals, and Genentech; Dr. Rixe, consulting and lecture fees from Pfizer; Dr. Oudard, consulting and lecture fees from Pfizer; Dr. Negrier, consulting fees from Pfizer and Bayer Pharmaceuticals; and Dr. Figlin, research grants from Pfizer, consulting fees from Pfizer and Onyx Pharmaceuticals, and lecture fees from Pfizer and Bayer Pharmaceuticals. Ms. Kim and Drs. Chen, Bycott, and Baum report being full-time employees of Pfizer and having equity ownership in the company. No other potential conflict of interest relevant to this article was reported.
We thank all the patients and their families for their participation in the study, and Acumed of Tytherington, United Kingdom, for editorial assistance.
Source Information
From the Memorial Sloan-Kettering Cancer Center, New York (R.J.M.); Baylor Sammons Cancer Center–Texas Oncology, Dallas (T.E.H.); Klinika Onkologii Oddzial Chemioterapii, Poznan, Poland (P.T.); Massachusetts General Hospital Cancer Center, Boston (M.D.M.); Cleveland Clinic Foundation, Cleveland (R.M.B.); Hôpital Pitié–Salpêtrière (O.R.) and Hôpital Européen Georges Pompidou (S.O.) — both in Paris; Centre Léon Bérard, Lyon, France (S.N.); Military Institute of Medicine, Warsaw, Poland (C.S.); Pfizer Global Research and Development, La Jolla, CA (S.T.K., I.C., P.W.B., C.M.B.); and City of Hope Comprehensive Cancer Center, Los Angeles (R.A.F.).
Address reprint requests to Dr. Motzer at the Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, or at motzerr@mskcc.org.
A list of additional investigators who participated in the study appears in the Appendix.
Appendix
In addition to the authors, the following investigators participated in the study: Australia — A. Boyce, I. Davis, P. Mainwaring, N. Pavlakis, K. Pittman, G. Toner, S. Troon; Brazil — C. Barrios, D. Herchenhorn, M. Zereu; Canada — G. Bjarnason, S. Ernst, C. Kollmannsberger, A. Lavoie, H. Martins, D. Ruether, F. Saad, J. Sutherland, I. Tannock, P. Venner; France — L. Geoffrois, B. Laguerre, F. Rolland; Germany — W. Eberhardt, V. Gruenwald, G. Jakse, M. Ringhoffer; Italy — G. Carteni, P. Conte, G. Gasparini, C. Porta, E. Ruggeri, C. Sternberg; Poland — T. Demkow, J. Lorenz, M. Mazurkiewicz, A. Pluzanska, J. Rolski, E. Solska; Russia — O. Gladkov, A. Kaprin, P. Karlov, O. Karyakin, M. Lichinitser, V. Moiseyenko, I. Rusakov, E. Slonimskaya; Spain — D. Castellano, X. Garcia del Muro, J.L. Gonzalez-Larriba, J.A. Moreno-Nogueira, J.L. Perez-Gracia; United Kingdom — J. Barber, T. Eisen, P. Harper, R. Hawkins, P. Nathan; United States — R. Amato, J.C. Barrett, R. Belt, P. Benedetto, J. Clark, M. Cooney, T. Cosgriff, C. Croot, H. Drabkin, A. Dudek, J. Dutcher, M. Ernstoff, M. Fishman, G. Hudes, R. Hauke, K. Karamlou, P. Kaywin, A. Keller, T. Kuzel, J. Lacy, F. Millard, D. Minor, M. Monte, R. Pili, L. Puneky, D. Richards, C. Ryan, W. Samlowski, L. Schwartzberg, J. Sosman, J. Thompson, U. Vaishampayan, J. Vuky, G. Wilding. Data and Safety Monitoring Committee: A. Tolcher, Cancer Therapy and Research Institute, San Antonio, TX; S. Bates, National Cancer Institute, Bethesda, MD; and S.L. George, Duke University Medical Center, Durham, NC.
- References
References
1
Parkin DM ,Bray F ,Ferlay J ,Pisani P . Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
CrossRef | Web of Science | Medline2
Lam JS ,Leppert JT ,Belldegrun AS ,Figlin RA . Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23:202-212
CrossRef | Web of Science | Medline3
Motzer RJ ,Bander NH ,Nanus DM . Renal-cell carcinoma. N Engl J Med 1996;335:865-875
Full Text | Web of Science | Medline4
Janzen NK ,Kim HL ,Figlin RA ,Belldegrun AS . Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843-852
CrossRef | Web of Science | Medline5
Fisher RI ,Rosenberg SA ,Fyfe G . Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6:Suppl 1:S55-S57
Web of Science | Medline6
McDermott DF ,Regan MM ,Clark JI , et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-141[Erratum, J Clin Oncol 2005;23:2877.]
CrossRef | Web of Science | Medline7
Motzer RJ ,Murphy BA ,Bacik J , et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2972-2980
Web of Science | Medline8
Negrier S ,Escudier B ,Lasset C , et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-1278
Full Text | Web of Science | Medline9
Yang JC ,Sherry RM ,Steinberg SM , et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-3132
CrossRef | Web of Science | Medline10
Motzer RJ ,Michaelson MD ,Redman BG , et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24
CrossRef | Web of Science | Medline11
Motzer RJ ,Rini BI ,Bukowski RM , et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524
CrossRef | Web of Science | Medline12
Abrams TJ ,Lee LB ,Murray LJ ,Pryer NK ,Cherrington JM . SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-478
Web of Science | Medline13
Mendel DB ,Laird AD ,Xin X , et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337
Web of Science | Medline14
O'Farrell AM ,Abrams TJ ,Yuen HA , et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605
CrossRef | Web of Science | Medline15
Gnarra JR ,Tory K ,Weng Y , et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90
CrossRef | Web of Science | Medline16
Iliopoulos O ,Levy AP ,Jiang C ,Kaelin WG Jr ,Goldberg MA . Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996;93:10595-10599
CrossRef | Web of Science | Medline17
Maxwell PH ,Wiesener MS ,Chang GW , et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275
CrossRef | Web of Science | Medline18
Na X ,Wu G ,Ryan CK ,Schoen SR ,di'Santagnese PA ,Messing EM . Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003;170:588-592
CrossRef | Web of Science | Medline19
Yang JC ,Haworth L ,Sherry RM , et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434
Full Text | Web of Science | Medline20
Motzer RJ ,Bacik J ,Murphy BA ,Russo P ,Mazumdar M . Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296
CrossRef | Web of Science | Medline21
Therasse P ,Arbuck SG ,Eisenhauer EA , et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216
CrossRef | Web of Science | Medline22
Cella DF ,Tulsky DS ,Gray G , et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579
Web of Science | Medline23
Cella D ,Yount S ,Du H , et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 2006;4:191-199
Medline24
Mekhail TM ,Abou-Jawde RM ,Boumerhi G , et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-841
CrossRef | Web of Science | Medline25
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline26
Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall, 1990.
27
Linear mixed effects models. In: Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Hoboken, NJ: Wiley-Interscience, 2004:187-236.
28
Doing data analysis with the multilevel model for change. In: Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press, 2003:75-137.
29
Lan KKG ,DeMets DL . Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663
CrossRef | Web of Science30
Brucker PS ,Yost K ,Cashy J ,Webster K ,Cella D . General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 2005;28:192-211[Erratum, Eval Health Prof 2005;28:370.]
CrossRef | Web of Science | Medline31
Motzer RJ ,Russo P . Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-417
CrossRef | Web of Science | Medline32
Coppin C ,Porzsolt F ,Awa A ,Kumpf J ,Coldman A ,Wilt T . Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;1:CD001425-CD001425
Medline33
Medical Research Council Renal Cancer Collaborators
CrossRef | Web of Science | Medline34
Pyrhonen S ,Salminen E ,Ruutu M , et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-2867
Web of Science | Medline35
Negrier S ,Perol D ,Ravaud A , et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc Am Soc Clin Oncol 2005;23:380s-380s
Web of Science36
Fyfe GA ,Fisher RI ,Rosenberg SA ,Sznol M ,Parkinson DR ,Louie AC . Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996;14:2410-2411
Web of Science | Medline37
Kammula US ,Whitte DE ,Rosenberg SA . Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998;83:797-805
CrossRef | Web of Science | Medline38
Escudier B ,Szczylik C ,Eisen T , et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005;24:380s-380s
- Citing Articles (1210)
Citing Articles
1
Timothy A. Yap, Paul Workman. (2012) Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology 52:1, 549-573
CrossRef2
Eduard Vrdoljak, Tudor Ciuleanu, Galina Kharkevich, Jozef Mardiak, Michal Mego, Peeter Padrik, Luboš Petruželka, Gunta Purkalne, Yaroslav Shparyk, Breda Škrbinc, Cezary Szczylik, Laszlo Torday. (2012) Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region. Expert Opinion on Pharmacotherapy 13:2, 159-174
CrossRef3
Javier González. (2012) Update on Surgical Management of Renal Cell Carcinoma with Venous Extension. Current Urology Reports 13:1, 8-15
CrossRef4
Ingrid M.E. Desar, Annemarie M.J. Thijs, Sasja F. Mulder, Cees J.J. Tack, Carla M.L. van Herpen, Winette T.A. van der Graaf. (2012) Weight loss induced by tyrosine kinase inhibitors of the vascular endothelial growth factor pathway. Anti-Cancer Drugs 23:2, 149-154
CrossRef5
Paul L. Crispen, Michael L. Blute. (2012) Role of Cytoreductive Nephrectomy in the Era of Targeted Therapy for Renal Cell Carcinoma. Current Urology Reports 13:1, 38-46
CrossRef6
Yi-Lo Lin, May-Jywan Tsai, Ming-Jei Lo, Shao-En Chang, Yang-Hsin Shih, Meng-Jen Lee, Huai-Sheng Kuo, Wen-Chun Kuo, Wen-Cheng Huang, Henrich Cheng, Ming-Chao Huang. (2012) Evaluation of the Antiangiogenic Effect of Kringle 1-5 in a Rat Glioma Model. Neurosurgery 70:2, 479-490
CrossRef7
Wani Arjumand, Sarwat Sultana. (2012) Role of VHL gene mutation in human renal cell carcinoma. Tumor Biology 33:1, 9-16
CrossRef8
Brian Patson, Roger B Cohen, Anthony J. Olszanski. (2012) Pharmacokinetic evaluation of axitinib. Expert Opinion on Drug Metabolism & Toxicology 8:2, 259-270
CrossRef9
Laleh Amiri-Kordestani, Antoinette R Tan, Sandra M Swain. (2012) Pazopanib for the treatment of breast cancer. Expert Opinion on Investigational Drugs 21:2, 217-225
CrossRef10
Guru Sonpavde, Toni K. Choueiri, Bernard Escudier, Vincenzo Ficarra, Thomas E. Hutson, Peter F. Mulders, Jean-Jacques Patard, Brian I. Rini, Michael Staehler, Cora N. Sternberg, Christian G. Stief. (2012) Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. European Urology 61:2, 307-316
CrossRef11
Ana M. Molina, Darren R. Feldman, Michelle S. Ginsberg, Glenn Kroog, Satish K. Tickoo, Xiaoyu Jia, Murielle Georges, Sujata Patil, Michael S. Baum, Victor E. Reuter, Robert J. Motzer. (2012) Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Investigational New Drugs 30:1, 335-340
CrossRef12
Richard M. Steingart, George L. Bakris, Helen X. Chen, Ming-Hui Chen, Thomas Force, S. Percy Ivy, Carl V. Leier, Glenn Liu, Daniel Lenihan, JoAnn Lindenfeld, Michael L. Maitland, Scot C. Remick, W.H. Wilson Tang. (2012) Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. American Heart Journal 163:2, 156-163
CrossRef13
Krastan B. Blagoev, Julia Wilkerson, Tito Fojo. (2012) Hazard ratios in cancer clinical trials—a primer. Nature Reviews Clinical Oncology
CrossRef14
Laura Horsley, Kalena Marti, GC Jayson. (2012) Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opinion on Drug Metabolism & Toxicology1-11
CrossRef15
Dirk Strumberg. (2012) Sorafenib for the treatment of renal cancer. Expert Opinion on Pharmacotherapy407-419
CrossRef16
T. Eisen, C. N. Sternberg, C. Robert, P. Mulders, L. Pyle, S. Zbinden, H. Izzedine, B. Escudier. (2012) Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies. JNCI Journal of the National Cancer Institute 104:2, 93-113
CrossRef17
G W A Lamb, M Aitchison, S Ramsey, S L Housley, D C McMillan. (2012) Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. British Journal of Cancer 106:2, 279-283
CrossRef18
G Groenewegen, M Walraven, J Vermaat, B de Gast, E Witteveen, R Giles, J Haanen, E Voest. (2012) Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. British Journal of Cancer 106:2, 284-289
CrossRef19
D Cella, A G Bushmakin, J C Cappelleri, C Charbonneau, M D Michaelson, R J Motzer. (2012) Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. British Journal of Cancer
CrossRef20
Jae-Lyun Lee, Inkeun Park, Kwonoh Park, Seongjoon Park, Yongcheol Ahn, Jin-Hee Ahn, Tae-Won Kim, Shin Ahn, Cheryn Song, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn. (2012) Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. Journal of Cancer Research and Clinical Oncology
CrossRef21
Lui Shiong Lee, Min-Han Tan. (2012) Predictive models for the practical management of renal cell carcinoma. Nature Reviews Urology
CrossRef22
J.- L. Lee, J.- H. Ahn, H. Y. Lim, S. H. Park, S. H. Lee, T. M. Kim, D.- H. Lee, Y. M. Cho, C. Song, J. H. Hong, C.- S. Kim, H. Ahn. (2012) Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Annals of Oncology
CrossRef23
Andrea Mancuso, Eugenio Donato Di Paola, Alvaro Leone, Alfonso Catalano, Fabio Calabrò, Linda Cerbone, Andrea Zivi, Carlo Messina, Silvia Alonso, Leonardo Vigna, Rita Caristo, Cora N. Sternberg. (2012) Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. BJU International 109:2, 200-206
CrossRef24
Elena Verzoni, Rodolfo Lanocita, Giuseppe Procopio. (2012) Complete Response After Sequential Sunitinib-Sorafenib Treatment In a Patient With Renal Cell Carcinoma: A Case Report. Clinical Genitourinary Cancer
CrossRef25
Andrew Gaya, Vivien Tse. (2012) A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treatment Reviews
CrossRef26
Caecilia S. Reiner, Robert Goetti, Daniel Eberli, Ernst Klotz, Andreas Boss, Thomas Pfammatter, Thomas Frauenfelder, Holger Moch, Tullio Sulser, Hatem Alkadhi. (2012) CT Perfusion of Renal Cell Carcinoma. Investigative Radiology 47:1, 33-40
CrossRef27
N. Starling, F. Vazquez-Mazon, D. Cunningham, I. Chau, J. Tabernero, F. J. Ramos, T. J. Iveson, M. P. Saunders, E. Aranda, A. M. Countouriotis, A. Ruiz-Garcia, G. Wei, J. M. Tursi, C. Guillen-Ponce, A. Carrato. (2012) A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Annals of Oncology 23:1, 119-127
CrossRef28
Rui-Tao Zhang, Steven D Bines, Carl Ruby, Howard L Kaufman. (2012) TroVax ® vaccine therapy for renal cell carcinoma. Immunotherapy 4:1, 27-42
CrossRef29
A. J. Zurita, E. Jonasch, X. Wang, M. Khajavi, S. Yan, D. Z. Du, L. Xu, M. H. Herynk, K. S. McKee, H. T. Tran, C. J. Logothetis, N. M. Tannir, J. V. Heymach. (2012) A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Annals of Oncology 23:1, 46-52
CrossRef30
Fengjuan Fan, Alexander Schimming, Dirk Jaeger, Klaus Podar. (2012) Targeting the Tumor Microenvironment: Focus on Angiogenesis. Journal of Oncology 2012, 1-16
CrossRef31
Wolfgang Lamm, Ursula Maria Vogl, Marija Bojic, Christoph Zielinski, Christoph Klingler, Gero Kramer, Manuela Schmidinger. (2012) Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma. Acta Oncologica 51:1, 101-106
CrossRef32
Abhimanyu Ghose, Zeeshan Tariq, Salvatore Veltri. (2012) Treatment of Multidrug Resistant Advanced Alveolar Soft Part Sarcoma With Sunitinib. American Journal of Therapeutics 19:1, e56-e58
CrossRef33
Vicky Goh, Quan Sing Ng, Ken Miles. (2012) Computed Tomography Perfusion Imaging for Therapeutic Assessment. Investigative Radiology 47:1, 2-4
CrossRef34
Daniel Keizman, Maya Ish-Shalom, Peng Huang, Mario A. Eisenberger, Roberto Pili, Hans Hammers, Michael A. Carducci. (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. European Journal of Cancer 48:2, 202-208
CrossRef35
Vesselina G. Cooke, Valerie S. LeBleu, Doruk Keskin, Zainab Khan, Joyce T. O'Connell, Yingqi Teng, Michael B. Duncan, Liang Xie, Genta Maeda, Sylvia Vong, Hikaru Sugimoto, Rafael M. Rocha, Aline Damascena, Ricardo R. Brentani, Raghu Kalluri. (2012) Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway. Cancer Cell 21:1, 66-81
CrossRef36
Seng Chuan Tang, Jurjen S. Lagas, Nienke A.G. Lankheet, Birk Poller, Michel J. Hillebrand, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel. (2012) Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. International Journal of Cancer 130:1, 223-233
CrossRef37
Conrad M. Tobert, Robert G. Uzzo, Christopher G. Wood, Brian R. Lane. (2012) Adjuvant and neoadjuvant therapy for renal cell carcinoma: A survey of the Society of Urologic Oncology. Urologic Oncology: Seminars and Original Investigations
CrossRef38
Peter Mulders, Robert Hawkins, Paul Nathan, Igle de Jong, Susanne Osanto, Emilio Porfiri, Andrew Protheroe, Carla M.L. van Herpen, Bijoyesh Mookerjee, Laura Pike, Juliane M. Jürgensmeier, Martin E. Gore. (2012) Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study. European Journal of Cancer
CrossRef39
Young-Kwang Yoon, Seock-Ah Im, Hwang-Phill Kim, Hyung-Seok Hur, Kyung-Hun Lee, Sae-Won Han, Sang-Hyun Song, Do Youn Oh, Tae-You Kim, Woo Ho Kim, Yung-Jue Bang. (2012) Sunitinib Synergizes the Antitumor Effect of Cisplatin via Modulation of ERCC1 Expression in Models of Gastric Cancer. Cancer Letters
CrossRef40
Joost S. Vermaat, Frank L. Gerritse, Astrid A. van der Veldt, Wijnand M. Roessingh, Tatjana M. Niers, Sjoukje F. Oosting, Stefan Sleijfer, Jeanine M. Roodhart, Jos H. Beijnen, Jan H. Schellens, Jourik A. Gietema, Epie Boven, Dick J. Richel, John B. Haanen, Emile E. Voest. (2012) Validation of Serum Amyloid α as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients. European Urology
CrossRef41
Stéphane Oudard, Reza-Thierry Elaidi. (2012) Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit. Cancer Treatment Reviews
CrossRef42
Camillo Porta, Emiliano Calvo, Miguel A. Climent, Ulka Vaishampayan, Susanne Osanto, Alain Ravaud, Sergio Bracarda, Thomas E. Hutson, Bernard Escudier, Viktor Grunwald, Dennis Kim, Ashok Panneerselvam, Oezlem Anak, Robert J. Motzer. (2012) Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. European Urology
CrossRef43
Yoram Fleissig, Eran Regev, Hadas Lehman. (2012) Sunitinib related osteonecrosis of jaw: a case report. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology
CrossRef44
Rosalie Fisher, James Larkin, Charles Swanton. (2011) Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. The EPMA Journal
CrossRef45
Y. Cao, J. Arbiser, R. J. D'Amato, P. A. D'Amore, D. E. Ingber, R. Kerbel, M. Klagsbrun, S. Lim, M. A. Moses, B. Zetter, H. Dvorak, R. Langer. (2011) Forty-Year Journey of Angiogenesis Translational Research. Science Translational Medicine 3:114, 114rv3-114rv3
CrossRef46
Steven G. DuBois, Suzanne Shusterman, Joel M. Reid, Ashish M. Ingle, Charlotte H. Ahern, Sylvain Baruchel, Julia Glade-Bender, Percy Ivy, Peter C. Adamson, Susan M. Blaney. (2011) Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study. Cancer Chemotherapy and Pharmacology
CrossRef47
T. Fojo, L. Amiri-Kordestani, S. E. Bates. (2011) Potential Pitfalls of Crossover and Thoughts on Iniparib in Triple-Negative Breast Cancer. JNCI Journal of the National Cancer Institute 103:23, 1738-1740
CrossRef48
F Di Fiore, O Rigal, C Ménager, P Michel, C Pfister. (2011) Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. British Journal of Cancer 105:12, 1811-1813
CrossRef49
Manish R. Sharma, Richard L. Schilsky. (2011) Role of randomized phase III trials in an era of effective targeted therapies. Nature Reviews Clinical Oncology
CrossRef50
Gillian Murphy, Kartik Jhaveri. (2011) The expanding role of imaging in the management of renal cell carcinoma. Expert Review of Anticancer Therapy 11:12, 1871-1888
CrossRef51
Emiliano Calvo Aller, Pablo Maroto, Noémi Kreif, José Luis González Larriba, Marta López-Brea, Daniel Castellano, Belén Martí, Silvia Díaz Cerezo. (2011) Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Clinical and Translational Oncology 13:12, 869-877
CrossRef52
J. Bellmunt, J. L. Gonzalez-Larriba, C. Prior, P. Maroto, J. Carles, D. Castellano, B. Mellado, E. Gallardo, J. L. Perez-Gracia, G. Aguilar, X. Villanueva, J. Albanell, A. Calvo. (2011) Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Annals of Oncology 22:12, 2646-2653
CrossRef53
Gaetan des Guetz, Bernard Uzzan, Kader Chouahnia, Jean-François Morère. (2011) Cardiovascular toxicity of anti-angiogenic drugs. Targeted Oncology 6:4, 197-202
CrossRef54
Nicholas A. Barber, Wais Afzal, Mojtaba Akhtari. (2011) Hematologic toxicities of small molecule tyrosine kinase inhibitors. Targeted Oncology 6:4, 203-215
CrossRef55
Joachim Beck, Joaquim Bellmunt, Bernard Escudier. (2011) Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. Medical Oncology 28:4, 1379-1383
CrossRef56
Yung-Jue Bang, Yoon-Koo Kang, Won K. Kang, Narikazu Boku, Hyun C. Chung, Jen-Shi Chen, Toshihiko Doi, Yan Sun, Lin Shen, Shukui Qin, Wai-Tong Ng, Jennifer M. Tursi, Maria J. Lechuga, Dongrui Ray Lu, Ana Ruiz-Garcia, Alberto Sobrero. (2011) Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs 29:6, 1449-1458
CrossRef57
L. M. Riesenbeck, S. Bierer, I. Hoffmeister, T. Köpke, P. Papavassilis, L. Hertle, B. Thielen, E. Herrmann. (2011) Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World Journal of Urology 29:6, 807-813
CrossRef58
E. Jonasch, I. E. McCutcheon, S. G. Waguespack, S. Wen, D. W. Davis, L. A. Smith, N. M. Tannir, D. S. Gombos, G. N. Fuller, S. F. Matin. (2011) Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Annals of Oncology 22:12, 2661-2666
CrossRef59
Rajesh Gupta, Michael L. Maitland. (2011) Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated Cardiotoxicity. Current Hypertension Reports 13:6, 430-435
CrossRef60
Ana M. Molina, Michelle S. Ginsberg, Robert J. Motzer. (2011) Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. Medical Oncology 28:4, 1527-1529
CrossRef61
Min-Han Tan, Huihua Li, Caroline Victoria Choong, Kee Seng Chia, Chee Keong Toh, Tiffany Tang, Puay Hoon Tan, Chin Fong Wong, Weber Lau, Christopher Cheng. (2011) The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. Cancer 117:23, 5314-5324
CrossRef62
Stephane Ederhy, Hassan Izzedine, Christophe Massard, Ghislaine Dufaitre, Jean Philippe Spano, Gerard Milano, Catherine Meuleman, Benjamin Besse, Franck Boccara, David Kahyat, Ariel Cohen, Jean Charles Soria. (2011) Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. Critical Reviews in Oncology/Hematology 80:3, 369-379
CrossRef63
B. Castagneto, I. Stevani, L. Giorcelli, F. Montefiore, G. L. Bigatti, P. Pisacco, M. F. Cosimi. (2011) Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. Medical Oncology 28:4, 1384-1388
CrossRef64
I. Yildiz, F. Sen, M. Basaran, M. Ekenel, F. Agaoglu, E. Darendeliler, H. M. Tunc, F. Ozcan, S. Bavbek. (2011) Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey. Japanese Journal of Clinical Oncology 41:12, 1380-1387
CrossRef65
Jaclyn Yoong, Geoffrey Chong, K. Hamilton. (2011) Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma. Medical Oncology 28:S1, 395-397
CrossRef66
M. F. Botteman, M. Meijboom, I. Foley, J. M. Stephens, Y. M. Chen, S. Kaura. (2011) Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. The European Journal of Health Economics 12:6, 575-588
CrossRef67
Ario Takeuchi, Masaki Shiota, Katsunori Tatsugami, Akira Yokomizo, Masatoshi Eto, Junichi Inokuchi, Kentaro Kuroiwa, Keijiro Kiyoshima, Seiji Naito. (2011) Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression. Cancer Chemotherapy and Pharmacology 68:6, 1557-1564
CrossRef68
Richard A Hubner, Juan W Valle. (2011) Sunitinib for advanced pancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy 11:12, 1817-1827
CrossRef69
Colin F. Greineder, Sarah Kohnstamm, Bonnie Ky. (2011) Heart Failure Associated with Sunitinib: Lessons Learned from Animal Models. Current Hypertension Reports 13:6, 436-441
CrossRef70
Deepak Kilari, Supriya Gupta Mohile. (2011) Management of Cancer in the Older Adult. Clinics in Geriatric Medicine
CrossRef71
Jean-Jacques Patard, Camillo Porta, John Wagstaff, Juergen E Gschwend. (2011) Optimizing treatment for metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 11:12, 1901-1911
CrossRef72
P. M. M. B. Soetekouw, A. Beeker, A. Bex, C. J. Groeningen, P. F. A. Mulders. (2011) Bevacizumab in combinatie met interferon-alfa voor gemetastaseerd niercelcarcinoom: veiligheid en toepasbaarheid in de praktijk. Tijdschrift voor Urologie 1:8, 170-177
CrossRef73
Fei Liu, Xianguo Chen, Ejun Peng, Wei Guan, Youyuan Li, Zhiquan Hu, Zhangqun Ye, Qianyuan Zhuang. (2011) VEGF pathway-targeted therapy for advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. Journal of Huazhong University of Science and Technology [Medical Sciences] 31:6, 799-806
CrossRef74
Nizar M. Tannir, Yu-Ning Wong, Christian K. Kollmannsberger, Marc S. Ernstoff, David J. Perry, Leonard J. Appleman, Edwin M. Posadas, Daniel Cho, Toni K. Choueiri, Andrew Coates, Neeraj Gupta, Rajendra Pradhan, Jiang Qian, Jihong Chen, Frank A. Scappaticci, Justin L. Ricker, Dawn M. Carlson, M. Dror Michaelson. (2011) Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer 47:18, 2706-2714
CrossRef75
Brian I Rini, Bernard Escudier, Piotr Tomczak, Andrey Kaprin, Cezary Szczylik, Thomas E Hutson, M Dror Michaelson, Vera A Gorbunova, Martin E Gore, Igor G Rusakov, Sylvie Negrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim, Robert J Motzer. (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. The Lancet 378:9807, 1931-1939
CrossRef76
Anne Flörcken, Anna Takvorian, Antje Van Lessen, Anju Singh, Werner Hopfenmüller, Bernd Dörken, Antonio Pezzutto, Jörg Westermann. (2011) Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma. Anti-Cancer Drugs1
CrossRef77
E. Calvo, B. Escudier, R.J. Motzer, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda, V. Grünwald, J.A. Thompson, A. Ravaud, D. Kim, A. Panneerselvam, O. Anak, R.A. Figlin. (2011) Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. European Journal of Cancer
CrossRef78
T. Schmidt, P. Carmeliet. (2011) Angiogenesis: A Target in Solid Tumors, Also in Leukemia?. Hematology 2011:1, 1-8
CrossRef79
N. Shinohara, T. Abe, A. Sazawa, S. Maruyama, J. Shindo, S. Sato, S. Suzuki, K. Nonomura. (2011) Interferon- -based Immunotherapy in Metastatic Renal Cell Carcinoma Patients with the Primary Tumor In Situ. Japanese Journal of Clinical Oncology
CrossRef80
David R. Yates, Morgan Rouprêt. (2011) Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response. World Journal of Urology
CrossRef81
V Grünwald, C Seidel, M Fenner, A Ganser, J Busch, S Weikert. (2011) Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. British Journal of Cancer 105:11, 1635-1639
CrossRef82
Ginil Kumar Pooleri, Tiyadath Balagopalan Nair, Kalavampara V. Sanjeevan, Appu Thomas. (2011) Neo Adjuvant Treatment with Targeted Molecules for Renal Cell Cancer in Current Clinical Practise. Indian Journal of Surgical Oncology
CrossRef83
D. Y. Heng, M. J. MacKenzie, U. N. Vaishampayan, G. A. Bjarnason, J. J. Knox, M. H. Tan, L. Wood, Y. Wang, C. Kollmannsberger, S. North, F. Donskov, B. I. Rini, T. K. Choueiri. (2011) Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Annals of Oncology
CrossRef84
Aymen A. Elfiky, Daniel C. Cho, David F. McDermott, Jonathan E. Rosenberg, Barry Fortner, Lucia Antràs, Kristina Chen, Mei Sheng Duh, Sujata S. Jayawant, William K. Oh, Michael B. Atkins, Toni K. Choueiri. (2011) Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 29:6, 756-763
CrossRef85
Manmeet S Ahluwalia, Mital Patel, David M Peereboom. (2011) Role of tyrosine kinase inhibitors in the management of high-grade gliomas. Expert Review of Anticancer Therapy 11:11, 1739-1748
CrossRef86
J.D. Cohen, J.E. Babiarz, R.M. Abrams, L. Guo, S. Kameoka, E. Chiao, J. Taunton, K.L. Kolaja. (2011) Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicology and Applied Pharmacology 257:1, 74-83
CrossRef87
M. H. G. Langenberg, P. O. Witteveen, J. Roodhart, M. P. Lolkema, H. M. W. Verheul, M. Mergui-Roelvink, E. Brendel, J. Kratzschmar, B. Loembe, A. Nol-Boekel, O. Christensen, J. H. M. Schellens, E. E. Voest. (2011) Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Annals of Oncology 22:11, 2508-2515
CrossRef88
C. Perrin, J.-J. Patard, F. Jouan, N. Collet, S. Théoleyre, J. Edeline, S. Zerrouki, B. Laguerre, M.-A. Bellaud-Roturaud, N. Rioux-Leclercq, C. Vigneau. (2011) La neutrophil gelatinase-associated lipocalin, ou LCN 2, facteur d’agressivité dans le carcinome rénal à cellules claires (CRCC). Progrès en Urologie 21:12, 851-858
CrossRef89
Jérôme Barrière, Benjamin Hoch, Jean-Marc Ferrero. (2011) New perspectives in the treatment of metastatic renal cell carcinoma. Critical Reviews in Oncology/Hematology
CrossRef90
Jesus Garcia-Donas, Emilio Esteban, Luis Javier Leandro-García, Daniel E Castellano, Aranzazu González del Alba, Miguel Angel Climent, José Angel Arranz, Enrique Gallardo, Javier Puente, Joaquim Bellmunt, Begoña Mellado, Esther Martínez, Fernando Moreno, Albert Font, Mercedes Robledo, Cristina Rodríguez-Antona. (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. The Lancet Oncology 12:12, 1143-1150
CrossRef91
Ateesha F. Mohamed, A. Brett Hauber, Maureen P. Neary. (2011) Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma. PharmacoEconomics 29:11, 977-988
CrossRef92
Takeshi Yuasa, Shunji Takahashi, Kiyohiko Hatake, Junji Yonese, Iwao Fukui. (2011) Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer Science 102:11, 1949-1957
CrossRef93
Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto, Hiro-omi Kanayama, Nobuo Shinohara, Hayakazu Nakazawa, Keiji Imai, Yoshiko Umeyama, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza. (2011) Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. European Journal of Cancer 47:17, 2592-2602
CrossRef94
Martin Pichler, Georg C. Hutterer, Thomas F. Chromecki, Johanna Jesche, Karin Kampel-Kettner, Peter Rehak, Karl Pummer, Richard Zigeuner. (2011) External Validation of the Leibovich Prognosis Score for Nonmetastatic Clear Cell Renal Cell Carcinoma at a Single European Center Applying Routine Pathology. The Journal of Urology 186:5, 1773-1778
CrossRef95
Jonathan Verma, Eric Jonasch, Pamela Allen, Nizar Tannir, Anita Mahajan. (2011) Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117:21, 4958-4965
CrossRef96
Y.-C. Liu, P. M.-H. Chang, C.-Y. Liu, C.-Y. Yang, M.-H. Chen, C.-C. Pan, M.-H. Chen. (2011) Sunitinib-induced Nephrotic Syndrome in Association with Drug Response in a Patient with Xp11.2 Translocation Renal Cell Carcinoma. Japanese Journal of Clinical Oncology 41:11, 1277-1281
CrossRef97
Stefan Zastrow, Steffen Leike, Sven Oehlschläger, Marc-Oliver Grimm, Manfred Wirth. (2011) Surgery for renal cell cancer extending into the inferior vena cava - evaluation of survival and perioperative complications using a standardized classification system. BJU International 108:9, 1439-1443
CrossRef98
Mi-Sook Kim. (2011) Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. Biomolecules and Therapeutics 19:4, 371-389
CrossRef99
Lesley J. Fallowfield, Anne Fleissig. (2011) The value of progression-free survival to patients with advanced-stage cancer. Nature Reviews Clinical Oncology 9:1, 41-47
CrossRef100
Ana M. Molina, Satish K. Tickoo, Nicole Ishill, Michael J. Trinos, Lawrence H. Schwartz, Sujata Patil, Darren R. Feldman, Victor E. Reuter, Paul Russo, Robert J. Motzer. (2011) Sarcomatoid-variant Renal Cell Carcinoma. American Journal of Clinical Oncology 34:5, 454-459
CrossRef101
Alexander Kutikov, Peter Makhov, Konstantin Golovine, Daniel J. Canter, Mohit Sirohi, Ryan Street, Jay Simhan, Robert G. Uzzo, Vladimir M. Kolenko. (2011) Interleukin-6: A Potential Biomarker of Resistance to Multitargeted Receptor Tyrosine Kinase Inhibitors in Castration-resistant Prostate Cancer. Urology 78:4, 968.e7-968.e11
CrossRef102
Axel Bex, Christian Blank, Wim Meinhardt, Harm van Tinteren, Simon Horenblas, John Haanen. (2011) A Phase II Study of Presurgical Sunitinib in Patients With Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ. Urology 78:4, 832-837
CrossRef103
Steven Knapper. (2011) The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opinion on Investigational Drugs 20:10, 1377-1395
CrossRef104
Shangwen Liu, Xin Ma, Qing Ai, Qingbo Huang, Taoping Shi, Mingyang Zhu, Baojun Wang, Xu Zhang. (2011) NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations
CrossRef105
Jean-Jacques Patard, Geraldine Pignot, Bernard Escudier, Tim Eisen, Axel Bex, Cora Sternberg, Brian Rini, Jan Roigas, Toni Choueiri, Ronald Bukowski, Robert Motzer, Ziya Kirkali, Peter Mulders, Joaquim Bellmunt. (2011) ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. European Urology 60:4, 684-690
CrossRef106
Shuchi S. Pandya, James W. Mier, David F. McDermott, Daniel C. Cho. (2011) Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer. BJU International 108:8b, E245-E249
CrossRef107
Peter H. O'Donnell. (2011) EFFICACY AND TOXICITY OF SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WITH SEVERE RENAL IMPAIRMENT OR ON HAEMODIALYSIS. BJU International 108:8, 1284-1285
CrossRef108
Pieter G. Postema, Madelien V. Regeer, Paul R. Valk, Erik S. G. Stroes, Dick J. Richel. (2011) Blue toe syndrome and sunitinib. International Journal of Clinical Oncology 16:5, 574-576
CrossRef109
David Bruce, Peng H Tan. (2011) Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?. Expert Opinion on Investigational Drugs 20:10, 1413-1434
CrossRef110
Maxine Sun, Shahrokh F. Shariat, Christopher Cheng, Vincenzo Ficarra, Masaru Murai, Stéphane Oudard, Allan J. Pantuck, Richard Zigeuner, Pierre I. Karakiewicz. (2011) Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review. European Urology 60:4, 644-661
CrossRef111
Alejandro D. Ricart, Edward A. Ashton, Matthew M. Cooney, John Sarantopoulos, Joanna M. Brell, Maria A. Feldman, Kale E. Ruby, Kazuko Matsuda, Mark S. Munsey, Gerardo Medina, Angela Zambito, Anthony W. Tolcher, Scot C. Remick. (2011) A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 68:4, 959-970
CrossRef112
Robert Abouassaly, Simon Yang, Antonio Finelli, Girish S. Kulkarni, Shabbir M.H. Alibhai. (2011) What is the best treatment strategy for incidentally detected small renal masses? A decision analysis. BJU International 108:8b, E223-E231
CrossRef113
D. Rottlaender, S. Reda, L.J. Motloch, U.C. Hoppe. (2011) Neue Tyrosinkinase- und EGFR-Inhibitoren in der Tumortherapie. Der Internist 52:10, 1245-1255
CrossRef114
Debra Josephs, Thomas E. Hutson, Charles L. Cowey, Lisa M. Pickering, James M. Larkin, Martin E. Gore, Mieke Van Hemelrijck, David F. McDermott, Thomas Powles, Paramit Chowdhury, Chris Karapetis, Peter G. Harper, Toni K. Choueiri, Simon Chowdhury. (2011) Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU International 108:8, 1279-1283
CrossRef115
Claudia Rossig, Heribert Juergens, Wolfgang E. Berdel. (2011) New Targets and Targeted Drugs for the Treatment of Cancer: An Outlook to Pediatric Oncology. Pediatric Hematology-Oncology 28:7, 539-555
CrossRef116
Yoshinori Hoshino, Hirotoshi Hasegawa, Yoshiyuki Ishii, Takashi Endo, Hiroki Ochiai, Koji Okabayashi, Gou Kaneko, Shuji Mikami, Makio Mukai, Mototsugu Oya, Yuko Kitagawa. (2011) Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma. International Journal of Clinical Oncology
CrossRef117
Andrea L. Harzstark, Eric J. Small, Vivian K. Weinberg, Janine Sun, Charles J. Ryan, Amy M. Lin, Lawrence Fong, Dion R. Brocks, Jonathan E. Rosenberg. (2011) A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 117:18, 4194-4200
CrossRef118
M. Franco, P. Roswall, E. Cortez, D. Hanahan, K. Pietras. (2011) Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 118:10, 2906-2917
CrossRef119
Fable Zustovich, Giuseppe Lombardi, Ornella Nicoletto, Davide Pastorelli. (2011) Second-line therapy for refractory renal-cell carcinoma. Critical Reviews in Oncology/Hematology
CrossRef120
Takeshi Yuasa, Norihiko Tsuchiya, Shinji Urakami, Yohei Horikawa, Shintaro Narita, Takamitsu Inoue, Mitsuru Saito, Shinya Yamamoto, Junji Yonese, Iwao Fukui, Kenji Nakano, Shunji Takahashi, Kiyohiko Hatake, Tomonori Habuchi. (2011) Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. BJU Internationalno-no
CrossRef121
Daniel Keizman, Peng Huang, Mario A. Eisenberger, Roberto Pili, Jenny J. Kim, Emmanuel S. Antonarakis, Hans Hammers, Michael A. Carducci. (2011) Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. European Journal of Cancer 47:13, 1955-1961
CrossRef122
Roman Casciano, Maruit Chulikavit, Giuseppe Di Lorenzo, Zhimei Liu, Jean-Francois Baladi, Xufang Wang, Justin Robertson, Lou Garrison. (2011) Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib. Value in Health 14:6, 846-851
CrossRef123
Nobuyuki Oyama, Noriko Takahara, Yoko Hasegawa, Kazuya Tanase, Yoshiji Miwa, Hironobu Akino, Hidehiko Okazawa, Takashi Kudo, Yasuhisa Fujibayashi, Osamu Yokoyama. (2011) Assessment of Therapeutic Effect of Sunitinib by 11C-Acetate PET Compared with FDG PET Imaging in a Patient with Metastatic Renal Cell Carcinoma. Nuclear Medicine and Molecular Imaging 45:3, 217-219
CrossRef124
Sergio Bracarda, Enzo Maria Ruggeri, Marcello Monti, Marco Merlano, Alessandro D’Angelo, Francesco Ferraù, Enrico Cortesi, Armando Santoro. (2011) Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group. Critical Reviews in Oncology/Hematology
CrossRef125
Gurpreet Lamba, Raveen Deol, Dhaval Shah, Ramandeep Sahni, Bharat Kumar Malhotra. (2011) Sunitinib and Thrombosis. Journal of Gastrointestinal Cancer
CrossRef126
Andrew D. Smith, Shetal N. Shah, Brian I. Rini, Michael L. Lieber, Erick M. Remer. (2011) Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis. Urologic Oncology: Seminars and Original Investigations
CrossRef127
Victoria Kunene, Emilio Porfiri. (2011) Sunitinib-induced Acute Psychosis: Case Report. Clinical Genitourinary Cancer 9:1, 70-72
CrossRef128
A. Ravaud, S. Roca, A. Quivy, M. Gross-Goupil. (2011) Pourquoi un traitement local des métastases ?. Journal de Radiologie 92:9, 821-824
CrossRef129
, M. Siebels, A. Hegele, Z. Varga, R. Oberneder, C. Doehn, H. Heinzer. (2011) Sequenztherapie beim metastasierten Nierenzellkarzinom in Deutschland 2010. Der Urologe 50:9, 1110-1117
CrossRef130
P. Fornara, M.R. Hoda. (2011) Das Nierenzellkarzinom. Der Urologe 50:S1, 219-222
CrossRef131
Axel Bex, Tom Powles. (2011) Reply from Authors re: Simon P. Kim, R. Houston Thompson. Sunitinib Prior to Planned Cytoreductive Nephrectomy: Is This the New Litmus Test for Metastatic Renal Cell Carcinoma? Eur Urol 2011;60:455–6. European Urology 60:3, 456-457
CrossRef132
Simon P. Kim, R. Houston Thompson. (2011) Sunitinib Prior to Planned Cytoreductive Nephrectomy: Is This the New Litmus Test for Metastatic Renal Cell Carcinoma?. European Urology 60:3, 455-456
CrossRef133
Peter C. Trask, Andrew G. Bushmakin, Joseph C. Cappelleri, Jamal Tarazi, Brad Rosbrook, Paul Bycott, Sinil Kim, Walter M. Stadler, Brian Rini. (2011) Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. Journal of Cancer Survivorship 5:3, 255-262
CrossRef134
K.K.H. Aben, S. Heskamp, M.L. Janssen-Heijnen, E.L. Koldewijn, C.M. van Herpen, L.A. Kiemeney, E. Oosterwijk, D.J. van Spronsen. (2011) Better survival in patients with metastasised kidney cancer after nephrectomy: A population-based study in the Netherlands. European Journal of Cancer 47:13, 2023-2032
CrossRef135
Susana Banerjee, Stan Kaye. (2011) The role of targeted therapy in ovarian cancer. European Journal of Cancer 47, S116-S130
CrossRef136
Nobuo Shinohara, Takashige Abe, Tango Mochizuki, Akira Kashiwagi, Kouichi Kanagawa, Satoru Maruyama, Ataru Sazawa, Koji Oba, Katsuya Nonomura. (2011) Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?. Urologic Oncology: Seminars and Original Investigations
CrossRef137
B. Amend, J. Hennenlotter, M. Scharpf, S. Kruck, U. Kuehs, E. Senger, A. S. Merseburger, M. A. Kuczyk, K. D. Sievert, A. Stenzl, J. Bedke. (2011) Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma. World Journal of Urology
CrossRef138
Sumanta K. Pal, Ari Vanderwalde, Arti Hurria, Robert A. Figlin. (2011) Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults. Drugs & Aging 28:8, 635-649
CrossRef139
Jose A. Karam, Christopher G. Wood. (2011) The Role of Surgery in Advanced Renal Cell Carcinoma: Cytoreductive Nephrectomy and Metastasectomy. Hematology/Oncology Clinics of North America 25:4, 753-764
CrossRef140
Lianjie Li, William G. Kaelin. (2011) New Insights into the Biology of Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, 667-686
CrossRef141
Silvia Stacchiotti, Paolo Giovanni Casali. (2011) Systemic Therapy Options for Unresectable and Metastatic Chordomas. Current Oncology Reports 13:4, 323-330
CrossRef142
P. Guyot-Caquelin, L. Geoffrois, A. Barbaud, P. Trechot, J.-L. Schmutz, F. Granel-Brocard. (2011) Évaluation d’une information pour prévenir et prendre en charge les réactions mains-pieds secondaires aux traitements anti-angiogéniques. Annales de Dermatologie et de Vénéréologie 138:8-9, 565-571
CrossRef143
Marc C. Smaldone, Chunkit Fung, Robert G. Uzzo, Naomi B. Haas. (2011) Adjuvant and Neoadjuvant Therapies in High-Risk Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, 765-791
CrossRef144
Timo T Purmonen. (2011) Cost–effectiveness of sunitinib in metastatic renal cell carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research 11:4, 383-393
CrossRef145
Martin H. Voss, Ana M. Molina, Robert J. Motzer. (2011) mTOR Inhibitors in Advanced Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, 835-852
CrossRef146
Katherine M. Krajewski, Angela A. Giardino, Katherine Zukotynski, Annick D. Van den Abbeele, Ivan Pedrosa. (2011) Imaging in Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, 687-715
CrossRef147
Daniel C. Cho, Michael B. Atkins. (2011) Future Directions in Renal Cell Carcinoma: 2011 and Beyond. Hematology/Oncology Clinics of North America 25:4, 917-935
CrossRef148
Gilles Ferry, Aurélie Studeny, Céline Bossard, Philip M. Kubara, Denis Zeyer, Jean-Paul Renaud, Patrick Casara, Guillaume de Nanteuil, Michel Wierzbicki, Bruno Pfeiffer, Michelle Prudhomme, Stephane Leonce, Alain Pierré, Jean A. Boutin, Roy M. Golsteyn. (2011) Characterization of novel Checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors. Life Sciences 89:7-8, 259-268
CrossRef149
David J. Gallagher, Hikmat Al-Ahmadie, Irina Ostrovnaya, Scott R. Gerst, Ashley Regazzi, Ilana Garcia-Grossman, Jamie Riches, Sivaraman K. Gounder, Anne-Marie Flaherty, Alisa Trout, Matthew I. Milowsky, Dean F. Bajorin. (2011) Sunitinib in Urothelial Cancer: Clinical, Pharmacokinetic, and Immunohistochemical Study of Predictors of Response. European Urology 60:2, 344-349
CrossRef150
Simon Chowdhury, Marc R. Matrana, Christopher Tsang, Bradley Atkinson, Toni K. Choueiri, Nizar M. Tannir. (2011) Systemic Therapy for Metastatic Non–Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions. Hematology/Oncology Clinics of North America 25:4, 853-869
CrossRef151
Domenico Ribatti. (2011) Novel angiogenesis inhibitors: Addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treatment Reviews 37:5, 344-352
CrossRef152
J.- C. Soria, J. Y. Blay, J. P. Spano, X. Pivot, Y. Coscas, D. Khayat. (2011) Added value of molecular targeted agents in oncology. Annals of Oncology 22:8, 1703-1716
CrossRef153
Laurie Appleby, Stephanie Morrissey, Joaquim Bellmunt, Jonathan Rosenberg. (2011) Management of Treatment-Related Toxicity with Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices. Hematology/Oncology Clinics of North America 25:4, 893-915
CrossRef154
Birgit Grünberger. (2011) Systemische Therapie des Nierenzellkarzinoms – aktuelle Behandlungsmöglichkeiten. Wiener Medizinische Wochenschrift 161:15-16, 382-386
CrossRef155
Patricia A. Tang, Michael M. Vickers, Daniel Y.C. Heng. (2011) Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far. Hematology/Oncology Clinics of North America 25:4, 871-891
CrossRef156
Laurence Albiges, Mohamed Salem, Brian Rini, Bernard Escudier. (2011) Vascular Endothelial Growth Factor–Targeted Therapies in Advanced Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, 813-833
CrossRef157
Jacalyn Rosenblatt, David F. McDermott. (2011) Immunotherapy for Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, 793-812
CrossRef158
H. Akaza, T. Tsukamoto, T. Fujioka, Y. Tomita, T. Kitamura, S. Ozono, T. Miki, S. Naito, H. Zembutsu, Y. Nakamura. (2011) Combined Immunotherapy with Low-dose IL-2 Plus IFN- for Metastatic Renal Cell Carcinoma: Survival Benefit for Selected Patients with Lung Metastasis and Serum Sodium Level. Japanese Journal of Clinical Oncology 41:8, 1023-1030
CrossRef159
K. Webber, A. Cooper, H. Kleiven, D. Yip, D. Goldstein. (2011) Management of metastatic renal cell carcinoma in the era of targeted therapies. Internal Medicine Journal 41:8, 594-605
CrossRef160
Georgios Meimarakis, Martin Angele, Michael Staehler, Dirk-Andre Clevert, Alexander Crispin, Dominik Rüttinger, Florian Löhe, Gerhard Preissler, Rudolf A. Hatz, Hauke Winter. (2011) Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. The American Journal of Surgery 202:2, 158-167
CrossRef161
O. Amit, F. Mannino, A.M. Stone, W. Bushnell, J. Denne, J. Helterbrand, H.U. Burger. (2011) Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis. European Journal of Cancer 47:12, 1772-1778
CrossRef162
Roberto Ravasio, Cinzia Ortega, Roberto Sabbatini, Camillo Porta. (2011) Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy. Clinical Drug Investigation 31:7, 507-517
CrossRef163
Steven L. Wood, Janet E. Brown. (2011) Skeletal metastasis in renal cell carcinoma: Current and future management options. Cancer Treatment Reviews
CrossRef164
B. Neyns, J. Sadones, C. Chaskis, M. Dujardin, H. Everaert, S. Lv, J. Duerinck, O. Tynninen, N. Nupponen, A. Michotte, J. Greve. (2011) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. Journal of Neuro-Oncology 103:3, 491-501
CrossRef165
A. Bamias, E. Manios, A. Karadimou, F. Michas, G. Lainakis, C. Constantinidis, C. Deliveliotis, N. Zakopoulos, M.A. Dimopoulos. (2011) The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. European Journal of Cancer 47:11, 1660-1668
CrossRef166
James Finke, Jennifer Ko, Brian Rini, Pat Rayman, Joanna Ireland, Peter Cohen. (2011) MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. International Immunopharmacology 11:7, 856-861
CrossRef167
Matthias Maruschke, D. Reuter, D. Koczan, O. W. Hakenberg, H.-J. Thiesen. (2011) Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management. BJU International 108:2b, E29-E35
CrossRef168
Rosalie Fisher, Lisa Pickering, James Larkin. (2011) New targeted therapies for renal cell carcinoma. Expert Opinion on Investigational Drugs 20:7, 933-945
CrossRef169
C. Wiesner, A. Haferkamp. (2011) Metastasiertes Nierenzellkarzinom. Der Urologe 50:7, 853-860
CrossRef170
M. Moehler, A. Mueller, J.T. Hartmann, M.P. Ebert, S.E. Al-Batran, P. Reimer, M. Weihrauch, F. Lordick, T. Trarbach, S. Biesterfeld, M. Kabisch, D. Wachtlin, P.R. Galle. (2011) An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. European Journal of Cancer 47:10, 1511-1520
CrossRef171
Camillo Porta, Cezary Szczylik, Bernard Escudier. (2011) Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review. Critical Reviews in Oncology/Hematology
CrossRef172
Giuseppe Di Lorenzo, Roman Casciano, Elisabetta Malangone, Carlo Buonerba, Steven Sherman, Jacob Willet, Xufang Wang, Zhimei Liu, Sabino De Placido. (2011) An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opinion on Pharmacotherapy 12:10, 1491-1497
CrossRef173
A Leary, JM Larkin, Lisa M Pickering. (2011) Cytokine therapy for renal cell cancer: the evolving role of immunomodulation. Therapy 8:4, 347-358
CrossRef174
Ronald M Bukowski. (2011) Renal cell carcinoma: immunotherapy revisited. Therapy 8:4, 335-338
CrossRef175
Meredith L. Rees, Aarif Y. Khakoo. (2011) Molecular Mechanisms of Hypertension and Heart Failure Due to Antiangiogenic Cancer Therapies. Heart Failure Clinics 7:3, 299-311
CrossRef176
Jordi Remon, Pilar Lianes, Susana Martínez. (2011) Brain metastases from renal cell carcinoma. Should we change the current standard?. Cancer Treatment Reviews
CrossRef177
Sylvie Négrier, Gwenaëlle Gravis, David Pérol, Christine Chevreau, Rémy Delva, Jacques-Olivier Bay, Ellen Blanc, Céline Ferlay, Lionnel Geoffrois, Frédéric Rolland, Eric Legouffe, Emmanuel Sevin, Brigitte Laguerre, Bernard Escudier. (2011) Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. The Lancet Oncology 12:7, 673-680
CrossRef178
S. Bauer. (2011) Systemtherapie des fortgeschrittenen Nierenzellkarzinoms. Der Nephrologe 6:4, 331-336
CrossRef179
Viktor Grünwald, Pierre I. Karakiewicz, Sevil E. Bavbek, Kurt Miller, Jean-Pascal Machiels, Se-Hoon Lee, James Larkin, Petri Bono, Sun Young Rha, Daniel Castellano, Christian U. Blank, Jennifer J. Knox, Robert Hawkins, Oezlem Anak, Marianne Rosamilia, Jocelyn Booth, Nicoletta Pirotta, István Bodrogi. (2011) An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer
CrossRef180
Cheng-yao WU, Zhen-sheng ZHANG, Chuan-liang XU, Yang WANG, Qin-song ZENG, Wei-dong XU, Tai-le JING, Dan SHEN, Jian SHEN, Fu-bo WANG, Ying-hao SUN. (2011) Diagnosis and treatment of gastric metastasis of clear cell renal cell carcinoma: a case report and review of literatures. Academic Journal of Second Military Medical University 31:5, 575-577
CrossRef181
John D. Hainsworth, Jeffrey R. Infante, David R. Spigel, Edward R. Arrowsmith, Ralph V. Boccia, Howard A. Burris. (2011) A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma. Cancer Investigation110622111845059
CrossRef182
E. E. Visvardis, F. Gao, M. N. Paes, O. Duprez, J. Waxman. (2011) Lung Aspergillosis in renal cell carcinoma patient treated with sunitinib: a case report. QJM
CrossRef183
Daniel Y. C. Heng, Wanling Xie, Georg A. Bjarnason, Ulka Vaishampayan, Min-Han Tan, Jennifer Knox, Frede Donskov, Lori Wood, Christian Kollmannsberger, Brian I. Rini, Toni K. Choueiri. (2011) Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 117:12, 2637-2642
CrossRef184
R. Sabatier, J. C. Eymard, J. Walz, J. L. Deville, H. Narbonne, J. M. Boher, N. Salem, M. Marcy, S. Brunelle, P. Viens, F. Bladou, G. Gravis. (2011) Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?. Annals of Oncology
CrossRef185
Nozomu Tanji, Masayoshi Yokoyama. (2011) Treatment of metastatic renal cell carcinoma and renal pelvic cancer. Clinical and Experimental Nephrology 15:3, 331-338
CrossRef186
Yutaka Enomoto. (2011) Exploring immune therapy for renal cancer. International Journal of Urology 18:6, 412-421
CrossRef187
Scott S Tykodi, Brenda M Sandmaier, Edus H Warren, John A Thompson. (2011) Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. Expert Opinion on Biological Therapy 11:6, 763-773
CrossRef188
Xing Lv, Yan-Qun Xiang, Su-Mei Cao, Chao-Nan Qian, Ning-Wei Li, Ling Guo, Hai-Qiang Mai, Qiu-Yan Chen, Pei-Yu Huang, DongHua Luo, Ka-Jia Cao, Ming-Huang Hong, Xiang Guo. (2011) Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: More distant metastases and shorter overall survival after treatment. Head & Neck 33:6, 780-785
CrossRef189
Wilson Gonsalves, Apar Kishor Ganti. (2011) Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology 78:3, 227-242
CrossRef190
Bernard Escudier, Laurence Albiges. (2011) Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma. Drugs 71:9, 1179-1191
CrossRef191
Hai-Liang Zhang, Yao Zhu, Chao-Fu Wang, Xu-Dong Yao, Shi-Lin Zhang, Bo Dai, Yi-Jun Shen, Yi-Ping Zhu, Guo-Hai Shi, Ding-Wei Ye. (2011) Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. International Journal of Urology 18:6, 422-430
CrossRef192
Robert O. Dillman, Neil M. Barth, Louis A. VanderMolen, Warren H. Fong, Khosrow K. Mahdavi, Stephanie E. McClure. (2011) Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?. Cancer Biotherapy & Radiopharmaceuticals 26:3, 273-277
CrossRef193
Ziya Kirkali. (2011) Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. BJU International 107:11, 1722-1732
CrossRef194
M.E. Revheim, A.K. Winge-Main, G. Hagen, J.G. Fjeld, S.D. Fosså, W. Lilleby. (2011) Combined Positron Emission Tomography/Computed Tomography in Sunitinib Therapy Assessment of Patients with Metastatic Renal Cell Carcinoma. Clinical Oncology 23:5, 339-343
CrossRef195
Michel Choueiri, Eric Jonasch. (2011) Have Molecularly Targeted Therapies Improved Overall Survival in Renal Cell Carcinoma?. Current Oncology Reports 13:3, 153-156
CrossRef196
Sara Di Bella, Filippo Venturini, Giovanna Marrapese, Emiliana Tarenzi, Salvatore Siena. (2011) Cardiotoxicity of novel molecular targeted therapies of cancer. Journal of Cardiovascular Echography 21:2, 78-85
CrossRef197
Axel Bex, James Larkin, Christian Blank. (2011) Non–Clear Cell Renal Cell Carcinoma: How New Biological Insight May Lead to New Therapeutic Modalities. Current Oncology Reports 13:3, 240-248
CrossRef198
Jill M. Hagenkord, Zoran Gatalica, Eric Jonasch, Federico A. Monzon. (2011) Clinical genomics of renal epithelial tumors. Cancer Genetics 204:6, 285-297
CrossRef199
Marco Bregni, Wolfgang Herr, Didier Blaise. (2011) Allogeneic stem cell transplantation for renal cell carcinoma. Expert Review of Anticancer Therapy 11:6, 901-911
CrossRef200
D. J. Jonker, L. S. Rosen, M. B. Sawyer, F. de Braud, G. Wilding, C. J. Sweeney, G. C. Jayson, G. A. McArthur, G. Rustin, G. Goss, J. Kantor, L. Velasquez, S. Syed, O. Mokliatchouk, D. M. Feltquate, G. Kollia, D. S. A. Nuyten, S. Galbraith. (2011) A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Annals of Oncology 22:6, 1413-1419
CrossRef201
C. Mogler, H.G. Augustin. (2011) Tumorangiogenese und aktuelle therapeutische Möglichkeiten der Inhibition. Der Onkologe 17:6, 513-519
CrossRef202
Jun Liu, Ming Li, Bo Song, Chunhong Jia, Lichao Zhang, Xiaochun Bai, Weilie Hu. (2011) Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urologic Oncology: Seminars and Original Investigations
CrossRef203
Toshikazu Izutsu, Ryuichiro Konda, Jun Sugimura, Kazuhiro Iwasaki, Tomoaki Fujioka. (2011) Brain-Specific Angiogenesis Inhibitor 1 is a Putative Factor for Inhibition of Neovascular Formation in Renal Cell Carcinoma. The Journal of Urology 185:6, 2353-2358
CrossRef204
Henry W.C. Leung, Agnes L.F. Chan. (2011) Multikinase Inhibitors in Metastatic Renal Cell Carcinoma: Indirect Comparison Meta-Analysis. Clinical Therapeutics 33:6, 708-716
CrossRef205
Sabine Brookman-May, Maximilian Burger, Wolf F Wieland, Wolfgang Rößler, Matthias May, Stefan Denzinger. (2011) Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Review of Vaccines 10:6, 837-852
CrossRef206
C. Seidel, M. Fenner, A. S. Merseburger, C. Reuter, P. Ivanyi, F. Länger, A. Ganser, V. Grünwald. (2011) Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. World Journal of Urology 29:3, 355-360
CrossRef207
Elżbieta Senkus, Jacek Jassem. (2011) Cardiovascular effects of systemic cancer treatment. Cancer Treatment Reviews 37:4, 300-311
CrossRef208
A.L. Watters, J.B. Epstein, M. Agulnik. (2011) Oral complications of targeted cancer therapies: A narrative literature review. Oral Oncology 47:6, 441-448
CrossRef209
Kanwal Pratap Singh Raghav, George R Blumenschein. (2011) Motesanib and advanced NSCLC: experiences and expectations. Expert Opinion on Investigational Drugs 20:6, 859-869
CrossRef210
D. Cella, A.S. Pickard, M.S. Duh, A. Guerin, N. Mishagina, L. Antràs, M.P. Neary, L. McCann, R. Hodge, C.N. Sternberg. (2011) Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer
CrossRef211
Bernard Escudier, Susanne Osanto, Börje Ljungberg, Camillo Porta, John Wagstaff, Peter Mulders, Martin Gore, Axel Bex, Joaquim Bellmunt, Sergio Bracarda, Alex Franklin, Per Hartvig Honoré, Alain Ravaud, Jeanne van Steijn, Zeba Aziz, Hideyuki Akaza. (2011) Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treatment Reviews
CrossRef212
Sylvie Négrier, Eric Raymond. (2011) Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Investigational New Drugs
CrossRef213
B. I. Rini, D. P. Cohen, D. R. Lu, I. Chen, S. Hariharan, M. E. Gore, R. A. Figlin, M. S. Baum, R. J. Motzer. (2011) Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. JNCI Journal of the National Cancer Institute 103:9, 763-773
CrossRef214
T. Buchler, R. Klapka, B. Melichar, P. Brabec, L. Dusek, R. Vyzula, J. Abrahamova. (2011) Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry. Annals of Oncology
CrossRef215
Curt Peterson. (2011) Drug therapy of cancer. European Journal of Clinical Pharmacology 67:5, 437-447
CrossRef216
Esther M. Bridges, Adrian L. Harris. (2011) The angiogenic process as a therapeutic target in cancer. Biochemical Pharmacology 81:10, 1183-1191
CrossRef217
T. Powles, I. Kayani, C. Blank, S. Chowdhury, S. Horenblas, J. Peters, J. Shamash, N. Sarwar, K. Boletti, A. Sadev, T. O'Brien, D. Berney, L. Beltran, J. Haanen, A. Bex. (2011) The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Annals of Oncology 22:5, 1041-1047
CrossRef218
Kevin V.S. Tan, Benjamin Namdarian, Anthony J. Costello, Christopher M. Hovens. (2011) Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 29:3, 237-243
CrossRef219
David Berz, Harold Wanebo. (2011) Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors. Journal of Surgical Oncology 103:6, 574-586
CrossRef220
Katherine M. Krajewski, Mengye Guo, Annick D. Van den Abbeele, Jeffrey Yap, Nikhil Ramaiya, Jyothi Jagannathan, Daniel Y.C. Heng, Michael B. Atkins, David F. McDermott, Fabio A.B. Schutz, Ivan Pedrosa, Toni K. Choueiri. (2011) Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. European Urology 59:5, 856-862
CrossRef221
E. Blasi, J. Heyen, S. Patyna, M. Hemkens, D. Ramirez, A. John-Baptiste, J. Steidl-Nichols, A. McHarg. (2011) Sunitinib, a Receptor Tyrosine Kinase Inhibitor, Increases Blood Pressure in Rats without Associated Changes in Cardiac Structure and Function. Cardiovascular Therapeuticsno-no
CrossRef222
S. L. Richey, S. H. Culp, E. Jonasch, P. G. Corn, L. C. Pagliaro, P. Tamboli, K. K. Patel, S. F. Matin, C. G. Wood, N. M. Tannir. (2011) Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Annals of Oncology 22:5, 1048-1053
CrossRef223
G. Wong, K. Howard, A. C. Webster, J. R. Chapman, J. C. Craig. (2011) Screening for renal cancer in recipients of kidney transplants. Nephrology Dialysis Transplantation 26:5, 1729-1739
CrossRef224
David F McDermott, Keith T Flaherty. (2011) Combination therapy for renal cell carcinoma: review of the clinical evidence. Clinical Investigation 1:5, 689-697
CrossRef225
Yoshinari Asaoka, Tsuneo Ikenoue, Kazuhiko Koike. (2011) New targeted therapies for gastric cancer. Expert Opinion on Investigational Drugs 20:5, 595-604
CrossRef226
Rena Buckstein, John Kuruvilla, Neil Chua, Christina Lee, David A. Macdonald, Abdulwahab J. Al-tourah, Alison H. Foo, Wendy Walsh, S. Percy ivy, Michael Crump, Elizabeth A. Eisenhauer. (2011) Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leukemia & Lymphoma 52:5, 833-841
CrossRef227
Eric A Singer, Gopal N Gupta, Ramaprasad Srinivasan. (2011) Update on targeted therapies for clear cell renal cell carcinoma. Current Opinion in Oncology 23:3, 283-289
CrossRef228
Guo Sufen, Yang Xianghong, Cheng Yongxia, Pan Qian. (2011) bFGF and PDGF-BB have a synergistic effect on the proliferation, migration and VEGF release of endothelial progenitor cells. Cell Biology International 35:5, 545-551
CrossRef229
Denise A. Chan, Amato J. Giaccia. (2011) Harnessing synthetic lethal interactions in anticancer drug discovery. Nature Reviews Drug Discovery 10:5, 351-364
CrossRef230
Brian Rini, Mhd Yaser Al-Marrawi. (2011) Pazopanib for the treatment of renal cancer. Expert Opinion on Pharmacotherapy 12:7, 1171-1189
CrossRef231
Michael S. Anglesio, Mark S. Carey, Martin Köbel, Helen MacKay, David G. Huntsman. (2011) Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecologic Oncology 121:2, 407-415
CrossRef232
Christian Martenstein, Simon Phipps, Ghulam Nabi, Anthony Riddick, Duncan McLaren, Alan McNeill. (2011) Cytoreductive nephrectomy preceding adjuvant immunotherapy for metastatic renal cell carcinoma: 8 years’ experience in a UK tertiary referral centre. British Journal of Medical and Surgical Urology 4:3, 101-107
CrossRef233
Matthew G. Kaag, Christien Toyen, Paul Russo, Angel Cronin, R. Houston Thompson, Jeffrey Schiff, Melanie Bernstein, Manjit Bains. (2011) Radical nephrectomy with vena caval thrombectomy: a contemporary experience. BJU International 107:9, 1386-1393
CrossRef234
Antonin Levy, Laurence Albiges-Sauvin, Christophe Massard, Hassan Izzedine, Stéphane Edhery, Ratio Bahleda, Carlos Gomez-Roca, Cyrus Chargari, Isabelle Brocheriou-Spelle, Jean-Charles Soria. (2011) Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Investigational New Drugs
CrossRef235
G Procopio, E Verzoni, S Bracarda, S Ricci, C Sacco, L Ridolfi, C Porta, R Miceli, N Zilembo, E Bajetta. (2011) Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. British Journal of Cancer 104:8, 1256-1261
CrossRef236
Bruce A. Feinberg, Pradeep Jolly, Si-Tien Wang, Barry Fortner, Jeffrey Scott, James Gilmore, Maureen P. Neary, Mei Sheng Duh. (2011) Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Medical Oncology
CrossRef237
Jorge Ayllon, Benoit Beuselinck, Alexandre Morel, Eduardo Barrascout, Jacques Medioni, Florian Scotte, Stéphane Oudard. (2011) Long-Term Response and Postsurgical Complete Remissions After Treatment With Sunitinib Malate, an Oral Multitargeted Receptor Tyrosine Kinase Inhibitor, in Patients With Metastatic Renal Cell Carcinoma. Cancer Investigation 29:4, 282-285
CrossRef238
Pankaj Bhargava, Murray O. Robinson. (2011) Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status. Current Oncology Reports 13:2, 103-111
CrossRef239
Christopher M. Booth, Pavlo Ohorodnyk, Liting Zhu, Dongsheng Tu, Ralph M. Meyer. (2011) Randomised controlled trials in oncology closed early for benefit: Trends in methodology, results, and interpretation. European Journal of Cancer 47:6, 854-863
CrossRef240
Giuseppe Di Lorenzo, Camillo Porta, Joaquim Bellmunt, Cora Sternberg, Ziya Kirkali, Michael Staehler, Steven Joniau, Francesco Montorsi, Carlo Buonerba. (2011) Toxicities of Targeted Therapy and Their Management in Kidney Cancer. European Urology 59:4, 526-540
CrossRef241
T. Powles, S. Chowdhury, J. Shamash, A. Bazeos, S. Gillessen, N. Saunders, L. Lim, N. Sarwar, A. Sadev, P. Wilson, P. Nathan, K. Boleti, J. Peters, S. Agrawal. (2011) Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib. Annals of Oncology 22:4, 815-820
CrossRef242
Nupura S Bhise, Ron B Shmueli, Joel C Sunshine, Stephany Y Tzeng, Jordan J Green. (2011) Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opinion on Drug Delivery 8:4, 485-504
CrossRef243
Matthew Campbell, Marian M. Humphries, Anna-Sophia Kiang, Anh T. H. Nguyen, Oliviero L. Gobbo, Lawrence C. S. Tam, Mayu Suzuki, Finnian Hanrahan, Ema Ozaki, G.-Jane Farrar, Paul F. Kenna, Peter Humphries. (2011) Systemic low-molecular weight drug delivery to pre-selected neuronal regions. EMBO Molecular Medicine 3:4, 235-245
CrossRef244
B. Beuselinck, S. Oudard, O. Rixe, P. Wolter, A. Blesius, J. Ayllon, R. Elaidi, P. Schoffski, E. Barrascout, A. Morel, B. Escudier, H. Lang, J. Zucman-Rossi, J. Medioni. (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Annals of Oncology 22:4, 794-800
CrossRef245
Siamack Sabrkhany, Arjan W. Griffioen, Mirjam G.A. oude Egbrink. (2011) The role of blood platelets in tumor angiogenesis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1815:2, 189-196
CrossRef246
James Larkin, Charles Swanton, Lisa Pickering. (2011) Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Review of Anticancer Therapy 11:4, 639-649
CrossRef247
Takeshi Yuasa, Shinji Urakami, Shinya Yamamoto, Junji Yonese, Kenji Nakano, Makoto Kodaira, Shunji Takahashi, Kiyohiko Hatake, Kentaro Inamura, Yuichi Ishikwa, Iwao Fukui. (2011) Tumor Size Is a Potential Predictor of Response to Tyrosine Kinase Inhibitors in Renal Cell Cancer. Urology 77:4, 831-835
CrossRef248
Anna C Navis, Bob C Hamans, An Claes, Arend Heerschap, Judith WM Jeuken, Pieter Wesseling, William PJ Leenders. (2011) Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. The Journal of Pathology 223:5, 626-634
CrossRef249
Christopher P. Filson, Bruce G. Redman, Rodney L. Dunn, David C. Miller. (2011) Initial Patterns of Care With Oral Targeted Therapies for Patients With Renal Cell Carcinoma. Urology 77:4, 825-830.e1
CrossRef250
Christopher L. Hallemeier, Richard Choo, Brian J. Davis, Thomas M. Pisansky, Leonard L. Gunderson, Bradley C. Leibovich, Michael G. Haddock. (2011) Long-Term Outcomes After Maximal Surgical Resection and Intraoperative Electron Radiotherapy for Locoregionally Recurrent or Locoregionally Advanced Primary Renal Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics
CrossRef251
Ronald M. Bukowski. (2011) Biomarkers in Renal Cell Carcinoma: What Next?. Current Oncology Reports 13:2, 87-89
CrossRef252
Alexander R. Guimaraes, Robert Ross, Jose L. Figuereido, Peter Waterman, Ralph Weissleder. (2011) MRI with Magnetic Nanoparticles Monitors Downstream Anti-Angiogenic Effects of mTOR Inhibition. Molecular Imaging and Biology 13:2, 314-320
CrossRef253
Takeshi Yuasa, Shinji Urakami, Shinya Yamamoto, Junji Yonese, Kazutaka Saito, Shunji Takahashi, Kiyohiko Hatake, Iwao Fukui. (2011) Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clinical & Experimental Metastasis 28:4, 405-411
CrossRef254
Joaquim Bellmunt, Tim Eisen, Cezary Szczylik, Peter Mulders, Camillo Porta. (2011) A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU International 107:8, 1190-1199
CrossRef255
Anikó Maráz. (2011) Új lehetőségek a vesedaganatok onkológiai kezelésében. Orvosi Hetilap 152:17, 655-662
CrossRef256
Timothy M. Clay, Takuya Osada, Zachary C. Hartman, Amy Hobeika, Gayathri Devi, Michael A. Morse, H. Kim Lyerly. (2011) Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunologic Research 49:1-3, 235-247
CrossRef257
Beatrice M. Seddon, Reena Davda. (2011) Uterine sarcomas—Recent progress and future challenges. European Journal of Radiology 78:1, 30-40
CrossRef258
Jurgen J. Fütterer, Stijn T. W. P. J. Heijmijnk. 2011. Imaging in Diagnosis and Staging of Urologic Cancers: Magnetic Resonance Imaging. , 118-140.
CrossRef259
F Farace, M Gross-Goupil, E Tournay, M Taylor, N Vimond, N Jacques, F Billiot, A Mauguen, C Hill, B Escudier. (2011) Levels of circulating CD45dimCD34+VEGFR2+ progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. British Journal of Cancer 104:7, 1144-1150
CrossRef260
Naveen S. Basappa, Paul Elson, Ali-Reza Golshayan, Laura Wood, Jorge A. Garcia, Robert Dreicer, Brian I. Rini. (2011) The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer 117:6, 1183-1189
CrossRef261
Yevgeniy Balagula, Shenhong Wu, Xiao Su, Darren R. Feldman, Mario E. Lacouture. (2011) The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Investigational New Drugs
CrossRef262
J C Welti, M Gourlaouen, T Powles, S C Kudahetti, P Wilson, D M Berney, A R Reynolds. (2011) Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 30:10, 1183-1193
CrossRef263
D. Zhang, E.-M. E. Hedlund, S. Lim, F. Chen, Y. Zhang, B. Sun, Y. Cao. (2011) Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proceedings of the National Academy of Sciences 108:10, 4117-4122
CrossRef264
Eric Tartour, H. Pere, B. Maillere, M. Terme, N. Merillon, J. Taieb, F. Sandoval, F. Quintin-Colonna, K. Lacerda, A. Karadimou, C. Badoual, A. Tedgui, W. H. Fridman, S. Oudard. (2011) Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer and Metastasis Reviews 30:1, 83-95
CrossRef265
Armin Gerger, Melissa LaBonte, Heinz-Josef Lenz. (2011) Molecular Predictors of Response to Antiangiogenesis Therapies. The Cancer Journal 17:2, 134-141
CrossRef266
Nielka P. Erp, Sharyn D. Baker, Anthe S. Zandvliet, Bart A. Ploeger, Margaret Hollander, Zhaoyuan Chen, Jan Hartigh, Jacqueline M. C. König-Quartel, Henk-Jan Guchelaar, Hans Gelderblom. (2011) Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemotherapy and Pharmacology 67:3, 695-703
CrossRef267
Y. Neuzillet. (2011) Cas cliniques de cancer du rein des JOUM 2010. Progrès en Urologie 21, S27-S33
CrossRef268
Flávia Gomes de Góes Rocha, Fernanda B. Calvo, Karen C. Chaves, Jean P. S. Peron, Rodolfo F. Marques, Tânia R. de Borba, Marina S. Braga, Cleide B. Pereira, Elisabete J. Vicente, Roger Chammas, Nestor Schor, Maria H. Bellini. (2011) Endostatin- and interleukin-2-expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinoma. The Journal of Gene Medicine 13:3, 148-157
CrossRef269
M. Johannsen, M. Staehler, C.- H. Ohlmann, A. Florcken, A. Schmittel, T. Otto, A. Bex, P. Hein, K. Miller, S. Weikert, V. Grunwald. (2011) Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Annals of Oncology 22:3, 657-663
CrossRef270
Nicholas J. Hellenthal, Ahmed M. Mansour, Matthew H. Hayn, Thomas Schwaab. (2011) Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma?. Urologic Oncology: Seminars and Original Investigations
CrossRef271
Michael S Gordon. (2011) Antiangiogenic therapies: is VEGF-A inhibition alone enough?. Expert Review of Anticancer Therapy 11:3, 485-496
CrossRef272
Bruce Ruggeri. 2011. Cellular and Animal Models in Oncology and Tumor Biology. .
CrossRef273
H. R. Mellor, A. R. Bell, J.-P. Valentin, R. R. A. Roberts. (2011) Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer. Toxicological Sciences 120:1, 14-32
CrossRef274
T Powles, S Chowdhury, R Jones, M Mantle, P Nathan, A Bex, L Lim, T Hutson. (2011) Sunitinib and other targeted therapies for renal cell carcinoma. British Journal of Cancer 104:5, 741-745
CrossRef275
Amir Fathi, Mark Levis. (2011) FLT3 inhibitors: a story of the old and the new. Current Opinion in Hematology 18:2, 71-76
CrossRef276
Stavros Sfoungaristos, Konstantinos Giannitsas, Petros Perimenis. (2011) Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma. Expert Opinion on Pharmacotherapy 12:4, 533-547
CrossRef277
Sumanta Kumar Pal, Robert A. Figlin. (2011) Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Targeted Oncology 6:1, 5-16
CrossRef278
Fabio A.B. Schutz, Toni K. Choueiri, Cora N. Sternberg. (2011) Pazopanib: Clinical development of a potent anti-angiogenic drug. Critical Reviews in Oncology/Hematology 77:3, 163-171
CrossRef279
Camillo Porta, Chiara Paglino. (2011) TREATMENT OF METASTATIC RENAL CARCINOMA PATIENTS WITH THE COMBINATION OF GEMCITABINE, CAPECITABINE AND BEVACIZUMAB AT A TERTIARY CANCER CENTRE. BJU International 107:5, 747-748
CrossRef280
Dah-Shyong Yu, Szu-Yuan Ping, Chia-Lun Wu, Hong-I Chen, Sun-Yran Chang, Cheng-Ping Ma. (2011) The Feasibility of BCG and Sunitinib Combination Therapy for Transitional Cell Carcinoma. Urological Science 22:1, 19-27
CrossRef281
Michael Millward, Paul Mainwaring, Alain Mita, Kristine Federico, G. K. Lloyd, Natasha Reddinger, Steffan Nawrocki, Monica Mita, Matthew A. Spear. (2011) Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Investigational New Drugs
CrossRef282
Brian I. Rini, Mark Stein, Pat Shannon, Simantini Eddy, Allison Tyler, Joe J. Stephenson, Lorie Catlett, Bo Huang, Diane Healey, Michael Gordon. (2011) Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117:4, 758-767
CrossRef283
Lauren C. Harshman, R. James Yu, Genevera I. Allen, Sandy Srinivas, Harcharan S. Gill, Benjamin I. Chung. (2011) Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urologic Oncology: Seminars and Original Investigations
CrossRef284
S. Patil, R. A. Figlin, T. E. Hutson, M. D. Michaelson, S. Negrier, S. T. Kim, X. Huang, R. J. Motzer. (2011) Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology 22:2, 295-300
CrossRef285
Karen E. Bullock, William P. Petros, Islam Younis, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, S. Yousuf Zafar, Jon P. Gockerman, Joanne J. Lager, Roxanne Truax, Kellen L. Meadows, Leigh A. Howard, Margot M. O’Neill, Gloria Broadwater, Herbert I. Hurwitz, Johanna C. Bendell. (2011) A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemotherapy and Pharmacology 67:2, 465-474
CrossRef286
David S Finley, Frederic Pouliot, Arnold I Chin, Brian Shuch, Alan J Pantuck, Arie S Belldegrun, Jean B Dekernion. (2011) Immunological therapy in urological malignancy: Novel combination strategies. International Journal of Urology 18:2, 94-101
CrossRef287
M. Siebels, K. Rohrmann, R. Oberneder, M. Stahler, N. Haseke, J. Beck, R. Hofmann, M. Kindler, P. Kloepfer, C. Stief. (2011) A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World Journal of Urology 29:1, 121-126
CrossRef288
Ryu Kanzaki, Masahiko Higashiyama, Ayako Fujiwara, Toshiteru Tokunaga, Jun Maeda, Jiro Okami, Kazuo Nishimura, Ken Kodama. (2011) Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. European Journal of Cardio-Thoracic Surgery 39:2, 167-172
CrossRef289
Jorge A. Garcia, Tarek Mekhail, Paul Elson, Pierre Triozzi, Cheryl Nemec, Robert Dreicer, Ronald M. Bukowski, Brian I Rini. (2011) Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial. BJU International 107:4, 562-570
CrossRef290
Ágnes Benedict, Robert A. Figlin, Per Sandström, Ulrika Harmenberg, Anders Ullén, Claudie Charbonneau, Rickard Sandin, Edit Remák, Subramanian Hariharan, Sylvie Négrier. (2011) Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Internationalno-no
CrossRef291
Manuela Schmidinger, Ursula M. Vogl, Marija Bojic, Wolfgang Lamm, Harald Heinzl, Andrea Haitel, Martin Clodi, Gero Kramer, Christoph C. Zielinski. (2011) Hypothyroidism in patients with renal cell carcinoma. Cancer 117:3, 534-544
CrossRef292
M E Gore, J M G Larkin. (2011) Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. British Journal of Cancer 104:3, 399-406
CrossRef293
H. Kirchner, A.S. Merseburger. (2011) Nebenwirkungen von zielgerichteten Medikamenten bei der Behandlung des metastasierenden Nierenzellkarzinoms. Der Onkologe 17:2, 155-162
CrossRef294
Patrick A Ott, Sylvia Adams. (2011) Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy 3:2, 213-227
CrossRef295
Jose A. Karam, Brian I. Rini, Leticia Varella, Jorge A. Garcia, Robert Dreicer, Toni K. Choueiri, Eric Jonasch, Surena F. Matin, Steven C. Campbell, Christopher G. Wood, Nizar M. Tannir. (2011) Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. The Journal of Urology 185:2, 439-444
CrossRef296
Loukas Kontovinis, Konstantinos Laschos, Alexandra Karadimou, Charalambos Andreadis, Aristotelis Bamias, Panagiotis Paraskevopoulos, Meletios Dimopoulos, Konstantinos Papazisis. (2011) Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Medical Oncology
CrossRef297
N Shinohara, M Takahashi, T Kamishima, H Ikushima, N Otsuka, A Ishizu, C Shimizu, H Kanayama, K Nonomura. (2011) The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. British Journal of Cancer 104:2, 241-247
CrossRef298
A. Ocana, I. F. Tannock. (2011) When Are "Positive" Clinical Trials in Oncology Truly Positive?. JNCI Journal of the National Cancer Institute 103:1, 16-20
CrossRef299
Anthony Jarkowski, Ashley E Glode, Edward J Spangenthal, Michael K. K Wong. (2011) Heart Failure Caused by Molecularly Targeted Therapies for Cancer. Pharmacotherapy 31:1, 62-75
CrossRef300
Jesús García-Donas, Susana Hernando, Nuria Romero, Carlos Jara. (2011) Knowledge of hereditary renal cancer syndromes. Anti-Cancer Drugs 22, S15-S20
CrossRef301
Michael Staehler, Nicolas Haseke, Philipp Nuhn, Cordula Tüllmann, Alexander Karl, Michael Siebels, Christian G. Stief, Berndt Wowra, Alexander Muacevic. (2011) Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Internationalno-no
CrossRef302
Camillo Porta, Chiara Paglino, Ilaria Imarisio, Cinzia Canipari, Kristina Chen, Maureen Neary, Mei Duh. (2011) Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer 11:1, 105
CrossRef303
T. Tsukamoto, N. Shinohara, N. Tsuchiya, Y. Hamamoto, M. Maruoka, H. Fujimoto, M. Niwakawa, H. Uemura, M. Usami, A. Terai, H.-o. Kanayama, Y. Sumiyoshi, M. Eto, H. Akaza. (2011) Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1. Japanese Journal of Clinical Oncology 41:1, 17-24
CrossRef304
Johnny Kao, Eric C. Ko, Samuel Eisenstein, Andrew G. Sikora, Shibo Fu, Shu-hsia Chen. (2011) Targeting immune suppressing myeloid-derived suppressor cells in oncology. Critical Reviews in Oncology/Hematology 77:1, 12-19
CrossRef305
Yu Luo, Feng Xiao, Shijing Qian, Qiaojun He, Wei Lu, Bo Yang. (2011) Synthesis and evaluation of novel 5-sulfonyl-indolin-2-ones as potent cytotoxic agents. MedChemComm 2:11, 1054
CrossRef306
Joseph Edmund Jamal, Thomas William Jarrett. (2011) The Current Role of Lymph Node Dissection in the Management of Renal Cell Carcinoma. International Journal of Surgical Oncology 2011, 1-5
CrossRef307
Thamara J. Abouantoun, Robert C. Castellino, Tobey J. MacDonald. (2011) Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. Journal of Neuro-Oncology 101:2, 215-226
CrossRef308
Hongzheng Zhang, Sujin Yun, Thil D. Batuwangala, Michael Steward, Steve D. Holmes, Lin Pan, Mourad Tighiouart, Hyung Ju C. Shin, Lydia Koenig, Wungki Park, Daniel Rycroft, Sreenivas Nannapaneni, Yuxiang Wang, Zhuo Georgia Chen, Dong M. Shin. (2011) A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. International Journal of Cancern/a-n/a
CrossRef309
Yasuhiko Nishioka, Yoshinori Aono, Saburo Sone. (2011) Role of tyrosine kinase inhibitors in tumor immunology. Immunotherapy 3:1, 107-116
CrossRef310
Xiaoen Wang, Liang Zhang, S Nahum Goldberg, Manoj Bhasin, Victoria Brown, David C Alsop, Sabina Signoretti, James W Mier, Michael B Atkins, Rupal S Bhatt. (2011) High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. Journal of Translational Medicine 9:1, 220
CrossRef311
C Lance Cowey, Thomas E Hutson, Robert Figlin. (2011) Pazopanib in the treatment of renal cell carcinoma. Clinical Investigation 1:1, 75-85
CrossRef312
Toshiharu Sakurai, Masatoshi Kudo. (2011) Signaling Pathways Governing Tumor Angiogenesis. Oncology 81:s1, 24-29
CrossRef313
Dalsan You, In Gab Jeong, Jin-Hee Ahn, Dae Ho Lee, Jae-Lyun Lee, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim. (2011) The Value of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. The Journal of Urology 185:1, 54-59
CrossRef314
Hyo Song Kim, Min Hee Hong, Kiyeol Kim, Sang-Joon Shin, Joong-Bae Ahn, Hei Chul Jeung, Hyun Cheol Chung, Youngil Koh, Se-Hoon Lee, Yung-Jue Bang, Sun Young Rha. (2011) Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. Oncology 80:5-6, 395-405
CrossRef315
Napoleon Santos, Justin B. Wenger, Pamela Havre, Yanxia Liu, Roi Dagan, Iman Imanirad, Alison M. Ivey, Robert A. Zlotecki, Chester B. Algood, Scott M. Gilbert, Carmen J. Allegra, Paul Okunieff, Johannes Vieweg, Nam H. Dang, Hendrik Luesch, Long H. Dang. (2011) Combination Therapy for Renal Cell Cancer: What Are Possible Options?. Oncology 81:3-4, 220-229
CrossRef316
Eiji HIGAKI, Naoto GOTOHDA, Masaru KONISHI, Shinichiro TAKAHASHI, Yuichiro KATO, Taira KINOSHITA. (2011) A case of seventeen pancreatic metastases from renal cell carcinoma resected by total pancreatectomy. Suizo 26:4, 517-523
CrossRef317
Patrick Schöffski, Jorge A. Garcia, Walter M. Stadler, Thierry Gil, Eric Jonasch, Scott T. Tagawa, Melanie Smitt, Xinqun Yang, Kelly S. Oliner, Abraham Anderson, Min Zhu, Fairooz Kabbinavar. (2011) A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Internationalno-no
CrossRef318
Mary K Samplaski, Ming Zhou, Brian R Lane, Brian Herts, Steve C Campbell. (2011) Renal mass sampling: An enlightened perspective. International Journal of Urology 18:1, 5-19
CrossRef319
Simon P. Kim, Paul L. Crispen, R. Houston Thompson, Christopher J. Weight, Stephen A. Boorjian, Brian A. Costello, Christine M. Lohse, Bradley C. Leibovich. (2011) Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma. Cancern/a-n/a
CrossRef320
E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, Surena F. Matin, Pheroze Tamboli, Eric Jonasch, Christopher G. Wood. (2011) Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma. European Urology 59:1, 10-15
CrossRef321
Ana M. Molina, Darren R. Feldman, Martin H. Voss, Michelle S. Ginsberg, Michael S. Baum, Dion R. Brocks, Patricia M. Fischer, Michael J. Trinos, Sujata Patil, Robert J. Motzer. (2011) Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancern/a-n/a
CrossRef322
Martin W Hoyle, William Henley. (2011) Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Medical Research Methodology 11:1, 139
CrossRef323
Aymen A Elfiky, Saadia A Aziz, Patricia J Conrad, Summar Siddiqui, Wolfgang Hackl, Michel Maira, Camp L Robert, Harriet M Kluger. (2011) Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. Journal of Translational Medicine 9:1, 133
CrossRef324
Jonas Busch, Christoph Seidel, Steffen Weikert, Ingmar Wolff, Carsten Kempkensteffen, Lisa Weinkauf, Stefan Hinz, Ahmed Magheli, Kurt Miller, Viktor Grünwald. (2011) Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer 11:1, 295
CrossRef325
G. Roubaud, M. Gross-Goupil, H. Wallerand, H. de Clermont, M.S. Dilhuydy, A. Ravaud. (2011) Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma. Oncology 80:3-4, 214-218
CrossRef326
Yves Allory, Stéphane Culine, Alexandre de la Taille. (2011) Kidney Cancer Pathology in the New Context of Targeted Therapy. Pathobiology 78:2, 90-98
CrossRef327
Manabu Tatokoro, Yasuhisa Fujii, Satoru Kawakami, Kazutaka Saito, Fumitaka Koga, Yoh Matsuoka, Yasumasa Iimura, Hitoshi Masuda, Kazunori Kihara. (2011) Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Science 102:1, 137-143
CrossRef328
Sergio Bracarda, Joaquim Bellmunt, Bohuslav Melichar, Sylvie Négrier, Emilio Bajetta, Alain Ravaud, Vesna Sneller, Bernard Escudier. (2011) Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU International 107:2, 214-219
CrossRef329
Guadalupe Aparicio-Gallego, Francisco J. Afonso-Afonso, Luis León-Mateos, Jose L. Fírvida-Pérez, Sergio Vázquez-Estévez, Martín Lázaro-Quintela, Manuel Ramos-Vázquez, Ovidio Fernández-Calvo, Begoña Campos-Balea, Luis M. Antón-Aparicio. (2011) Molecular basis of hypertension side effects induced by sunitinib. Anti-Cancer Drugs 22:1, 1-8
CrossRef330
Michael Grundbichler, Brigitte Mlineritsch, Sigrun Ressler, Martin Moik, Andrea Kappacher, Sabine Rosenlechner, Richard Greil. (2011) Efficacy of Temsirolimus after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer. Oncology 80:1-2, 34-41
CrossRef331
Krisztian Homicsko, Dominik R. Berthold. (2011) Neoadjuvant and adjuvant strategies in renal cell carcinoma. Anti-Cancer Drugs 22, S4-S8
CrossRef332
Carlos H. Barrios, David Hernandez-Barajas, Michael P. Brown, Se-Hoon Lee, Luis Fein, Jin-Hwang Liu, Subramanian Hariharan, Bridget A. Martell, Jinyu Yuan, Akintunde Bello, Zhixiao Wang, Rajiv Mundayat, Sun-Young Rha. (2011) Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancern/a-n/a
CrossRef333
Azusa HOSHINO-YOSHINO, Motohiro KATO, Kohnosuke NAKANO, Masaki ISHIGAI, Toshiyuki KUDO, Kiyomi ITO. (2011) Bridging from Preclinical to Clinical Studies for Tyrosine Kinase Inhibitors Based on Pharmacokinetics/Pharmacodynamics and Toxicokinetics/Toxicodynamics. Drug Metabolism and Pharmacokinetics 26:6, 612-620
CrossRef334
Tobias Klatte, Jonathan W. Said, David B. Seligson, P. Nagesh Rao, Michela de Martino, Brian Shuch, Nazy Zomorodian, Fairooz F. Kabbinavar, Arie S. Belldegrun, Allan J. Pantuck. (2011) Pathological, Immunohistochemical and Cytogenetic Features of Papillary Renal Cell Carcinoma With Clear Cell Features. The Journal of Urology 185:1, 30-36
CrossRef335
M. Dror Michaelson. (2011) Combination of targeted agents in metastatic renal cell carcinoma. Cancern/a-n/a
CrossRef336
Arnt F.A. Schellekens, Sasja F. Mulder, Philip F.P. van Eijndhoven, Tineke J. Smilde, Carla M.L. van Herpen. (2011) Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases. General Hospital Psychiatry 33:1, 83.e1-83.e3
CrossRef337
Henry Chow, Adam Jung, Jason Talbott, Amy M. Lin, Adil I. Daud, Fergus V. Coakley. (2011) Tumor Fistulization Associated With Targeted Therapy. Journal of Computer Assisted Tomography 35:1, 86-90
CrossRef338
Kumiko Matsumoto, Akihiko Yokohama, Akinori Yuzuriha, Kohtarou Toyama, Takeki Mitsui, Yoko Hashimoto, Hiromi Koiso, Takayuki Saitoh, Hideki Uchiumi, Hiroshi Handa, Masamitsu Karasawa, Hirokazu Murakami, Hiroshi Matsui, Kazuhiro Suzuki, Norifumi Tsukamoto, Yoshihisa Nojima. (2011) Sunitinib Induced Immune Thrombocytopenia. The Kitakanto Medical Journal 61:2, 175-177
CrossRef339
Astrid A.M. van der Veldt, Laura Vroling, Richard R. de Haas, Pieter Koolwijk, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, Victor W.M. van Hinsbergh, Henk J. Broxterman, Epie Boven. (2011) Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. International Journal of Cancern/a-n/a
CrossRef340
M. J. MacKenzie, B. I. Rini, P. Elson, A. Schwandt, L. Wood, M. Trinkhaus, G. Bjarnason, J. Knox. (2011) Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Annals of Oncology 22:1, 145-148
CrossRef341
Ignacio Durán. (2011) Renal cell cancer. Anti-Cancer Drugs 22, S1-S3
CrossRef342
Shintaro Tomita, Kei Ishibashi, Koichi Hashimoto, Takashi Sugino, Tomohiko Yanagida, Nobuhiro Kushida, Keiichi Shishido, Ken Aikawa, Yuka Sato, Tatsuo Suzutani, Osamu Yamaguchi. (2011) Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-α. Cancer Science 102:1, 57-63
CrossRef343
Cristina Suarez, Brian I. Rini. (2011) Determining the optimal dose and schedule of sunitinib. Cancern/a-n/a
CrossRef344
Jodi M. Saunus, Majid Momeny, Peter T. Simpson, Sunil R. Lakhani, Leonard Da Silva. (2011) Molecular Aspects of Breast Cancer Metastasis to the Brain. Genetics Research International 2011, 1-9
CrossRef345
Thomas Powles, Simon Chowdhury, Mark Bower, Nataile Saunders, Louise Lim, Jonathan Shamash, Naveed Sarwar, Anju Sadev, John Peters, James Green, Katia Boleti, Samir Augwal. (2011) The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer. Urologia Internationalis 86:1, 53-59
CrossRef346
Naveen S. Vasudev, Rosamonde E. Banks. 2011. Biomarkers of Renal Cancer. , 313-350.
CrossRef347
Justine Yang Bruce, Jens Eickhoff, Roberto Pili, Theodore Logan, Michael Carducci, Jamie Arnott, Anthony Treston, George Wilding, Glenn Liu. (2010) A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Investigational New Drugs
CrossRef348
Tadaaki Yamada, Koushiro Ohtsubo, Kouji Izumi, Shinji Takeuchi, Hisatsugu Mouri, Kaname Yamashita, Kazuo Yasumoto, Peter Ghenev, Satoshi Kitagawa, Seiji Yano. (2010) Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. International Journal of Clinical Oncology 15:6, 638-641
CrossRef349
Martina Walter, Christian Heinze, Thomas Steiner, Rico Pilchowski, Ferdinand von Eggeling, Heiko Wunderlich, Kerstin Junker. (2010) Immunochemotherapy-associated protein patterns in tumour tissue and serum of patients with metastatic renal cell carcinoma. Archives Of Physiology And Biochemistry 116:4-5, 197-207
CrossRef350
Jorge A. Garcia, Thomas E. Hutson, Paul Elson, C. Lance Cowey, Timothy Gilligan, Cheryl Nemec, Robert Dreicer, Ronald M. Bukowski, Brian I. Rini. (2010) Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 116:23, 5383-5390
CrossRef351
Ario Takeuchi, Masatoshi Eto, Katsunori Tatsugami, Hisakata Yamada, Toshihiro Oki, Keijiro Kiyoshima, Yasunobu Yoshikai, Seiji Naito. (2010) Mechanism of Synergistic Antitumor Effect of Sorafenib and Interferon-α on Treatment of Renal Cell Carcinoma. The Journal of Urology 184:6, 2549-2556
CrossRef352
Krisztina Biró, Zsófia Küronya. (2010) Az előrehaladott vesedaganat kezelésének újabb lehetőségei a nemzetközi ajánlások tükrében. Magyar Onkológia 54:4, 369-376
CrossRef353
Ryogo Minamimoto, Noboru Nakaigawa, Ukihide Tateishi, Akiko Suzuki, Kazuya Shizukuishi, Takeshi Kishida, Takeshi Miura, Kazuhide Makiyama, Masahiro Yao, Yoshinobu Kubota, Tomio Inoue. (2010) Evaluation of Response to Multikinase Inhibitor in Metastatic Renal Cell Carcinoma by FDG PET/Contrast-Enhanced CT. Clinical Nuclear Medicine 35:12, 918-923
CrossRef354
Nicola Maurea, Carmela Coppola, Gianluca Ragone, Giuseppe Frasci, Annamaria Bonelli, Carmela Romano, Rosario Vincenzo Iaffaioli. (2010) Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. Journal of Cardiovascular Medicine 11:12, 861-868
CrossRef355
Filippo Spreafico, Paola Collini, Monica Terenziani, Alfonso Marchianò, Luigi Piva. (2010) Renal cell carcinoma in children and adolescents. Expert Review of Anticancer Therapy 10:12, 1967-1978
CrossRef356
G. Maarten-Friso Ruinemans, Corinne Balemans, Vera Mattijssen, Anne J. Wiersma-van Tilburg, Hans J.M. Smit. (2010) Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib. Lung Cancer 70:3, 364-365
CrossRef357
Christos S. Georgiades, Ronald Rodriguez, Peter J. Littrup, Constantine E. Frangakis, Raymond Leveille, Kamran Ahrar, Thomas D. Atwell, Jeffrey Cadeddu, Clayton Trimmer, Jeremy C. Durack, Hans-Joerg Hammers, Maxwell V. Meng, Steven Raman, Stephen B. Solomon, Ronald J. Zagoria, Gordon McLennan, Jeanne M. LaBerge, Debra A. Gervais, Stephen T. Kee. (2010) Development of a Research Agenda for Percutaneous Renal Tumor Ablation: Proceedings from a Multidisciplinary Research Consensus Panel. Journal of Vascular and Interventional Radiology 21:12, 1807-1816
CrossRef358
Martin Augsten, Christina Hägglöf, Cristina Peña, Arne Östman. (2010) A Digest on the Role of the Tumor Microenvironment in Gastrointestinal Cancers. Cancer Microenvironment 3:1, 167-176
CrossRef359
T. Kondo, Y. Hashimoto, H. Kobayashi, J. Iizuka, T. Nishikawa, M. Nakano, K. Tanabe. (2010) Presurgical Targeted Therapy with Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma: Clinical Results and Histopathological Therapeutic Effects. Japanese Journal of Clinical Oncology 40:12, 1173-1179
CrossRef360
Martin Reck. (2010) Examining the safety profile of angiogenesis inhibitors: implications for clinical practice. Targeted Oncology 5:4, 257-267
CrossRef361
Ivan N. Zama, Thomas E. Hutson, Paul Elson, James M. Cleary, Toni K. Choueiri, Daniel Y.C. Heng, Nikhil Ramaiya, M. Dror Michaelson, Jorge A. Garcia, Jennifer J. Knox, Bernard Escudier, Brian I. Rini. (2010) Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116:23, 5400-5406
CrossRef362
Hitomi Nagayama, Kazufumi Matsumoto, Naoyuki Isoo, Hideki Ohno, Naoyuki Takahashi, Takashi Nakaoka, Masaru Shinozaki, Makoto Watanabe, Yusuke Inoue, Fumitaka Nagamura, Naoki Oyaizu, Naohide Yamashita. (2010) Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clinical Journal of Gastroenterology 3:6, 307-317
CrossRef363
Tait Shanafelt, Clive Zent, John Byrd, Charles Erlichman, Betsy Laplant, Asish Ghosh, Timothy Call, Miguel Villalona-Calero, Diane Jelinek, Deborah Bowen, Kristina Laumann, Wenting Wu, Curtis Hanson, Neil Kay. (2010) Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 51:12, 2222-2229
CrossRef364
Gopa Iyer, Matthew I Milowsky, Dean F Bajorin. (2010) Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Review of Anticancer Therapy 10:12, 1917-1932
CrossRef365
Ilse Roodink, William P.J. Leenders. (2010) Targeted therapies of cancer: Angiogenesis inhibition seems not enough. Cancer Letters 299:1, 1-10
CrossRef366
Eric Jonasch, Lance C Pagliaro, Nizar M Tannir. (2010) Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Review of Anticancer Therapy 10:12, 1883-1889
CrossRef367
J. C. Soria, C. Massard, T. Le Chevalier. (2010) Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Annals of Oncology 21:12, 2324-2332
CrossRef368
A. Trabelsi, O. Gharbi, A. Gaieb, M. Mokni, L. Jaidane, B. Sriha, S. Korbi. (2010) Carcinome papillaire du rein: étude rétrospective à propos de six cas. Oncologie 12:S1, 40-44
CrossRef369
Axel Bex, Eric Jonasch, Ziya Kirkali, Arnaud Mejean, Peter Mulders, Stephane Oudard, Jean-Jacques Patard, Thomas Powles, Hendrik van Poppel, Christopher G Wood. (2010) Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. European Urology 58:6, 819-828
CrossRef370
T Dolley-Hitze, F Jouan, B Martin, S Mottier, J Edeline, O Moranne, P Le Pogamp, M-A Belaud-Rotureau, J-J Patard, N Rioux-Leclercq, C Vigneau. (2010) Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?. British Journal of Cancer 103:11, 1698-1705
CrossRef371
Dok Hyun Yoon, Min-Hee Ryu, Baek-Yeol Ryoo, Moyeol Beck, Dae Ro Choi, Yoojin Cho, Jae-Lyun Lee, Heung-Moon Chang, Tae Won Kim, Yoon-Koo Kang. (2010) Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Investigational New Drugs
CrossRef372
Ming-Mo Hou, Jia-Juan Hsieh, Nai-Jen Chang, Hsuan-Ying Huang, Hung-Ming Wang, Cheng-Keng Chuang, Todd Hsu, John Wen-Cheng Chang. (2010) Response to Sorafenib in a Patient with Metastatic Xp11 Translocation Renal Cell Carcinoma. Clinical Drug Investigation 30:11, 799-804
CrossRef373
Hauke Winter, Georgios Meimarakis, Martin K. Angele, Manuela Hummel, Michael Staehler, Ralf-Thorsten Hoffmann, Rudolf A. Hatz, Florian Löhe. (2010) Tumor Infiltrated Hilar and Mediastinal Lymph Nodes are an Independent Prognostic Factor for Decreased Survival After Pulmonary Metastasectomy in Patients With Renal Cell Carcinoma. The Journal of Urology 184:5, 1888-1894
CrossRef374
R. Goodwin, K. Ding, L. Seymour, A. LeMaitre, A. Arnold, F. A. Shepherd, M. Dediu, T. Ciuleanu, D. Fenton, M. Zukin, D. Walde, F. Laberge, M. Vincent, P. M. Ellis, S. A. Laurie, . (2010) Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Annals of Oncology 21:11, 2220-2226
CrossRef375
Nicole A. Johnson, Bing-Hung Chen, Shian-Ying Sung, Chia-Hui Liao, Wan-Chi Hsiao, Leland W. K. Chung, Chia-Ling Hsieh. (2010) A novel targeting modality for renal cell carcinoma: human osteocalcin promoter-mediated gene therapy synergistically induced by vitamin C and vitamin D3. The Journal of Gene Medicine 12:11, 892-903
CrossRef376
Manfred Johannsen, Gianluca Spitaleri, Giuseppe Curigliano, Jan Roigas, Steffen Weikert, Carsten Kempkensteffen, Andreas Roemer, Christian Kloeters, Patrik Rogalla, Gabriele Pecher, Kurt Miller, Alexander Berndt, Hartwig Kosmehl, Eveline Trachsel, Manuela Kaspar, Valeria Lovato, Reinerio González-Iglesias, Leonardo Giovannoni, Hans D. Menssen, Dario Neri, Filippo de Braud. (2010) The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. European Journal of Cancer 46:16, 2926-2935
CrossRef377
Seiji Naito, Taiji Tsukamoto, Michiyuki Usami, Hiroyuki Fujimoto, Hideyuki Akaza. (2010) An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology 66:6, 1065-1070
CrossRef378
Olivier Adotevi, Helene Pere, Patrice Ravel, Nacilla Haicheur, Cecile Badoual, Nathalie Merillon, Jacques Medioni, Severine Peyrard, Stephane Roncelin, Virginie Verkarre, Arnaud Mejean, Wolf H. Fridman, Stephane Oudard, Eric Tartour. (2010) A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients. Journal of Immunotherapy 33:9, 991-998
CrossRef379
Juan Barbastefano, Jorge A. Garcia, Paul Elson, Laura S. Wood, Brian R. Lane, Robert Dreicer, Steven C. Campbell, Brian I. Rini. (2010) Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU International 106:9, 1266-1269
CrossRef380
A.E. HUGHES, S. GORNELL, P. FISCHER, S. HUGHES. (2010) The management of kidney cancer. European Journal of Cancer Care 19:6, 706-706
CrossRef381
Jerry C Wu, Keola K Beale, Joseph D Ma. (2010) Evaluation of current and upcoming therapies in oral mucositis prevention. Future Oncology 6:11, 1751-1770
CrossRef382
Jonathan L. Silberstein, Frederick Millard, Reza Mehrazin, Ryan Kopp, Wassim Bazzi, Christopher J. DiBlasio, Anthony L. Patterson, Tracy M. Downs, Furhan Yunus, Christopher J. Kane, Ithaar H. Derweesh. (2010) Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU International 106:9, 1270-1276
CrossRef383
G. Di Lorenzo, C. Buonerba, M. Biglietto, F. Scognamiglio, B. Chiurazzi, F. Riccardi, G. Cartenì. (2010) The therapy of kidney cancer with biomolecular drugs. Cancer Treatment Reviews 36, S16-S20
CrossRef384
Fausto Petrelli, Mary Cabiddu, Marinella Carpo, Mara Ghilardi, Sandro Barni. (2010) Progression of intramedullary metastasis during perioperative cessation of sunitinib. Nature Reviews Urology 7:11, 634-637
CrossRef385
Isamu Okamoto, Toshio Shimizu, Masaki Miyazaki, Junji Tsurutani, Yasuko Ichikawa, Masaki Terashima, Masayuki Takeda, Soichi Fumita, Emiko Ohki, Nobuyuki Kimura, Junichi Hashimoto, Kazuhiko Nakagawa. (2010) Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Investigational New Drugs
CrossRef386
J-F Rossi, S Négrier, N D James, I Kocak, R Hawkins, H Davis, U Prabhakar, X Qin, P Mulders, B Berns. (2010) A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. British Journal of Cancer 103:8, 1154-1162
CrossRef387
G H J Mickisch, B Escudier, S Walzer, M Nuijten. (2010) Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. British Journal of Cancer 103:8, 1309-1310
CrossRef388
Stephane Ederhy, Christophe Massard, Ghislaine Dufaitre, Ratio Balheda, Catherine Meuleman, Carlos Gomez Rocca, Hassane Izzedine, Ariel Cohen, Jean-Charles Soria. (2010) Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials. Investigational New Drugs
CrossRef389
Przemyslaw Twardowski, Walter M. Stadler, Paul Frankel, Primo N. Lara, Christopher Ruel, Gurkamal Chatta, Elisabeth Heath, David I. Quinn, David R. Gandara. (2010) Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial. Urology 76:4, 923-926
CrossRef390
David J. Gallagher, Andrew Feifer, Jonathan A. Coleman. (2010) Genitourinary Cancer Predisposition Syndromes. Hematology/Oncology Clinics of North America 24:5, 861-883
CrossRef391
Robert Goldstein, Lisa Pickering, James Larkin. (2010) Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. Expert Review of Anticancer Therapy 10:10, 1545-1557
CrossRef392
Yihai Cao. (2010) Off-tumor target—beneficial site for antiangiogenic cancer therapy?. Nature Reviews Clinical Oncology 7:10, 604-608
CrossRef393
C. Yoo, J. E. Kim, J.-L. Lee, J.-H. Ahn, D. H. Lee, J.-S. Lee, S. Na, C.-S. Kim, J. H. Hong, B. Hong, C. Song, H. Ahn. (2010) The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction. Japanese Journal of Clinical Oncology 40:10, 980-985
CrossRef394
Kenya Yamaguchi, Nozomu Kawata, Yusuke Nagane, Hiroshi Igarashi, Shuji Sugimoto, Hitoshi Hirakata, Satoru Takahashi, Tokio Higaki. (2010) Metastasectomy for renal cell carcinoma as a strategy to obtain complete remission. International Journal of Clinical Oncology 15:5, 519-522
CrossRef395
Cristina Grávalos, Enrique Grande, Joan Manel Gasent. (2010) The potential role of sunitinib in gastrointestinal cancers other than GIST. Critical Reviews in Oncology/Hematology 76:1, 36-43
CrossRef396
I. Brana, J. Tabernero. (2010) Cardiotoxicity. Annals of Oncology 21:Supplement 7, vii173-vii179
CrossRef397
Debra Meerkotter, John De Sousa, Joanna Wright, Sue Gelston. (2010) Unusual presentation of a renal cell carcinoma. European Journal of Radiology Extra 76:1, e27-e30
CrossRef398
Efstathia Giannopoulou, Konstantinos Dimitropoulos, Andreas A. Argyriou, Angelos K. Koutras, Fotinos Dimitrakopoulos, Haralabos P. Kalofonos. (2010) An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. Investigational New Drugs 28:5, 554-560
CrossRef399
P. Guyot-Caquelin, F. Granel-Brocard, J.-F. Cuny, P. Trechot, D. Spaeth, A. Marchal, A. Barbaud, J.-L. Schmutz. (2010) Ulcérations des membres inférieurs sous sunitinib. Annales de Dermatologie et de Vénéréologie 137:10, 626-629
CrossRef400
William G. Kaelin Jr.. (2010) New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Annals of the New York Academy of Sciences 1210:1, 1-7
CrossRef401
Nicholas W. Choong, Mark Kozloff, David Taber, H. Shawn Hu, James Wade, Percy Ivy, Theodore G. Karrison, Allison Dekker, Everett E. Vokes, Ezra E. W. Cohen. (2010) Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Investigational New Drugs 28:5, 677-683
CrossRef402
Steven E. Finkelstein, Timothy Carey, Ingo Fricke, Daohai Yu, Dawn Goetz, Megan Gratz, Mary Dunn, Patricia Urbas, Adil Daud, Ronald DeConti, Scott Antonia, Dmitry Gabrilovich, Mayer Fishman. (2010) Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma. Journal of Immunotherapy 33:8, 817-827
CrossRef403
Michael Friedlander, Kenneth C. Hancock, Danny Rischin, Mark J. Messing, Claude A. Stringer, Gemma M. Matthys, Bo Ma, Jeffrey P. Hodge, Joanne J. Lager. (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic Oncology 119:1, 32-37
CrossRef404
Steven E. Canfield, Shahnaz Sultan, Philipp Dahm. (2010) Evidence-based urology in practice: randomized controlled trials stopped early for benefit. BJU International 106:7, 962-963
CrossRef405
B. Escudier, L. Albiges, A. Blesius, Y. Loriot, C. Massard, K. Fizazi. (2010) How to select targeted therapy in renal cell cancer. Annals of Oncology 21:Supplement 7, vii59-vii62
CrossRef406
Judith Michels, Nathalie Lassau, Marine Gross-Goupil, Christophe Massard, Arnaud Mejean, Bernard Escudier. (2010) Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Investigational New Drugs 28:5, 690-693
CrossRef407
Miguel Quintela-Fandino, Antonio González-Martín, Ramon Colomer. (2010) Targeting cytoskeleton reorganisation as antimetastatic treatment. Clinical and Translational Oncology 12:10, 662-669
CrossRef408
M.W. Kramer, S. Krege, I. Peters, A.S. Merseburger, M.A. Kuczyk. (2010) Die Target-Therapie urologischer Tumoren. Der Urologe 49:10, 1260-1265
CrossRef409
Y Zhang, X Jiang, X Qin, D Ye, Z Yi, M Liu, O Bai, W Liu, X Xie, Z Wang, J Fang, Y Chen. (2010) RKTG inhibits angiogenesis by suppressing MAPK-mediated autocrine VEGF signaling and is downregulated in clear-cell renal cell carcinoma. Oncogene 29:39, 5404-5415
CrossRef410
E Boven, C Massard, J P Armand, C Tillier, V Hartog, N M Brega, A M Countouriotis, A Ruiz-Garcia, J C Soria. (2010) A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. British Journal of Cancer 103:7, 993-1000
CrossRef411
Robert J. Motzer, Bernard Escudier, Stephane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Andrea Kay, Alain Ravaud. (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer 116:18, 4256-4265
CrossRef412
T W Flaig, L J Costa, D L Gustafson, K Breaker, M K Schultz, F Crighton, F J Kim, H Drabkin. (2010) Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. British Journal of Cancer 103:6, 796-801
CrossRef413
Isabelle Chabot, Angela Rocchi. (2010) How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma. Value in Health 13:6, 837-845
CrossRef414
G. G. Malouf, P. Camparo, S. Oudard, G. Schleiermacher, C. Theodore, A. Rustine, J. Dutcher, B. Billemont, O. Rixe, E. Bompas, A. Guillot, L. Boccon-Gibod, J. Couturier, V. Molinie, B. Escudier. (2010) Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Annals of Oncology 21:9, 1834-1838
CrossRef415
Eddie Fridman, Zohar Dotan, Iris Barshack, Miriam Ben David, Avital Dov, Sarit Tabak, Orit Zion, Sima Benjamin, Hila Benjamin, Hagit Kuker, Camila Avivi, Kinneret Rosenblatt, Sylvie Polak-Charcon, Jacob Ramon, Nitzan Rosenfeld, Yael Spector. (2010) Accurate Molecular Classification of Renal Tumors Using MicroRNA Expression. The Journal of Molecular Diagnostics 12:5, 687-696
CrossRef416
Halit Karaca, Ayhan Lale, Mustafa Dikilitas, Metin Ozkan, Ozlem Er. (2010) Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature. Medical Oncology 27:3, 1023-1026
CrossRef417
Deborah Mukherji, James Larkin, Lisa Pickering. (2010) Sunitinib for metastatic renal cell carcinoma. Future Oncology 6:9, 1377-1385
CrossRef418
Rodney H Breau, Michael L Blute. (2010) Surgery for renal cell carcinoma metastases. Current Opinion in Urology 20:5, 375-381
CrossRef419
Agnieszka Michael, Kate Relph, Hardev Pandha. (2010) Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents. International Journal of Cancer 127:6, 1251-1258
CrossRef420
Nicholas J. Hellenthal, Willie Underwood, Remedios Penetrante, Alan Litwin, Shaozeng Zhang, Gregory E. Wilding, Bin T. Teh, Hyung L. Kim. (2010) Prospective Clinical Trial of Preoperative Sunitinib in Patients With Renal Cell Carcinoma. The Journal of Urology 184:3, 859-864
CrossRef421
Takeshi Ueda, Yusuke Imamura, Atsushi Komaru, Satoshi Fukasawa, Tomokazu Sazuka, Takahito Suyama, Yukio Naya, Naoki Nihei, Tomohiko Ichikawa, Masayuki Maruoka. (2010) Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. International Journal of Urology 17:9, 811-815
CrossRef422
Toni K. Choueiri, Meredith M. Regan, Jonathan E. Rosenberg, William K. Oh, Jessica Clement, Angela M. Amato, David McDermott, Daniel C. Cho, Michael B. Atkins, Sabina Signoretti. (2010) Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU International 106:6, 772-778
CrossRef423
Sebastiano Buti, Silvia Lazzarelli, Matteo Dalla Chiesa, Cecilia Simonelli, Giovanni Lo Re, Arvin Lheshi, Spazzapan Simon, Rodolfo Mattioli, Caterina Caminiti, Giancarlo Mazza, Maddalena Donini, Rodolfo Passalacqua. (2010) Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study. Journal of Immunotherapy 33:7, 735-741
CrossRef424
Frédéric Pouliot, Brian Shuch, Jeffrey C. LaRochelle, Allan Pantuck, Arie S. Belldegrun. (2010) Contemporary Management of Renal Tumors With Venous Tumor Thrombus. The Journal of Urology 184:3, 833-841
CrossRef425
Michael Staehler, Nicolas Haseke, Thomas Stadler, Philipp Nuhn, Alexander Roosen, Christian G. Stief, Ralf Wilkowski. (2010) Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. Urologic Oncology: Seminars and Original Investigations
CrossRef426
Flávia Gomes Góes Rocha, Karen Cristina Barbosa Chaves, Roger Chammas, Jean Pierre Schatzmann Peron, Luiz Vicente Rizzo, Nestor Schor, Maria Helena Bellini. (2010) Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice. Cancer Immunology, Immunotherapy 59:9, 1357-1365
CrossRef427
Priscilla K. Brastianos, Tracy T. Batchelor. (2010) Vascular endothelial growth factor inhibitors in malignant gliomas. Targeted Oncology 5:3, 167-174
CrossRef428
Thomas E. Hutson, Joaquim Bellmunt, Camillo Porta, Cezary Szczylik, Michael Staehler, Andrea Nadel, Sibyl Anderson, Ronald Bukowski, Tim Eisen, Bernard Escudier. (2010) Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET. European Journal of Cancer 46:13, 2432-2440
CrossRef429
Janakiraman Subramanian, Daniel Morgensztern, Ramaswamy Govindan. (2010) Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:5, 311-319
CrossRef430
Rita Graça da Silva, Bernardo Tavora, Stephen D. Robinson, Louise E. Reynolds, Charles Szekeres, John Lamar, Sílvia Batista, Vassiliki Kostourou, Mitchel A. Germain, Andrew R. Reynolds, Dylan T. Jones, Alan R. Watson, Janet L. Jones, Adrian Harris, Ian R. Hart, M. Luisa Iruela-Arispe, C. Michael DiPersio, Jordan A. Kreidberg, Kairbaan M. Hodivala-Dilke. (2010) Endothelial α3β1-Integrin Represses Pathological Angiogenesis and Sustains Endothelial-VEGF. The American Journal of Pathology 177:3, 1534-1548
CrossRef431
Francisco Robert, Alan Sandler, Joan H. Schiller, Glenn Liu, Karen Harper, Lev Verkh, Xin Huang, Jennifer Ilagan, Lesley Tye, Richard Chao, Anne M. Traynor. (2010) Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemotherapy and Pharmacology 66:4, 669-680
CrossRef432
R. Kirkdale, J. Krell, C. O'Hanlon Brown, M. Tuthill, J. Waxman. (2010) The cost of a QALY. QJM 103:9, 715-720
CrossRef433
Manuela Schmidinger, Dirk Arnold, Cezary Szczylik, John Wagstaff, Alain Ravaud. (2010) Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice. Cancer Investigation 28:8, 856-864
CrossRef434
Maxine Sun, Shahrokh F Shariat, Pierre I Karakiewicz. (2010) Factors affecting outcome in renal cell carcinoma. Current Opinion in Urology 20:5, 355-360
CrossRef435
Giuseppe Curigliano, Erica L. Mayer, Harold J. Burstein, Eric P. Winer, Aron Goldhirsch. (2010) Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress in Cardiovascular Diseases 53:2, 94-104
CrossRef436
S. Naito, Y. Tomita, S. Y. Rha, H. Uemura, M. Oya, H. Z. Song, L. H. Zhong, M. I. B. A. Wahid. (2010) Kidney Cancer Working Group Report. Japanese Journal of Clinical Oncology 40:Supplement 1, i51-i56
CrossRef437
Szu-Yuan Ping, Chia-Lun Wu, Dah-Shyong Yu. (2010) Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway
. Urologic Oncology: Seminars and Original Investigations
CrossRef438
Adnan R. Khan, Simon J. Dovedi, Robert W. Wilkinson, David I. Pritchard. (2010) Tumor Infiltrating Regulatory T Cells: Tractable Targets for Immunotherapy. International Reviews of Immunology 29:5, 461-484
CrossRef439
H. Wildiers, C. Fontaine, P. Vuylsteke, M. Martens, J. L. Canon, W. Wynendaele, C. Focan, J. Greve, P. Squifflet, R. Paridaens. (2010) Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment 123:2, 463-469
CrossRef440
N P van Erp, R H J Mathijssen, A A van der Veldt, J B Haanen, A K L Reyners, K Eechoute, E Boven, J A M Wessels, H-J Guchelaar, H Gelderblom. (2010) Myelosuppression by sunitinib is flt-3 genotype dependent. British Journal of Cancer 103:5, 757-758
CrossRef441
S. I. Pascu, R. L. Arrowsmith, S. R. Bayly, S. Brayshaw, Z. Hu. (2010) Towards nanomedicines: design protocols to assemble, visualize and test carbon nanotube probes for multi-modality biomedical imaging. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences 368:1924, 3683-3712
CrossRef442
Tao QIAN, Li-ping LIN, Wen-jun CHANG, Ting-hu CAO, Xing-xing XU, Yin-hui YANG, Hong-wei ZHANG, Jian-guo HOU, Guang-wen CAO. (2010) Types of alternative splice variants of transcription factor 19 and their expression patterns in clear cell renal cell carcinoma tissues. Academic Journal of Second Military Medical University 30:7, 706-710
CrossRef443
S S Tykodi, L N Voong, E H Warren. (2010) Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma. Bone Marrow Transplantation 45:8, 1360-1362
CrossRef444
Darren R. Feldman, Stefan Turkula, Michelle S. Ginsberg, Nicole Ishill, Sujata Patil, Maryann Carousso, George J. Bosl, Robert J. Motzer. (2010) Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Investigational New Drugs 28:4, 523-528
CrossRef445
Hiu-yan Chan, Ashley B. Grossman, Ronald M. Bukowski. (2010) Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Advances in Therapy 27:8, 495-511
CrossRef446
GERMAINE WONG, KIRSTEN HOWARD, JONATHAN C CRAIG. (2010) Clinical Research for Nephrologists: Economic evaluation in clinical nephrology: Part 2. Applying economic evaluations in clinical nephrology. Nephrology 15:5, 533-539
CrossRef447
Emiliano Calvo, Pablo Maroto, Xavier García Muro, Miguel Ángel Climent, José Luis González-Larriba, Emilio Esteban, Rafael López, Luis Paz-Ares, Joaquim Bellmunt, Daniel Castellano. (2010) Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer and Metastasis Reviews 29:S1, 1-10
CrossRef448
Michael M. Vickers, Toni K. Choueiri, Miranda Rogers, Andrew Percy, Daygen Finch, Ivan Zama, Tina Cheng, Scott North, Jennifer J. Knox, Christian Kollmannsberger, David F. McDermott, Brian I. Rini, Daniel Y. Heng. (2010) Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. Urology 76:2, 430-434
CrossRef449
Emiliano Calvo, Pablo Maroto, Xavier García Muro, Miguel Ángel Climent, José Luis González-Larriba, Emilio Esteban, Rafael López, Luis Paz-Ares, Joaquim Bellmunt, Daniel Castellano. (2010) Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer and Metastasis Reviews 29:S1, 11-20
CrossRef450
Thomas Powles, Rob Jones, Simon Chowdhury, Jonathan Shamash, Mark Mantle, Louise Lim, Tom Hutson. (2010) THE APPLICATION OF THE NATIONAL INSTITUTE OF CLINICAL EXCELLENCE GUIDELINES FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN THE UNITED KINGDOM: FRIEND OR FOE?. BJU International 106:4, 453-457
CrossRef451
Sander R. Piersma, Mariette Labots, Henk M. W. Verheul, Connie R. Jiménez. (2010) Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. Analytical and Bioanalytical Chemistry 397:8, 3163-3171
CrossRef452
James Larkin, Martin Gore. (2010) Is advanced renal cell carcinoma becoming a chronic disease?. The Lancet 376:9741, 574-575
CrossRef453
G. Khan, A. Golshayan, P. Elson, L. Wood, J. Garcia, R. Bukowski, B. Rini. (2010) Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Annals of Oncology 21:8, 1618-1622
CrossRef454
F. M. Iwamoto, K. R. Lamborn, H. I. Robins, M. P. Mehta, S. M. Chang, N. A. Butowski, L. M. DeAngelis, L. E. Abrey, W.-T. Zhang, M. D. Prados, H. A. Fine. (2010) Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncology 12:8, 855-861
CrossRef455
Carolina Muriel, Emilio Esteban, Norberto Corral, Paula J. Fonseca, María Luque, José Pablo Berros, Yolanda Fernández, Pilar Blay, Joaquín Fra, Noemí Villanueva, Miguel Sanmamed, Pablo Pardo, Marta Izquierdo, José María Vieitez, Enrique Estrada, Ángel J. Lacave. (2010) Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. Clinical and Translational Oncology 12:8, 562-567
CrossRef456
Timo Purmonen, Päivi Nuttunen, Riikka Vuorinen, Seppo Pyrhönen, Vesa Kataja, Pirkko Kellokumpu-Lehtinen. (2010) Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta Oncologica 49:6, 837-843
CrossRef457
Odile Jeanniard-Malet, Gwenaëlle Gravis, Fabrice Caillol, Christian Pesenti, Erwan Bories, Marc Giovannini. (2010) Three Cases of Severe Ulcerative Esophagitis Induced by SUTENT®. Journal of Gastrointestinal Cancer
CrossRef458
P Ströbel, R Bargou, A Wolff, D Spitzer, C Manegold, A Dimitrakopoulou-Strauss, L Strauss, C Sauer, F Mayer, P Hohenberger, A Marx. (2010) Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience. British Journal of Cancer 103:2, 196-200
CrossRef459
Roberto Iacovelli, Cristina Raimondi, Antonella Palazzo, Enrico Cortesi, Giuseppe Procopio. (2010) Neoadjuvant targeted therapy in renal cell carcinoma. Nature Reviews Urology 7:7,
CrossRef460
J. S. Vermaat, I. van der Tweel, N. Mehra, S. Sleijfer, J. B. Haanen, J. M. Roodhart, J. Y. Engwegen, C. M. Korse, M. H. Langenberg, W. Kruit, G. Groenewegen, R. H. Giles, J. H. Schellens, J. H. Beijnen, E. E. Voest. (2010) Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Annals of Oncology 21:7, 1472-1481
CrossRef461
P J Wysocki, U Kazimierczak, W Suchorska, M Kotlarski, J Malicki, A Mackiewicz. (2010) Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Therapy 17:7, 465-475
CrossRef462
Blanca Homet Moreno, Elena Garralda Cabanas, Ricardo Hitt. (2010) Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas. Clinical and Translational Oncology 12:7, 468-472
CrossRef463
Manuela Schmidinger, Christoph C. Zielinski. (2010) Defining risk status in the first-line treatment of metastatic renal cell carcinoma. Journal of Cancer Research and Clinical Oncology 136:7, 961-968
CrossRef464
Hyun-Woo Shin, Chung-Hyun Cho, Tae-You Kim, Jong-Wan Park. (2010) Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1α synthesis in HT-29 colon cancer cells. Biochemical and Biophysical Research Communications 398:2, 205-211
CrossRef465
Alexander Kutikov, Robert G. Uzzo, Aaron Caraway, Carl T. Reese, Brian L. Egleston, David Y.T. Chen, Rosalia Viterbo, Richard E. Greenberg, Yu-Ning Wong, Jay D. Raman, Stephen A. Boorjian. (2010) Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU International 106:2, 218-223
CrossRef466
Alexander B. Stillebroer, Peter F.A. Mulders, Otto C. Boerman, Wim J.G. Oyen, Egbert Oosterwijk. (2010) Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy. European Urology 58:1, 75-83
CrossRef467
Filip Janku, David J. Stewart, Razelle Kurzrock. (2010) Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. Nature Reviews Clinical Oncology 7:7, 401-414
CrossRef468
H. Akaza, K. Kawai, T. Tsukamoto, T. Fujioka, Y. Tomita, T. Kitamura, S. Ozono, T. Miki, S. Naito, H. Zembutsu, Y. Nakamura. (2010) Successful Outcomes Using Combination Therapy of Interleukin-2 and Interferon- for Renal Cell Carcinoma Patients with Lung Metastasis. Japanese Journal of Clinical Oncology 40:7, 684-689
CrossRef469
Maria Alsina, Manuel Ruiz-Echarri, Jaume Capdevila, Eva Muñoz, Josep Tabernero. (2010) Biomarkers for Therapies Directed at Angiogenesis. Current Colorectal Cancer Reports 6:3, 133-143
CrossRef470
RA George, J Debnath, SS Kumar, D Banerjee, R Bhardwaj, L Satija. (2010) Pancreatic metastases from renal cell carcinoma presenting as intestinal obstruction. Medical Journal Armed Forces India 66:3, 275-277
CrossRef471
Min S Park, Vinod Ravi, Dejka M Araujo. (2010) Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Current Opinion in Oncology 22:4, 351-355
CrossRef472
Jennifer L Spratlin, Karen E Mulder, John R Mackey. (2010) Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncology 6:7, 1085-1094
CrossRef473
Joaquim Bellmunt, Pablo Maroto-Rey, José M. Trigo, Joan Carles, Vicente Guillem, José A. López-Martín, Antonio Antón-Torres, Leyrer Urruticoechea. (2010) A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clinical and Translational Oncology 12:7, 503-508
CrossRef474
P Hamberg, N Steeghs, W J Loos, D van de Biessen, M den Hollander, M Tascilar, J Verweij, H Gelderblom, S Sleijfer. (2010) Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. British Journal of Cancer 102:12, 1699-1706
CrossRef475
Philipp Ivanyi, Thomas Winkler, Anika Großhennig, Christoph Reuter, Axel S. Merseburger, Arnold Ganser, Viktor Grünwald. (2010) Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. World Journal of Urology 28:3, 311-317
CrossRef476
Alessandro Volpe, Jean Jacques Patard. (2010) Prognostic factors in renal cell carcinoma. World Journal of Urology 28:3, 319-327
CrossRef477
E. Herrmann, S. Bierer, C. Wülfing. (2010) Update on systemic therapies of metastatic renal cell carcinoma. World Journal of Urology 28:3, 303-309
CrossRef478
Sabine Brookman-May, Matthias May, Christian Gilfrich, Wolf Ferdinand Wieland, Maximilian Burger. (2010) Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?. Expert Review of Anticancer Therapy 10:6, 813-823
CrossRef479
Eva Ciric, Gregor Sersa. (2010) Radiotherapy in combination with vascular-targeted therapies. Radiology and Oncology 44:2, 67-78
CrossRef480
Hiroyuki Konno, Masayoshi Yamamoto, Manabu Ohta. (2010) Recent concepts of antiangiogenic therapy. Surgery Today 40:6, 494-500
CrossRef481
Astrid A. M. Veldt, Martijn R. Meijerink, Alfons J. M. Eertwegh, Epie Boven. (2010) Targeted therapies in renal cell cancer: recent developments in imaging. Targeted Oncology 5:2, 95-112
CrossRef482
Qiang Chen, Rong-Bo Lin, Yun-Bin Ye, Nan-Feng Fan, Zeng-Qing Guo, Zhi-Feng Zhou, Xiao-Jie Wang, Min-Shui Chen, Shu-Pin Chen, Jie-Yu Li. (2010) The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report. Medical Oncology 27:2, 554-558
CrossRef483
S. Danilin, C. Sourbier, L. Thomas, V. Lindner, S. Rothhut, V. Dormoy, J.-J. Helwig, D. Jacqmin, H. Lang, T. Massfelder. (2010) Role of the RNA-binding protein HuR in human renal cell carcinoma. Carcinogenesis 31:6, 1018-1026
CrossRef484
Thomas Steiner, Hartmut Kirchner, Michael Siebels, Christian Doehn, Hans Heynemann, Zoltan Varga, Detlef Rohde, Joerg Schubert, Dieter Jocham, Christian Stief, Paolo Fornara, Rainer Hofmann, Stefan Loening, Jan Roigas. (2010) The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma. Journal of Cancer Research and Clinical Oncology 136:6, 905-910
CrossRef485
Viktor Grünwald, Daniel Kalanovic, Axel S. Merseburger. (2010) Management of sunitinib-related adverse events: an evidence- and expert-based consensus approach. World Journal of Urology 28:3, 343-351
CrossRef486
Claudio Jeldres, Maxine Sun, Paul Perrotte, Pierre I. Karakiewicz. (2010) Pazopanib trial data cannot support first-line use. Nature Reviews Urology 7:6, 307-308
CrossRef487
Kyle A Furge, Jeffrey P MacKeigan, Bin T Teh. (2010) Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. The Lancet Oncology 11:6, 571-578
CrossRef488
Min-Han Tan, Ravindran Kanesvaran, Huihua Li, Hwei Ling Tan, Puay Hoon Tan, Chin Fong Wong, Kee Seng Chia, Bin Tean Teh, John Yuen, Tsung Wen Chong. (2010) Comparison of the UCLA Integrated Staging System and the Leibovich Score in Survival Prediction for Patients With Nonmetastatic Clear Cell Renal Cell Carcinoma. Urology 75:6, 1365-1370.e3
CrossRef489
Holger Gerullis, Lothar Bergmann, Luise Maute, Thorsten Holger Ecke, Christoph Eimer, Jens Willem Bagner, Thomas Otto. (2010) Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Medical Oncology 27:2, 373-378
CrossRef490
Marcella M Baldewijns, Iris JH van Vlodrop, Peter B Vermeulen, Patricia MMB Soetekouw, Manon van Engeland, Adriaan P de Bruïne. (2010) VHL and HIF signalling in renal cell carcinogenesis. The Journal of Pathology 221:2, 125-138
CrossRef491
Maxine Sun, Giovanni Lughezzani, Paul Perrotte, Pierre I. Karakiewicz. (2010) Treatment of metastatic renal cell carcinoma. Nature Reviews Urology 7:6, 327-338
CrossRef492
Aleksander Sochanik, Iwona Mitrus, Ryszard Smolarczyk, Tomasz Cichoń, Mirosław Śnietura, Maria Czaja, Stanisław Szala. (2010) Experimental Anticancer Therapy with Vascular-disruptive Peptide and Liposome-entrapped Chemotherapeutic Agent. Archivum Immunologiae et Therapiae Experimentalis 58:3, 235-245
CrossRef493
Fabio Calabrò, Cora N Sternberg. (2010) Is there a role for presurgical therapy for renal cell carcinoma?. Expert Review of Anticancer Therapy 10:6, 807-812
CrossRef494
Eric Jonasch, Nizar M. Tannir. (2010) Targeted therapy for locally advanced renal cell carcinoma. Targeted Oncology 5:2, 113-118
CrossRef495
Kathryn E. Hacker, W. Kimryn Rathmell. (2010) Emerging molecular classification in renal cell carcinoma: implications for drug development. Targeted Oncology 5:2, 75-84
CrossRef496
Peter Staller. (2010) Genetic heterogeneity and chromatin modifiers in renal clear cell carcinoma. Future Oncology 6:6, 897-900
CrossRef497
Eric A. Singer, Gennady Bratslavsky, W. Marston Linehan, Ramaprasad Srinivasan. (2010) Targeted therapies for non-clear renal cell carcinoma. Targeted Oncology 5:2, 119-129
CrossRef498
S Yang, P de Souza, E Alemao, J Purvis. (2010) Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α. British Journal of Cancer 102:10, 1456-1460
CrossRef499
M. L. Maitland, G. L. Bakris, H. R. Black, H. X. Chen, J. B. Durand, W. J. Elliott, S. P. Ivy, C. V. Leier, J. Lindenfeld, G. Liu, S. C. Remick, R. Steingart, W. H. W. Tang, . (2010) Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. JNCI Journal of the National Cancer Institute 102:9, 596-604
CrossRef500
Yihai Cao. (2010) Angiogenesis: What can it offer for future medicine?. Experimental Cell Research 316:8, 1304-1308
CrossRef501
Nicholas Fidelman, Robert C. Freed, Eric K. Nakakura, Jonathan Rosenberg, Allan I. Bloom. (2010) Arterial Embolization for the Management of Gastrointestinal Hemorrhage from Metastatic Renal Cell Carcinoma. Journal of Vascular and Interventional Radiology 21:5, 741-744
CrossRef502
Damien Masson, Nathalie Rioux-Leclercq, Patricia Fergelot, Florence Jouan, Stéphanie Mottier, Sandrine Théoleyre, Kalyane Bach-Ngohou, Jean-Jacques Patard, Marc G. Denis. (2010) Loss of expression of TIMP3 in clear cell renal cell carcinoma. European Journal of Cancer 46:8, 1430-1437
CrossRef503
Toni K. Choueiri, Mei Sheng Duh, Jessica Clement, Ashley J. Brick, Miranda J. Rogers, Christabel Kwabi, Karishma Shah, Andrew G. Percy, Lucia Antràs, Sujata S. Jayawant, Kristina Chen, Si-Tien Wang, Andi Luka, Maureen P. Neary, David McDermott, William K. Oh. (2010) Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU International 105:9, 1247-1254
CrossRef504
Ronald M Bukowski. (2010) Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Review of Anticancer Therapy 10:5, 635-645
CrossRef505
Matthias May, Sabine Brookman-May, Bernd Hoschke, Christian Gilfrich, Friederike Kendel, Susann Baxmann, Stefan Wittke, Stephan T. Kiessig, Kurt Miller, Manfred Johannsen. (2010) Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunology, Immunotherapy 59:5, 687-695
CrossRef506
David F. McDermott, Daniel J. George. (2010) Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data. Cancer Treatment Reviews 36:3, 216-223
CrossRef507
Paul Swinburn, Andrew Lloyd, Paul Nathan, Toni K. Choueiri, David Cella, Maureen P. Neary. (2010) Elicitation of health state utilities in metastatic renal cell carcinoma. Current Medical Research and Opinion 26:5, 1091-1096
CrossRef508
Nathan Lawrentschuk, Ian D. Davis, Damien M. Bolton, Andrew M. Scott. (2010) Functional imaging of renal cell carcinoma. Nature Reviews Urology 7:5, 258-266
CrossRef509
R. Thiam, L. S. Fournier, L. Trinquart, J. Medioni, G. Chatellier, D. Balvay, B. Escudier, C. Dromain, C. A. Cuenod, S. Oudard. (2010) Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Annals of Oncology 21:5, 936-941
CrossRef510
Geoffrey Y. Ku, David H. Ilson. (2010) Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews 36:3, 235-248
CrossRef511
Prasad Devarajan. (2010) The promise of biomarkers for personalized renal cancer care. Kidney International 77:9, 755-757
CrossRef512
Alessandro Volpe. (2010) mRCC stage migration: implications for trial design and analysis. Nature Reviews Urology 7:5, 242-244
CrossRef513
B. Escudier, V. Kataja, . (2010) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v137-v139
CrossRef514
Sandra Waalkes, Mario Kramer, Thomas RW Herrmann, Andres J Schrader, Markus A Kuczyk, Axel S Merseburger. (2010) Present state of target therapy for disseminated renal cell carcinoma. Immunotherapy 2:3, 393-398
CrossRef515
Kaisa Leea Sunela, Sanna Koskinen, Pirkko-Liisa Kellokumpu-Lehtinen. (2010) A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer. Cancer Chemotherapy and Pharmacology 66:1, 59-67
CrossRef516
Xiao Hua Ma, Zhe Shi, Chunyan Tan, Yuyang Jiang, Mei Lin Go, Boon Chuan Low, Yu Zong Chen. (2010) In-Silico Approaches to Multi-target Drug Discovery. Pharmaceutical Research 27:5, 739-749
CrossRef517
C-F Xu, B H Reck, Z Xue, L Huang, K L Baker, M Chen, E P Chen, H E Ellens, V E Mooser, L R Cardon, C F Spraggs, L Pandite. (2010) Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. British Journal of Cancer 102:9, 1371-1377
CrossRef518
Joseph R. Carver, Chaitali J. Desai. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings. , 127-199.
CrossRef519
F. Elice, F. Rodeghiero. (2010) Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thrombosis Research 125, S55-S57
CrossRef520
Giuseppe Lombardi, Fable Zustovich, Martin Donach, Maurizia Dalla Palma, Ornella Nicoletto, Davide Pastorelli. (2010) An update on targeted therapy in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations
CrossRef521
Barbara Seliger, Chiara Massa, Brian Rini, Jennifer Ko, Jim Finke. (2010) Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends in Molecular Medicine 16:4, 184-192
CrossRef522
Andreas Pircher, I. Heidegger, E. Gunsilius, W. Hilbe. (2010) Biomarkers of angiogenesis and their role in clinical oncology. memo - Magazine of European Medical Oncology 3:1, 27-32
CrossRef523
Sreenath V. Sharma, Daniel A. Haber, Jeff Settleman. (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews Cancer 10:4, 241-253
CrossRef524
Hartmut Kirchner, Dirk Strumberg, Amit Bahl, Friedrich Overkamp. (2010) Patient-based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 10:4, 585-596
CrossRef525
Rodolfo Passalacqua, Carlo Buzio, Sebastiano Buti, Camillo Porta, Roberto Labianca, Debora Pezzuolo, Roberta Camisa, Roberto Sabbatini, Luigi Benecchi, Caterina Messina, Rita Cengarle, Augusto Vaglio, Matteo Dalla Chiesa, Gianluca Tomasello, Caterina Caminiti. (2010) Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer. Cancer Immunology, Immunotherapy 59:4, 553-561
CrossRef526
C Porta. (2010) Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’. British Journal of Cancer 102:7, 1196-1197
CrossRef527
T Hosono, T Tanaka, K Tanji, T Nakatani, T Kamitani. (2010) NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation. British Journal of Cancer 102:5, 873-882
CrossRef528
A A M van der Veldt, M R Meijerink, A J M van den Eertwegh, J B A G Haanen, E Boven. (2010) Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. British Journal of Cancer 102:5, 803-809
CrossRef529
Takeshi Kishida, Masahiro Yao, Hirotsugu Uemura, Carsten Ohlmann, Yoshihiko Tomita, Ronald M Bukowski, Sei Naito. (2010) Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy. International Journal of Urology 17:3, 198-205
CrossRef530
Alvaro Pinto Marín, Andrés Redondo Sánchez, Enrique Espinosa Arranz, Pilar Zamora Auñón, Beatriz Castelo Fernández, Manuel González Barón. (2010) mTOR pathway inhibition in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations
CrossRef531
Youssef Bennis, Benjamin Guillet, Christophe Curti, Pascale Pisano. (2010) Intérêts thérapeutiques des médicaments antiangiogéniques disponibles en cancérologie. Thérapie 65:2, 95-105
CrossRef532
L. Paz-Ares, J. G. del Muro, E. Grande, S. Díaz. (2010) A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. Journal of Clinical Pharmacy and Therapeutics
CrossRef533
Jakub Żołnierek, Pawel Nurzyński, Przemysław Langiewicz, Sylwia Oborska, Anna Waśko-Grabowska, Ewa Kuszatal, Beata Obrocka, Cezary Szczylik. (2010) Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. Journal of Cancer Research and Clinical Oncology 136:3, 371-378
CrossRef534
Anne Katrin Berger, Thomas Herrmann. (2010) „Targeted therapies“ in der Behandlung solider Tumoren. Onkopipeline 3:1, 48-51
CrossRef535
Thean Hsiang TAN, Ganesalingam PRANAVAN, Hodo Z HAXHIMOLLA, Desmond YIP. (2010) New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Asia-Pacific Journal of Clinical Oncology 6:1, 5-18
CrossRef536
Hester van Cruijsen, Emile E. Voest, Cornelis J.A. Punt, Klaas Hoekman, Petronella O. Witteveen, Martijn R. Meijerink, Thomas A. Puchalski, Jane Robertson, Owain Saunders, Juliane M. Jürgensmeier, Carla M.L. van Herpen, Giuseppe Giaccone. (2010) Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. European Journal of Cancer 46:5, 901-911
CrossRef537
Jia Liu, Thomas Mittendorf, J.-Matthias von der Schulenburg. (2010) A Structured Review and Guide Through Studies on Health-Related Quality of Life in Kidney Cancer, Hepatocellular Carcinoma, and Leukemia. Cancer Investigation 28:3, 312-322
CrossRef538
Ronald M. Bukowski. (2010) Is Pazopanib Safe and Efficacious in Patients with Metastatic Renal Cell Carcinoma?. Current Oncology Reports 12:2, 77-79
CrossRef539
Jaskarn S. Rai, Michael J. Henley, Hari L. Ratan. (2010) Mammalian target of rapamycin: A new target in prostate cancer. Urologic Oncology: Seminars and Original Investigations 28:2, 134-138
CrossRef540
P. C. De Witt Hamer. (2010) Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro-Oncology 12:3, 304-316
CrossRef541
Walter M. Stadler, Robert A. Figlin, David F. McDermott, Janice P. Dutcher, Jennifer J. Knox, Wilson H. Miller, John D. Hainsworth, Charles A. Henderson, Jeffrey R. George, Julio Hajdenberg, Tamila L. Kindwall-Keller, Marc S. Ernstoff, Harry A. Drabkin, Brendan D. Curti, Luis Chu, Christopher W. Ryan, Sebastien J. Hotte, Chenghua Xia, Lisa Cupit, Ronald M. Bukowski, . (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116:5, 1272-1280
CrossRef542
Peter de Bruijn, Stefan Sleijfer, Mei-Ho Lam, Ron H.J. Mathijssen, Erik A.C. Wiemer, Walter J. Loos. (2010) Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 51:4, 934-941
CrossRef543
Michael Staehler, Nico Haseke, Ekaterina Zilinberg, Thomas Stadler, Alexander Karl, Michael Siebels, Hans-Roland Dürr, Sabine Siegert, Karl W. Jauch, Christiane J. Bruns, Christian G. Stief. (2010) Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urologic Oncology: Seminars and Original Investigations 28:2, 139-144
CrossRef544
Bernard Escudier. (2010) Sunitinib for the management of advanced renal cell carcinoma. Expert Review of Anticancer Therapy 10:3, 305-317
CrossRef545
Michele Basso, Alessandra Cassano, Carlo Barone. (2010) A survey of therapy for advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 28:2, 121-133
CrossRef546
Iman El-Hariry, Thomas Powles, Mike R. Lau, Cora N. Sternberg, Alain Ravaud, Hans von der Maase, Niko Zantl, Peter Harper, Frédéric Rolland, Bruno Audhuy, Friederike Barthel, Jean-Pascal Machiels, Pina Patel, Ernst-Dietrick Kreuser, Robert E. Hawkins. (2010) Amplification of epidermal growth factor receptor gene in renal cell carcinoma. European Journal of Cancer 46:5, 859-862
CrossRef547
Noriko Makita, Megumi Miyakawa, Toshiro Fujita, Taroh Iiri. (2010) Sunitinib Induces Hypothyroidism with a Markedly Reduced Vascularity. Thyroid 20:3, 323-326
CrossRef548
Alexander Buchner, Heike Pohla, Gerald Willimsky, Bernhard Frankenberger, Ronald Frank, Andrea Baur-Melnyk, Michael Siebels, Christian G. Stief, Alfons Hofstetter, Joachim Kopp, Antonio Pezzutto, Thomas Blankenstein, Ralph Oberneder, Dolores J. Schendel. (2010) Phase 1 Trial of Allogeneic Gene-Modified Tumor Cell Vaccine RCC-26/CD80/IL-2 in Patients with Metastatic Renal Cell Carcinoma. Human Gene Therapy 21:3, 285-297
CrossRef549
Henk M.W. Verheul, Karen van Erp, Marjolein Y.V. Homs, G.S. Yoon, Petra van Der Groep, Craig Rogers, Donna E. Hansel, George J. Netto, Roberto Pili. (2010) The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and Fibrinogen) Expression in Clear Cell Renal Cell Carcinoma. Urology 75:3, 608-614
CrossRef550
D Cella, M D Michaelson, A G Bushmakin, J C Cappelleri, C Charbonneau, S T Kim, J Z Li, R J Motzer. (2010) Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis. British Journal of Cancer 102:4, 658-664
CrossRef551
Peter C. Austin, Andrea Manca, Merrick Zwarenstein, David N. Juurlink, Matthew B. Stanbrook. (2010) A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. Journal of Clinical Epidemiology 63:2, 142-153
CrossRef552
Eva Juengel, Johanna Engler, Ausra Mickuckyte, Jon Jones, Lukasz Hudak, Dietger Jonas, Roman A. Blaheta. (2010) Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. BJU International 105:4, 549-557
CrossRef553
Danielle Park, Pierre J. Dilda. (2010) Mitochondria as targets in angiogenesis inhibition. Molecular Aspects of Medicine 31:1, 113-131
CrossRef554
Robyn J. Macfarlane, Kim N. Chi. (2010) Novel Targeted Therapies for Prostate Cancer. Urologic Clinics of North America 37:1, 105-119
CrossRef555
Ore Ogunyemi, A. Rojas, K. Hematpour, D. Rogers, C. Head, C. Bennett. (2010) Metastasis of genitourinary tumors to the head and neck region. European Archives of Oto-Rhino-Laryngology 267:2, 273-279
CrossRef556
J.-Y. Blay. (2010) Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Annals of Oncology 21:2, 208-215
CrossRef557
Helen J. Mackay, Anna Tinker, Eric Winquist, Gillian Thomas, Kenneth Swenerton, Amit Oza, Joana Sederias, Percy Ivy, Elizabeth A. Eisenhauer. (2010) A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecologic Oncology 116:2, 163-167
CrossRef558
M. Autenrieth, H. Kübler, J.E. Gschwend. (2010) Adjuvante postoperative Therapie beim Nierenzellkarzinom. Der Onkologe 16:2, 150-156
CrossRef559
Bernard Escudier. (2010) Chemo-immunotherapy in RCC: the end of a story. The Lancet 375:9715, 613-614
CrossRef560
Napoleone Ferrara. (2010) Pathways mediating VEGF-independent tumor angiogenesis. Cytokine & Growth Factor Reviews 21:1, 21-26
CrossRef561
Zachary A. Knight, Henry Lin, Kevan M. Shokat. (2010) Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10:2, 130-137
CrossRef562
G. Sonpavde, P. O. Periman, D. Bernold, D. Weckstein, M. T. Fleming, M. D. Galsky, W. R. Berry, F. Zhan, K. A. Boehm, L. Asmar, T. E. Hutson. (2010) Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Annals of Oncology 21:2, 319-324
CrossRef563
Martin E Gore, Clare L Griffin, Barry Hancock, Poulam M Patel, Lynda Pyle, Michael Aitchison, Nicholas James, Roderick TD Oliver, Jozef Mardiak, Tahera Hussain, Richard Sylvester, Mahesh KB Parmar, Patrick Royston, Peter FA Mulders. (2010) Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. The Lancet 375:9715, 641-648
CrossRef564
Vincenzo Ficarra, Giacomo Novara. (2010) Kidney cancer: Neoadjuvant targeted therapies in renal cell carcinoma. Nature Reviews Urology 7:2, 63-64
CrossRef565
Camillo Porta, Joaquim Bellmunt, Tim Eisen, Cezary Szczylik, Peter Mulders. (2010) Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treatment Reviews 36:1, 16-23
CrossRef566
Amir Abdollahi, Judah Folkman. (2010) Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resistance Updates 13:1-2, 16-28
CrossRef567
Yihai Cao. (2010) Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nature Reviews Drug Discovery 9:2, 107-115
CrossRef568
W. Marston Linehan, Gennady Bratslavsky, Peter A. Pinto, Laura S. Schmidt, Len Neckers, Donald P. Bottaro, Ramaprasad Srinivasan. (2010) Molecular Diagnosis and Therapy of Kidney Cancer*. Annual Review of Medicine 61:1, 329-343
CrossRef569
Emanuel Raschi, Valentina Vasina, Maria Grazia Ursino, Giuseppe Boriani, Andrea Martoni, Fabrizio De Ponti. (2010) Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacology & Therapeutics 125:2, 196-218
CrossRef570
M. Schenck, L.-O. Muegge. (2010) „Targeted therapy“ bei metastasiertem Nierenzellkarzinom. Der Onkologe 16:2, 157-167
CrossRef571
Ying-Kiat Zee, James P. B. O'Connor, Geoff J. M. Parker, Alan Jackson, Andrew R. Clamp, M. Ben Taylor, Noel W. Clarke, Gordon C. Jayson. (2010) Imaging angiogenesis of genitourinary tumors. Nature Reviews Urology 7:2, 69-82
CrossRef572
E. A. Perez, D. W. Hillman, T. Dentchev, N. A. Le-Lindqwister, L. H. Geeraerts, T. R. Fitch, H. Liu, D. L. Graham, S. P. Kahanic, H. M. Gross, T. A. Patel, F. M. Palmieri, A. C. Dueck. (2010) North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Annals of Oncology 21:2, 269-274
CrossRef573
G. Bar-Sela, E. Kedem, S. Hadad, S. Pollack, N. Haim, F. Atrash, E. Shahar. (2010) Successful Desensitization Protocol for Hypersensitivity Reaction Caused by Sunitinib in a Patient with a Gastrointestinal Stromal Tumor. Japanese Journal of Clinical Oncology 40:2, 163-165
CrossRef574
S. I. Cunha, E. Pardali, M. Thorikay, C. Anderberg, L. Hawinkels, M.-J. Goumans, J. Seehra, C.-H. Heldin, P. ten Dijke, K. Pietras. (2010) Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. Journal of Experimental Medicine 207:1, 85-100
CrossRef575
Sujata Patil, Nicole Ishill, John Deluca, Robert J. Motzer. (2010) Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients. Cancer 116:2, 347-354
CrossRef576
N Murukesh, C Dive, G C Jayson. (2010) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. British Journal of Cancer 102:1, 8-18
CrossRef577
G Mickisch, M Gore, B Escudier, G Procopio, S Walzer, M Nuijten. (2010) Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. British Journal of Cancer 102:1, 80-86
CrossRef578
Norihiko Tsuchiya, Tomonori Habuchi. (2010) Current status and future issue of molecular targeted agents in solid tumors: lessons learned from renal cell carcinoma. Drug Delivery System 25:2, 134-142
CrossRef579
Richard Zigeuner, Georg Hutterer, Thomas Chromecki, Arvin Imamovic, Karin Kampel-Kettner, Peter Rehak, Cord Langner, Karl Pummer. (2010) External Validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear-Cell Renal Cell Carcinoma in a Single European Centre Applying Routine Pathology. European Urology 57:1, 102-111
CrossRef580
Andrew R. Reynolds. (2010) Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer. Dose-Response 8:3, 253-284
CrossRef581
Eugene Hwang, Hyo Jin Lee, Chong Koo Sul, Jae Sung Lim. (2010) Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience. Korean Journal of Urology 51:7, 450
CrossRef582
W. Kimryn Rathmell, Raj Pruthi, Eric Wallen. (2010) Neoadjuvant treatment of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 28:1, 69-73
CrossRef583
Grzegorz Korpanty, Laura A. Sullivan, Elizabeth Smyth, Desmond N. Carney, Rolf A. Brekken. (2010) Molecular and Clinical Aspects of Targeting the VEGF Pathway in Tumors. Journal of Oncology 2010, 1-12
CrossRef584
Ovidio Fernández Calvo, Diana Dopico Vázquez, Margarita Reboredo López, Luis Miguel Antón Aparicio. (2010) Renal cell carcinoma: complete response. Anti-Cancer Drugs 21:Supplement 1, S17-S18
CrossRef585
Alfredo Carrato Mena, Enrique Grande Pulido, Carmen Guillén-Ponce. (2010) Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anti-Cancer Drugs 21:Supplement 1, S3-S11
CrossRef586
Hassane Izzedine, Christophe Massard, Jean Philippe Spano, François Goldwasser, David Khayat, Jean Charles Soria. (2010) VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. European Journal of Cancer 46:2, 439-448
CrossRef587
Han-Chung Wu, De-Kuan Chang. (2010) Peptide-Mediated Liposomal Drug Delivery System Targeting Tumor Blood Vessels in Anticancer Therapy. Journal of Oncology 2010, 1-8
CrossRef588
Ronald M. Bukowski, Uma Yasothan, Peter Kirkpatrick. (2010) Pazopanib. Nature Reviews Drug Discovery 9:1, 17-18
CrossRef589
Stephen M. Keefe, Angela DeMichele. (2010) The Expanding Role of Bevacizumab in the Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Current Oncology Reports 12:1, 22-25
CrossRef590
Nicole M. Agostino, Rebecca Gingrich, Joseph J. Drabick. (2010) Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature. Advances in Urology 2010, 1-4
CrossRef591
P. A. Tang, G. R. Pond, E. X. Chen. (2010) Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. Annals of Oncology 21:1, 19-26
CrossRef592
Ingrid A. Boere, Paul Hamberg, Stefan Sleijfer. (2010) It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factorâvascular endothelial growth factor receptor pathway in patients with solid malignancies. Cancer Science 101:1, 7-15
CrossRef593
Javier Puente, Aranzazu Manzano, Miguel Martin, Sonia López-Tarruella, Eduardo Díaz-Rubio. (2010) Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. Anti-Cancer Drugs 21:Supplement 1, S19-S22
CrossRef594
Kyung Seok Han, Dae Chul Jung, Hyuck Jae Choi, Min Soo Jeong, Kang Su Cho, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung. (2010) Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. CancerNA-NA
CrossRef595
Michael Medinger, Natalie Fischer, Alexandar Tzankov. (2010) Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies. Journal of Oncology 2010, 1-13
CrossRef596
Martin Hoyle, Colin Green, Jo Thompson-Coon, Zulian Liu, Karen Welch, Tiffany Moxham, Ken Stein. (2010) Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma. Value in Health 13:1, 55-60
CrossRef597
Cristina Suárez, Rafael Morales, Eva Muñoz, Jordi Rodón, Claudia M. Valverde, Joan Carles. (2010) Molecular basis for the treatment of renal cell carcinoma. Clinical and Translational Oncology 12:1, 15-21
CrossRef598
Jason E. Faris, M. Dror Michaelson. (2010) Targeted therapies: Sunitinib versus interferon-α in metastatic RCC. Nature Reviews Clinical Oncology 7:1, 7-8
CrossRef599
Rosario García-Campelo, Maria Quindós, Diana Dopico Vázquez, Margarita Reboredo López, Alberto Carral, Ovidio Fernández Calvo, José Manuel Rois Soto, Enrique Grande, Jesús Durana, Luis Miguel Antón-Aparicio. (2010) Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma. Anti-Cancer Drugs 21:Supplement 1, S13-S15
CrossRef600
Jee Han Lee, Sung-Goo Chang, Seung Hyun Jeon, Gyeong Eun Min, Koo Han Yoo. (2010) Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea. Korean Journal of Urology 51:6, 379
CrossRef601
Martin Hoyle, Colin Green, Jo Thompson-Coon, Zulian Liu, Karen Welch, Tiffany Moxham, Ken Stein. (2010) Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma. Value in Health 13:1, 61-68
CrossRef602
Yair Lotan. (2010) Role of biomarkers to predict outcomes and response to therapy. Urologic Oncology: Seminars and Original Investigations 28:1, 97-101
CrossRef603
James Larkin, Martin Gore. (2009) Health policy: The UK 'postcode lottery' in renal cell carcinoma. Nature Reviews Urology 6:12, 636-638
CrossRef604
David Cella. (2009) Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes. Cancer Treatment Reviews 35:8, 733-737
CrossRef605
Giuseppe Di Lorenzo, Riccardo Autorino, Cora N. Sternberg. (2009) Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era. European Urology 56:6, 959-971
CrossRef606
Ronan J. Kelly, Olivier Rixe. (2009) Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Targeted Oncology 4:4, 297-305
CrossRef607
Rebecca A. Miksad, Kuan-Chi Lai, Marion C. Stein, Megan E. Healy, Rafael Rojas, Katherine M. Krajewski, Andrew X. Zhu. (2009) Imbalance and Gait Disturbance from Tyrosine Kinase Inhibition in Hepatocellular Cancer. Journal of Gastrointestinal Cancer 40:3-4, 119-122
CrossRef608
Laura S. Wood. (2009) Management of Vascular Endothelial Growth Factor and Multikinase Inhibitor Side Effects. Clinical Journal of Oncology Nursing 13:0, 13-18
CrossRef609
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef610
Ila Tamaskar, Roberto Pili. (2009) Update on novel agents in renal cell carcinoma. Expert Review of Anticancer Therapy 9:12, 1817-1827
CrossRef611
Peter Mulders. (2009) Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU International 104:11, 1585-1589
CrossRef612
Georgios S. Papaetis, Kostas N. Syrigos. (2009) Sunitinib. BioDrugs 23:6, 377-389
CrossRef613
Nicola L Ainsworth, Jean SZ Lee, Tim Eisen. (2009) Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 9:12, 1793-1805
CrossRef614
J L Perez-Gracia, C Prior, F Guillén-Grima, V Segura, A Gonzalez, A Panizo, I Melero, E Grande-Pulido, A Gurpide, I Gil-Bazo, A Calvo. (2009) Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. British Journal of Cancer 101:11, 1876-1883
CrossRef615
K. Ishiyama, A. Takami, S. Suzuki, H. Konaka, M. Namiki, A. Ooi, S. Nakao. (2009) Relationship Between Tumor-infiltrating T Lymphocytes and Clinical Response After Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Renal Cell Carcinoma: A Single Center Prospective Study. Japanese Journal of Clinical Oncology 39:12, 807-812
CrossRef616
Yongping Crawford, Napoleone Ferrara. (2009) Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends in Pharmacological Sciences 30:12, 624-630
CrossRef617
(2009) Cardiac toxicity from sunitinib: Do we need to be more vigilant?. Asia-Pacific Journal of Clinical Oncology 5:4, 217-218
CrossRef618
Bruce Ruggeri. 2009. Cellular and Animal Models in Oncology and Tumor Biology. .
CrossRef619
Toni K. Choueiri, Michael B. Atkins. (2009) Targeted therapies: Sunitinib in RCC—expanded access equals expanded benefit?. Nature Reviews Clinical Oncology 6:12, 679-680
CrossRef620
I. C. Song, J. S. Lim, H. J. Yun, S. Kim, D. Y. Kang, H. J. Lee. (2009) Biochemical and Pathological Response of Prostate Cancer in a Patient with Metastatic Renal Cell Carcinoma on Sunitinib Treatment. Japanese Journal of Clinical Oncology 39:12, 833-836
CrossRef621
Eric Raymond, Sandrine Faivre, Pascal Hammel, Philippe Ruszniewski. (2009) Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Targeted Oncology 4:4, 253-254
CrossRef622
Mariëtte HW Kappers, Joep HM van Esch, Stefan Sleijfer, AH Jan Danser, Anton H van den Meiracker. (2009) Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. Journal of Hypertension 27:12, 2297-2309
CrossRef623
Brenda C. Salumbides, Kristin M. Lehet, Georges Ndikuyeze, Roberto Pili. 2009. Pre-Clinical Models of Renal Carcinoma and Their Utility in Drug Development. .
CrossRef624
R Kumar, M-C Crouthamel, D H Rominger, R R Gontarek, P J Tummino, R A Levin, A G King. (2009) Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. British Journal of Cancer 101:10, 1717-1723
CrossRef625
S. L. C. Lee, P. Rouhi, L. D. Jensen, D. Zhang, H. Ji, G. Hauptmann, P. Ingham, Y. Cao. (2009) Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proceedings of the National Academy of Sciences 106:46, 19485-19490
CrossRef626
Sergio Bracarda, Jean-Jacques Patard, Alain Ravaud. (2009) Current Perspectives in Metastatic Renal Cell Carcinoma Treatment: The Role of Mammalian Target of Rapamycin (mTOR) Inhibition. European Urology Supplements 8:10, 785-786
CrossRef627
Gaetano Facchini, Francesco Perri, Michele Caraglia, Carmela Pisano, Stefano Striano, Luigi Marra, Francesco Fiore, Pasquale Aprea, Sandro Pignata, Rosario Vincenzo Iaffaioli. (2009) New treatment approaches in renal cell carcinoma. Anti-Cancer Drugs 20:10, 893-900
CrossRef628
Peter E Clark. (2009) The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney International 76:9, 939-945
CrossRef629
Carlos A Castaneda, Henry L Gomez. (2009) Pazopanib: an antiangiogenic drug in perspective. Future Oncology 5:9, 1335-1348
CrossRef630
N. Shinohara, A. Kumagai, K. Kanagawa, S. Maruyama, T. Abe, A. Sazawa, K. Nonomura. (2009) Multicenter Phase II Trial of Combination Therapy with Meloxicam, a COX-2 Inhibitor, and Natural Interferon- for Metastatic Renal Cell Carcinoma. Japanese Journal of Clinical Oncology 39:11, 720-726
CrossRef631
Yann Neuzillet, Stéphane Culine, Jean-Jacques Patard. (2009) Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine. International Journal of Urology 16:11, 855-861
CrossRef632
Marie-Christine Etienne-Grimaldi, Nicole Renée, Hassan Izzedine, Gérard Milano. (2009) A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. Journal of Chromatography B 877:29, 3757-3761
CrossRef633
D. Castellano, X. G. del Muro, J. L. Perez-Gracia, J. L. Gonzalez-Larriba, M. V. Abrio, M. A. Ruiz, A. Pardo, C. Guzman, S. D. Cerezo, E. Grande. (2009) Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon- as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Annals of Oncology 20:11, 1803-1812
CrossRef634
Bristi Basu, Swethajit Biswas, Jessica Wrigley, Bhawna Sirohi, Pippa Corrie. (2009) Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Review of Anticancer Therapy 9:11, 1583-1598
CrossRef635
M. Ringhoffer, L. Rinnab, R. Küfer, J. Greiner. (2009) Systemtherapie des metastasierten Nierenzellkarzinoms. Der Urologe 48:11, 1308-1317
CrossRef636
Sergio Bracarda. (2009) Metastatic Renal Cell Carcinoma: Pathogenesis and the Current Medical Landscape. European Urology Supplements 8:10, 787-792
CrossRef637
Sergio Bracarda, Alain Ravaud, Marino Chiodi. (2009) Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma. European Urology Supplements 8:10, 815-819
CrossRef638
Hideaki Miyake, Toshifumi Kurahashi, Atsushi Takenaka, Taka-aki Inoue, Masato Fujisawa. (2009) Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 27:6, 598-603
CrossRef639
Ziya Kirkali. (2009) Kidney cancer in the elderly. Urologic Oncology: Seminars and Original Investigations 27:6, 673-676
CrossRef640
Jean-Jacques Patard. (2009) Treatment Algorithms in Metastatic Renal Cell Carcinoma, Including the Potential Role of the Novel Oral Mammalian Target of Rapamycin Inhibitor Everolimus. European Urology Supplements 8:10, 809-814
CrossRef641
Noboru Yamamoto, Tomohide Tamura, Nobuyuki Yamamoto, Kazuhiko Yamada, Yasuhide Yamada, Hiroshi Nokihara, Yutaka Fujiwara, Toshiaki Takahashi, Haruyasu Murakami, Narikazu Boku, Kentaro Yamazaki, Thomas A. Puchalski, Eisei Shin. (2009) Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 64:6, 1165-1172
CrossRef642
Rodney H. Breau, Bradley C. Leibovich. (2009) Kidney cancer: Therapy for metastatic RCC—questions remain. Nature Reviews Urology 6:11, 580-581
CrossRef643
Alain Ravaud, Hervé Wallerand. (2009) Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin Inhibitors. European Urology Supplements 8:10, 793-798
CrossRef644
Sergio Bracarda, Alain Ravaud. (2009) Current and Future Treatment Options for Metastatic Renal Cell Carcinoma. European Urology Supplements 8:10, 799-808
CrossRef645
J-J Patard, N Rioux-Leclercq, D Masson, S Zerrouki, F Jouan, N Collet, C Dubourg, B Lobel, M Denis, P Fergelot. (2009) Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. British Journal of Cancer 101:8, 1417-1424
CrossRef646
H Rezaei Kalantari. (2009) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. British Journal of Cancer 101:7, 1222-1223
CrossRef647
Hans Petter Eikesdal, Raghu Kalluri. (2009) Drug resistance associated with antiangiogenesis therapy. Seminars in Cancer Biology 19:5, 310-317
CrossRef648
Gottfried Wozel, Michael Sticherling, Michael P. Schön. (2009) Cutaneous side effects of inhibition of VEGF signal transduction. Journal der Deutschen Dermatologischen Gesellschaft
CrossRef649
Peter J. Van Veldhuizen, Michael Hussey, Primo N. Lara, Philip C. Mack, Regina Gandour-Edwards, Joseph I. Clark, Marianne K. Lange, David E. Crawford. (2009) A Phase II Study of Gemcitabine and Capecitabine in Patients With Advanced Renal Cell Cancer. American Journal of Clinical Oncology 32:5, 453-459
CrossRef650
N. James, J. Pascoe, A. Zachariah, D. Ray, A. Oldroyd, H. Parry, H. Benghiat, M. Karina, S. Collins, E. Porfiri. (2009) Effect of the UK Postcode Lottery on Survival of Patients with Metastatic Renal Cancer: an Audit of Outcomes in Patients with Metastatic Renal Cancer Suitable for Treatment with Tyrosine Kinase Inhibitors. Clinical Oncology 21:8, 610-616
CrossRef651
Youjin Je, Fabio AB Schutz, Toni K Choueiri. (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. The Lancet Oncology 10:10, 967-974
CrossRef652
Enrique Ramos-Barcelo, Jorge Rioja, Pilar Laguna Pes, Jean J.M.C.H. de la Rosette, Theo M. de Reijke. (2009) Is age a prognostic factor for treatment outcome in renal cell cancer—A comprehensive review. Critical Reviews in Oncology/Hematology 72:1, 83-89
CrossRef653
Claudio Jeldres, Sara Baillargeon-Gagne, Daniel Liberman, Hendrik Isbarn, Umberto Capitanio, Shahrokh F. Shariat, Maxine Sun, Giovanni Lughezzani, Paul Perrotte, Francesco Montorsi, Markus Graefen, Pierre I. Karakiewicz. (2009) A Population-based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States. Urology 74:4, 837-841
CrossRef654
Kim N. Chi, Anders Bjartell, David Dearnaley, Fred Saad, Fritz H. Schröder, Cora Sternberg, Bertrand Tombal, Tapio Visakorpi. (2009) Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. European Urology 56:4, 594-605
CrossRef655
Chi Young Park. (2009) Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis. Anti-Cancer Drugs 20:9, 848-849
CrossRef656
Narayan Sundaresan, Stefano Boriani, Scott Okuno. (2009) State of the Art Management in Spine Oncology. Spine 34:Supplement, S7-S20
CrossRef657
Denis Soulières. (2009) Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy?. Current Opinion in Supportive and Palliative Care 3:3, 153-156
CrossRef658
Sen H. Zhuang, Liang Xiu, Yusri A. Elsayed. (2009) Overall Survival: A Gold Standard in Search of a Surrogate. The Cancer Journal 15:5, 395-400
CrossRef659
David B. T. La Vine, Teresa A. Coleman, Carol H. Davis, Christine E. Carbonell, Wendy B. Davis. (2009) Frequent Dose Interruptions are Required for Patients Receiving Oral Kinase Inhibitor Therapy for Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology1
CrossRef660
Brett S. Carver. (2009) The Case for Cytoreductive Nephrectomy for the Management of Metastatic Renal Cell Carcinoma. The Journal of Urology 182:3, 833-834
CrossRef661
A.S. Merseburger, S. Waalkes, M.A. Kuczyk. (2009) Aktuelles zur Systemtherapie des metastasierten Nierenzellkarzinoms. Der Urologe 48:9, 983-989
CrossRef662
Kevin G Kwan, Anil Kapoor. (2009) Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. Current Opinion in Supportive and Palliative Care 3:3, 157-165
CrossRef663
Kenneth L. Hill, Adam C. Lipson, Jonas M. Sheehan. (2009) Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. Journal of Neurosurgery 111:3, 497-503
CrossRef664
Catherine Guevremont, Ahmed Alasker, Pierre I Karakiewicz. (2009) Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Current Opinion in Supportive and Palliative Care 3:3, 170-179
CrossRef665
John F Deeken, Liron Pantanowitz, Bruce J Dezube. (2009) Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Current Opinion in Oncology 21:5, 445-454
CrossRef666
Nathalie Theou-Anton, Sandrine Faivre, Chantal Dreyer, Eric Raymond. (2009) Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer. Drug Safety 32:9, 717-734
CrossRef667
G. Di Lorenzo, R. Autorino, G. Bruni, G. Carteni, E. Ricevuto, M. Tudini, C. Ficorella, C. Romano, M. Aieta, A. Giordano, M. Giuliano, A. Gonnella, C. De Nunzio, M. Rizzo, V. Montesarchio, M. Ewer, S. De Placido. (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Annals of Oncology 20:9, 1535-1542
CrossRef668
David Lebwohl, Andrea Kay, William Berg, Jean Francois Baladi, Ji Zheng. (2009) Progression-Free Survival. The Cancer Journal 15:5, 386-394
CrossRef669
Tatiana Vidaurre, Julia Wilkerson, Richard Simon, Susan E. Bates, Tito Fojo. (2009) Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug Development. The Cancer Journal 15:5, 366-373
CrossRef670
Toru Shimazui, Takahiro Kojima, Kazuhiro Yoshikawa, Yoshihiro Ami, Takehiro Oikawa, Kazuhiko Uchida, Hideyuki Akaza. (2009) Low expression of microphthalmia-associated transcription factor, a potential molecular target for interferon-alpha susceptibility, is associated with metastasis in renal cell carcinoma. Cancer Science 100:9, 1714-1718
CrossRef671
Anil A. Thomas, Brian I. Rini, Andrew J. Stephenson, Jorge A. Garcia, Amr Fergany, Venkatesh Krishnamurthi, Andrew C. Novick, Inderbir S. Gill, Eric A. Klein, Ming Zhou, Steven C. Campbell. (2009) Surgical Resection of Renal Cell Carcinoma After Targeted Therapy. The Journal of Urology 182:3, 881-886
CrossRef672
T. Otto. (2009) Uro-Onkologie – Update 2009. Der Urologe 48:9, 1056-1058
CrossRef673
Elizabeth L. Strevel, Lillian L. Siu. (2009) Cardiovascular toxicity of molecularly targeted agents. European Journal of Cancer 45, 318-331
CrossRef674
Cora N. Sternberg, Joaquim Bellmunt, Viktor Grünwald, James Larkin, Peter Mulders. (2009) Advances in the Management of Metastatic Renal Cell Cancer. European Urology Supplements 8:9, 758-761
CrossRef675
Wilfred D. Stein, Hui Huang, Michael Menefee, Maureen Edgerly, Herb Kotz, Andrew Dwyer, James Yang, Susan E. Bates. (2009) Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell Carcinoma. The Cancer Journal 15:5, 441-447
CrossRef676
J. -M. Halimi, M. Azizi, G. Bobrie, O. Bouché, G. Deray, G. Guetz, T. Lecomte, B. Levy, J. -J. Mourad, D. Nochy, S. Oudard, P. Rieu, D. Sahali. (2009) Effets vasculaires et rénaux des médicaments anti-angiogéniques: recommandations françaises pour la pratique. Oncologie 11:9-10, 476-489
CrossRef677
John M. Fitzpatrick, Cora N. Sternberg, Fred Saad, Martine Extermann, Orazio Caffo, Susan Halabi, Gero Kramer, Stéphane Oudard, Ronald de Wit. (2009) Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. European Urology Supplements 8:9, 738-746
CrossRef678
Robert A. Figlin, Paul de Souza, David McDermott, Janice P. Dutcher, Anna Berkenblit, Alexandra Thiele, Mizue Krygowski, Andrew Strahs, Jay Feingold, Joseph Boni, Gary Hudes. (2009) Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α. Cancer 115:16, 3651-3660
CrossRef679
Anil Kapoor, Robert A. Figlin. (2009) Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 115:16, 3618-3630
CrossRef680
Mei Sheng Duh, Ellison Dial, Toni K. Choueiri, Andree-Anne Fournier, Lucia Antras, Douglas Rodermund, Maureen P. Neary, William K. Oh. (2009) Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*. Current Medical Research and Opinion 25:8, 2081-2090
CrossRef681
Helen X. Chen, Jessica N. Cleck. (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nature Reviews Clinical Oncology 6:8, 465-477
CrossRef682
Evon Poon, Adrian L. Harris, Margaret Ashcroft. (2009) Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Reviews in Molecular Medicine 11,
CrossRef683
Sandrine Faivre, Eric Raymond, Eveline Boucher, Jean Douillard, Ho Y Lim, Jun S Kim, Magaly Zappa, Silvana Lanzalone, Xun Lin, Samuel DePrimo, Charles Harmon, Ana Ruiz-Garcia, Maria J Lechuga, Ann Lii Cheng. (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. The Lancet Oncology 10:8, 794-800
CrossRef684
J.M.L. Roodhart, M.H.G. Langenberg, L.G.M. Daenen, E.E. Voest. (2009) Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:1, 41-49
CrossRef685
Axel Bex, Astrid A. M. Veldt, Christian Blank, Alfons J. M. Eertwegh, Epie Boven, Simon Horenblas, John Haanen. (2009) Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World Journal of Urology 27:4, 533-539
CrossRef686
M Bregni, M Bernardi, P Servida, A Pescarollo, R Crocchiolo, E Treppiedi, P Corradini, F Ciceri, J Peccatori. (2009) Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplantation 44:4, 237-242
CrossRef687
Astrid A.M. van der Veldt, Epie Boven, Axel Bex. (2009) Re: Response of the Primary Tumor to Neoadjuvant Sunitinib in Patients With Advanced Renal Cell Carcinoma. The Journal of Urology 182:2, 797-798
CrossRef688
Swethajit Biswas, Tim Eisen. (2009) Immunotherapeutic strategies in kidney cancer—when TKIs are not enough. Nature Reviews Clinical Oncology 6:8, 478-487
CrossRef689
Edmund Chiong, Christopher G Wood, Vitaly Margulis. (2009) Role of cytoreductive nephrectomy in renal cell carcinoma. Future Oncology 5:6, 859-869
CrossRef690
Johnny Kao, Stuart Packer, Ha Linh Vu, Myron E. Schwartz, Max W. Sung, Richard G. Stock, Yeh-Chi Lo, Delphine Huang, Shu-Hsia Chen, Jamie A. Cesaretti. (2009) Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases. Cancer 115:15, 3571-3580
CrossRef691
Deepa Rao, Zeeshan Butt, Sarah Rosenbloom, Don Robinson, Jamie Von Roenn, Timothy M. Kuzel, David Cella. (2009) A Comparison of the Renal Cell Carcinoma–Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI). Journal of Pain and Symptom Management 38:2, 291-298
CrossRef692
Sandy Pelletier, Simon Tanguay, Stephen Lee, Lakshman Gunaratnam, Nathalie Arbour, Réjean Lapointe. (2009) TGF-alpha as a candidate tumor antigen for renal cell carcinomas. Cancer Immunology, Immunotherapy 58:8, 1207-1218
CrossRef693
Gianluigi Lunardi, Andrea Armirotti, Maurizio Nicodemo, Lucia Cavallini, Gianluca Damonte, Maria O. Vannozzi, Marco Venturini. (2009) Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series. Clinical Therapeutics 31:8, 1812-1819
CrossRef694
Ziya Kirkali, Emre Tüzel. (2009) Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?. Future Oncology 5:6, 871-888
CrossRef695
Sumanta Kumar Pal, Joanne Mortimer. (2009) Triple-negative breast cancer: Novel therapies and new directions. Maturitas 63:4, 269-274
CrossRef696
Toni K Choueiri, Joaquim Bellmunt. (2009) Sunitinib in renal-cell carcinoma: expanded indications. The Lancet Oncology 10:8, 740
CrossRef697
N. Mellas, S. Mellas, O. Masbah, H. Errihani. (2009) Mise au point sur le traitement médical du cancer du rein métastatique. Journal africain du cancer / African Journal of Cancer 1:3, 154-158
CrossRef698
Martin E Gore, Cezary Szczylik, Camillo Porta, Sergio Bracarda, Georg A Bjarnason, Stéphane Oudard, Subramanian Hariharan, Se-Hoon Lee, John Haanen, Daniel Castellano, Eduard Vrdoljak, Patrick Schöffski, Paul Mainwaring, Alejandra Nieto, Jinyu Yuan, Ronald Bukowski. (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. The Lancet Oncology 10:8, 757-763
CrossRef699
J S Thompson Coon, Z Liu, M Hoyle, G Rogers, C Green, T Moxham, K Welch, K Stein. (2009) Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. British Journal of Cancer 101:2, 238-243
CrossRef700
Michael Darmon, Elie Azoulay. (2009) Critical care management of cancer patients: cause for optimism and need for objectivity. Current Opinion in Oncology 21:4, 318-326
CrossRef701
Hendrik-Tobias Arkenau. (2009) Gastric cancer in the era of molecularly targeted agents: current drug development strategies. Journal of Cancer Research and Clinical Oncology 135:7, 855-866
CrossRef702
Sedat Doğan, İlknur Haberal Can, Meral Sayn, Elif Özer, Ünal Bayz, Gözde Yazc, Ethem Erdal Samim. (2009) The Nasal Septum. Journal of Craniofacial Surgery 20:4, 1204-1206
CrossRef703
Guru Sonpavde, Weiguo Jian, Hao Liu, Meng-Fen Wu, Steven S. Shen, Seth P. Lerner. (2009) Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urologic Oncology: Seminars and Original Investigations 27:4, 391-399
CrossRef704
Anne Marie Asemissen, Peter Brossart. (2009) Vaccination strategies in patients with renal cell carcinoma. Cancer Immunology, Immunotherapy 58:7, 1169-1174
CrossRef705
Elena Soto-Vega, Carlos Arroyo, Yvonne Richaud-Patin, Mario García-Carrasco, Luis G. Vázquez-Lavista, Luis Llorente. (2009) P-glycoprotein activity in renal clear cell carcinoma. Urologic Oncology: Seminars and Original Investigations 27:4, 363-366
CrossRef706
Joaquim Bellmunt, Per Flodgren, Jan Roigas, Stéphane Oudard. (2009) Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU International 104:1, 10-18
CrossRef707
M.P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni, B. Escudier. (2009) Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma. The Journal of Urology 182:1, 29-34
CrossRef708
E. Jason Abel, Christopher G. Wood. (2009) Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nature Reviews Urology 6:7, 375-383
CrossRef709
Camillo Porta, Chiara Paglino, Ilaria Imarisio, Elisa Ferraris. (2009) Sorafenib tosylate in advanced kidney cancer: past, present and future. Anti-Cancer Drugs 20:6, 409-415
CrossRef710
Andrew S. Chi, Andrew D. Norden, Patrick Y. Wen. (2009) Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 6:3, 513-526
CrossRef711
Andrew X. Zhu, Dan G. Duda, Dushyant V. Sahani, Rakesh K. Jain. (2009) Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies. The Cancer Journal 15:4, 263-268
CrossRef712
Peter Mulders. (2009) Editorial Comment on: Mode-of-Action, Efficacy, and Safety of a Homologous Multi-Epitope Vaccine in a Murine Model for Adjuvant Treatment of Renal Cell Carcinoma. European Urology 56:1, 132-133
CrossRef713
Jacques Medioni, Eugeniu Banu, Dominique Helley, Florian Scotte, Laure Fournier, Arnaud Mejean, Antoine Chedid, Michel Azizi, Jean-Marie Andrieu, Stéphane Oudard. (2009) Salvage Therapy with Bevacizumab–Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series. European Urology 56:1, 207-211
CrossRef714
I Chau, D Cunningham. (2009) Treatment in advanced colorectal cancer: what, when and how?. British Journal of Cancer 100:11, 1704-1719
CrossRef715
Rakesh K. Jain, Dan G. Duda, Christopher G. Willett, Dushyant V. Sahani, Andrew X. Zhu, Jay S. Loeffler, Tracy T. Batchelor, A. Gregory Sorensen. (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nature Reviews Clinical Oncology 6:6, 327-338
CrossRef716
Ronan J. Kelly, Bertrand Billemont, Olivier Rixe. (2009) Renal toxicity of targeted therapies. Targeted Oncology 4:2, 121-133
CrossRef717
Jacques Medioni, Toni K. Choueiri, Franck Zinzindohoué, Daniel Cho, Laure Fournier, Stephane Oudard. (2009) Response of Renal Cell Carcinoma Pancreatic Metastasis to Sunitinib Treatment: A Retrospective Analysis. The Journal of Urology 181:6, 2470-2475
CrossRef718
Xuemei Luo, Joseph C. Cappelleri, David Cella, Jim Z. Li, Claudie Charbonneau, Sindy T. Kim, Isan Chen, Robert J. Motzer. (2009) Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapy–Kidney Symptom Index—Disease-Related Symptoms Scale. Value in Health 12:4, 580-586
CrossRef719
Robert J. Amato, Jaroslaw Jac, Sarah Giessinger, Somyata Saxena, James P. Willis. (2009) A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115:11, 2438-2446
CrossRef720
Aristotle Bamias. (2009) Editorial Comment on: Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis. European Urology 55:6, 1439
CrossRef721
Thomas Köpke, Stefan Bierer, Christian Wülfing, Arne Tiemann, Lothar Hertle, Edwin Herrmann. (2009) Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents. Expert Review of Anticancer Therapy 9:6, 763-771
CrossRef722
Stéphane Oudard, Jacques Medioni, Jorge Aylllon, Eduardo Barrascourt, Reza-Thierry Elaidi, José Balcaceres, Florian Scotte. (2009) Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 9:6, 705-717
CrossRef723
Lauren C. Harshman, Sandy Srinivas, Aya Kamaya, Benjamin I. Chung. (2009) Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nature Reviews Urology 6:6, 338-343
CrossRef724
Edward T.H. Yeh, Courtney L. Bickford. (2009) Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology 53:24, 2231-2247
CrossRef725
Seth A. Strope. (2009) Editorial Comment. The Journal of Urology 181:6, 2469
CrossRef726
Emma S Rennel, Steven J Harper, David O Bates. (2009) Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncology 5:5, 703-712
CrossRef727
Shruti N. Tapiawala, Joanne M. Bargman, Dimitrios G. Oreopoulos, Martin Simons. (2009) Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates. International Urology and Nephrology 41:2, 431-434
CrossRef728
David J. Reeves, Chin Y. Liu. (2009) Treatment of metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology 64:1, 11-25
CrossRef729
A. d’Onofrio, A. Gandolfi, A. Rocca. (2009) The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings. Cell Proliferation 42:3, 317-329
CrossRef730
Grégoire Robert, Grégoire Gabbay, Raphaël Bram, Hervé Wallerand, Colette Deminière, François Cornelis, Jean-Christophe Bernhard, Alain Ravaud, Philippe Ballanger. (2009) Complete Histologic Remission after Sunitinib Neoadjuvant Therapy in T3b Renal Cell Carcinoma. European Urology 55:6, 1477-1480
CrossRef731
Kelly L. Snider, Michael L. Maitland. (2009) Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Targeted Oncology 4:2, 67-76
CrossRef732
Hernán Cortés-Funes. (2009) The role of antiangiogenesis therapy: Bevacizumab and beyond. Clinical and Translational Oncology 11:6, 349-355
CrossRef733
M. Retz, J.E. Gschwend, J. Lehmann. (2009) Chemotherapie des Harnblasenkarzinoms. Der Urologe 48:6, 655-662
CrossRef734
Dale R Shepard, Jorge A Garcia. (2009) Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy 9:6, 795-805
CrossRef735
Janice P. Dutcher, Paul Souza, David McDermott, Robert A. Figlin, Anna Berkenblit, Alexandra Thiele, Mizue Krygowski, Andrew Strahs, Jay Feingold, Gary Hudes. (2009) Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Medical Oncology 26:2, 202-209
CrossRef736
Pierluigi Ballardini, Guido Margutti, Camillo Aliberti, Roberto Manfredini. (2009) Onset of Male Gynaecomastia in a Patient Treated with Sunitinib for Metastatic Renal Cell Carcinoma. Clinical Drug Investigation 29:7, 487-490
CrossRef737
Manfred Johannsen, Anne Flörcken, Axel Bex, Jan Roigas, Marco Cosentino, Vincenzo Ficarra, Christian Kloeters, Matthias Rief, Patrik Rogalla, Kurt Miller, Viktor Grünwald. (2009) Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis. European Urology 55:6, 1430-1439
CrossRef738
C.-H. Ohlmann. (2009) Prognosefaktoren für das Überleben des metastasierten Nierenzellkarzinoms. Der Urologe 48:6, 625-627
CrossRef739
Jeffrey Sosman, Igor Puzanov. (2009) Combination targeted therapy in advanced renal cell carcinoma. Cancer 115:S10, 2368-2375
CrossRef740
Brian I. Rini. (2009) Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer 115:S10, 2306-2312
CrossRef741
Bernard Escudier, Marine Gross Goupil, Christophe Massard, Karim Fizazi. (2009) Sequential therapy in renal cell carcinoma. Cancer 115:S10, 2321-2326
CrossRef742
David F. McDermott. (2009) Immunotherapy of metastatic renal cell carcinoma. Cancer 115:S10, 2298-2305
CrossRef743
Michael B. Atkins, Toni K. Choueiri, Daniel Cho, Meredith Regan, Sabina Signoretti. (2009) Treatment selection for patients with metastatic renal cell carcinoma. Cancer 115:S10, 2327-2333
CrossRef744
Thomas E. Hutson, Robert A. Figlin. (2009) Novel therapeutics for metastatic renal cell carcinoma. Cancer 115:S10, 2361-2367
CrossRef745
William G. Kaelin. (2009) Treatment of kidney cancer. Cancer 115:S10, 2262-2272
CrossRef746
Amado J. Zurita, Eric Jonasch, Hua-Kang Wu, Hai T. Tran, John V. Heymach. (2009) Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 115:S10, 2346-2354
CrossRef747
David A. Reardon, Merrill J. Egorin, Annick Desjardins, James J. Vredenburgh, Jan H. Beumer, Theodore F. Lagattuta, Sridharan Gururangan, James E. Herndon, August J. Salvado, Henry S. Friedman. (2009) Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 115:10, 2188-2198
CrossRef748
Arianna Di Napoli, Sabina Signoretti. (2009) Tissue biomarkers in renal cell carcinoma: Issues and solutions. Cancer 115:S10, 2290-2297
CrossRef749
W. Marston Linehan, Peter A. Pinto, Gennady Bratslavsky, Elizabeth Pfaffenroth, Maria Merino, Cathy D. Vocke, Jorge R. Toro, Donald Bottaro, Len Neckers, Laura S. Schmidt, Ramaprasad Srinivasan. (2009) Hereditary kidney cancer. Cancer 115:S10, 2252-2261
CrossRef750
Brian L. Egleston, Yu-Ning Wong. (2009) Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data. Statistics in Medicine 28:10, 1498-1511
CrossRef751
Robert E. Hawkins, Catriona Macdermott, Alaaeldin Shablak, Caroline Hamer, Fiona Thistlethwaite, Noel L. Drury, Priscilla Chikoti, William Shingler, Stuart Naylor, Richard Harrop. (2009) Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α. Journal of Immunotherapy 32:4, 424-429
CrossRef752
C. Dreyer, E. Raymond, S. Faivre. (2009) Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de Médecine Interne 30:5, 416-424
CrossRef753
Yoichi Mizutani. (2009) Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. International Journal of Urology 16:5, 444-448
CrossRef754
Colin R Lindsay, Iain RJ MacPherson, Jim Cassidy. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology 5:4, 421-432
CrossRef755
Manuela Schmidinger, Christoph C. Zielinski. (2009) Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. Cancer Treatment Reviews 35:3, 289-296
CrossRef756
H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, J. P. Spano. (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Annals of Oncology 20:5, 807-815
CrossRef757
Ming Hui Chen. (2009) Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue. Current Cardiology Reports 11:3, 167-174
CrossRef758
Ronald M. Bukowski. (2009) Targeted Therapies: Bevacizumab and interferon-α in metastatic renal-cell carcinoma. Nature Reviews Clinical Oncology 6:5, 253-254
CrossRef759
C. N. Sternberg. (2009) Expanding the boundaries of clinical practice: building on experience with targeted therapies. Annals of Oncology 20:Supplement 1, i1-i6
CrossRef760
C. Perrin, J. Edeline, C. Vigneau, J. -J. Patard, N. Rioux-Leclercq. (2009) Carcinomes à cellules rénales: de la pathologie aux voies moléculaires de la carcinogenèse. Oncologie 11:5, 254-259
CrossRef761
V. Grünwald, J. Gschwend. (2009) Einsatz von RAD001 bei Patienten mit metastasiertem Nierenzellkarzinom. Der Onkologe 15:5, 512-518
CrossRef762
D. Pouessel, J. -J. Patard, S. Culine. (2009) Stratégie de la prise en charge médicale dans les stades métastatiques. Oncologie 11:5, 278-284
CrossRef763
Jorge A Garcia, C Lance Cowey, Paul A Godley. (2009) Renal cell carcinoma. Current Opinion in Oncology 21:3, 266-271
CrossRef764
Hideaki Miyake, Iori Sakai, Mototsugu Muramaki, Toshifumi Kurahashi, Atsushi Takenaka, Masato Fujisawa. (2009) Prediction of response to combined immunotherapy with interferon-α and low-dose interleukin-2 in metastatic renal cell carcinoma: Expression patterns of potential molecular markers in radical nephrectomy specimens. International Journal of Urology 16:5, 465-471
CrossRef765
J. Bellmunt. (2009) Future developments in renal cell carcinoma. Annals of Oncology 20:Supplement 1, i13-i17
CrossRef766
Marc C. Smaldone, Jodi K. Maranchie. (2009) Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 27:3, 238-245
CrossRef767
A. Ravaud. (2009) How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Annals of Oncology 20:Supplement 1, i7-i12
CrossRef768
Holger Gerullis, Lothar Bergmann, Luise Maute, Christoph Eimer, Thomas Otto. (2009) Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemotherapy and Pharmacology 63:6, 1097-1102
CrossRef769
Francesco Torino, Salvatore Maria Corsello, Raffaele Longo, Agnese Barnabei, Giampietro Gasparini. (2009) Is Hypothyroidism a Clinically Relevant Toxicity of Tyrosine Kinase Inhibitors?. Thyroid 19:5, 539-540
CrossRef770
Jens Soltau, Joachim Drevs. (2009) Mode of action and clinical impact of VEGF signaling inhibitors. Expert Review of Anticancer Therapy 9:5, 649-662
CrossRef771
C. Chevreau. (2009) Les effets secondaires des anti-angiogéniques (à l’exception des effets cutanés). Oncologie 11:5, 285-290
CrossRef772
B. Escudier, V. Kataja, . (2009) Renal cell carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv81-iv82
CrossRef773
Laurence Bastien, Stéphane Culine, Bernard Paule, Souhil Ledbai, Jean Jacques Patard, Alexandre de la Taille. (2009) Targeted therapies in metastatic renal cancer in 2009. BJU International 103:10, 1334-1342
CrossRef774
Camillo Porta, Cezary Szczylik. (2009) Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treatment Reviews 35:3, 297-307
CrossRef775
P. Schoffski, R. Bukowski, P. Flodgren, A. Ravaud. (2009) Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports. Annals of Oncology 20:Supplement 1, i25-i30
CrossRef776
Zaher K. Otrock, Hassan A. Hatoum, Ahmad H. Awada, Rim S. Ishak, Ali I. Shamseddine. (2009) Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives. Critical Reviews in Oncology/Hematology 70:2, 93-102
CrossRef777
Ursula Maria Vogl, Walter Berger, Michael Micksche, Christine Pirker, Wolfgang Lamm, Oskar Pichelmeyer, Christoph C. Zielinski, Manuela Schmidinger. (2009) Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. Cancer Letters 277:2, 218-226
CrossRef778
Vitaly Margulis, Michelle McDonald, Pheroze Tamboli, David A. Swanson, Christopher G. Wood. (2009) Predictors of Oncological Outcome After Resection of Locally Recurrent Renal Cell Carcinoma. The Journal of Urology 181:5, 2044-2051
CrossRef779
Elizabeth R. Plimack, Nizar Tannir, E Lin, B. Nebiyou Bekele, Eric Jonasch. (2009) Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon. Cancer 115:9, 1859-1866
CrossRef780
Kevin D. Courtney, Toni K. Choueiri. (2009) Optimizing recent advances in metastatic renal cell carcinoma. Current Oncology Reports 11:3, 218-226
CrossRef781
Maria J Soares, Mafalda Pinto, Rui Henrique, Joana Vieira, Nuno Cerveira, Ana Peixoto, Ana T Martins, Jorge Oliveira, Carmen Jerónimo, Manuel R Teixeira. (2009) CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. Modern Pathology
CrossRef782
C Alfaro, N Suarez, A Gonzalez, S Solano, L Erro, J Dubrot, A Palazon, S Hervas-Stubbs, A Gurpide, J M Lopez-Picazo, E Grande-Pulido, I Melero, J L Perez-Gracia. (2009) Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. British Journal of Cancer 100:7, 1111-1119
CrossRef783
Hendrik Van Poppel. (2009) Treatment of Advanced and Metastatic Renal Cancer: A Revolution?. European Urology Supplements 8:5, 483-488
CrossRef784
Andrew R Reynolds, Ian R Hart, Alan R Watson, Jonathan C Welti, Rita G Silva, Stephen D Robinson, Georges Da Violante, Morgane Gourlaouen, Mishal Salih, Matt C Jones, Dylan T Jones, Garry Saunders, Vassiliki Kostourou, Françoise Perron-Sierra, Jim C Norman, Gordon C Tucker, Kairbaan M Hodivala-Dilke. (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature Medicine 15:4, 392-400
CrossRef785
Sebastian Ruppin, Chris Protzel, Klaus-Jürgen Klebingat, Oliver W. Hakenberg. (2009) Successful Sorafenib Treatment for Metastatic Renal Cell Carcinoma in a Case with Chronic Renal Failure. European Urology 55:4, 986-988
CrossRef786
Laurent Zini, Paul Perrotte, Umberto Capitanio, Claudio Jeldres, Alain Duclos, Philippe Arjane, Arnauld Villers, Francesco Montorsi, Jean-Jacques Patard, Pierre I. Karakiewicz. (2009) Race affects access to nephrectomy but not survival in renal cell carcinoma. BJU International 103:7, 889-893
CrossRef787
Francesco Torino, Salvatore Maria Corsello, Raffaele Longo, Agnese Barnabei, Giampietro Gasparini. (2009) Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nature Reviews Clinical Oncology 6:4, 219-228
CrossRef788
Tobias Klatte, Jonathan W. Said, Michela de Martino, Jeffrey LaRochelle, Brian Shuch, Jian Yu Rao, George V. Thomas, Fairooz F. Kabbinavar, Arie S. Belldegrun, Allan J. Pantuck. (2009) Presence of Tumor Necrosis is Not a Significant Predictor of Survival in Clear Cell Renal Cell Carcinoma: Higher Prognostic Accuracy of Extent Based Rather Than Presence/Absence Classification. The Journal of Urology 181:4, 1558-1564
CrossRef789
Michael Dougan, Glenn Dranoff. (2009) Immune Therapy for Cancer. Annual Review of Immunology 27:1, 83-117
CrossRef790
Michael K. K Wong, Anthony Jarkowski. (2009) Response to Sorafenib After Sunitinib-Induced Acute Heart Failure in a Patient with Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature. Pharmacotherapy 29:4, 473-478
CrossRef791
Masahiro Shiba, Norio Nonomura, Yasutomo Nakai, Masashi Nakayama, Hitoshi Takayama, Hitoshi Inoue, Akira Tsujimura, Kazuo Nishimura, Akihiko Okuyama. (2009) Type-I interferon receptor expression: Its circadian rhythm and downregulation after interferon-α administration in peripheral blood cells from renal cancer patients. International Journal of Urology 16:4, 356-359
CrossRef792
Faina Gurevich, Mark A. Perazella. (2009) Renal Effects of Anti-angiogenesis Therapy: Update for the Internist. The American Journal of Medicine 122:4, 322-328
CrossRef793
Nicolas Grenier, Catherine Douws, Vincent Pérot, Jean-Marie Ferrière, Alain Ravaud. (2009) Combined Radiofrequency Ablation and Antiangiogenic Drug for the Treatment of Recurrent Renal Tumor. Urology 73:4, 928.e11-928.e12
CrossRef794
Stefan Zastrow, Michael Froehner, Ivan Platzek, Vladimir Novotny, Manfred P. Wirth. (2009) Treatment of Metastatic Renal Cell Cancer with Sunitinib During Chronic Hemodialysis. Urology 73:4, 868-870
CrossRef795
Takeshi Yuasa, Kiyoshi Sato, Eishi Ashihara, Miki Takeuchi, Shinya Maita, Norihiko Tsuchiya, Tomonori Habuchi, Taira Maekawa, Shinya Kimura. (2009) Intravesical administration of γδ T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunology, Immunotherapy 58:4, 493-502
CrossRef796
Marcus Czabanka, Mara Vinci, Frank Heppner, Axel Ullrich, Peter Vajkoczy. (2009) Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. International Journal of Cancer 124:6, 1293-1300
CrossRef797
Theo M. de Reijke, Joaquim Bellmunt, Hein van Poppel, Sandrine Marreaud, Matti Aapro. (2009) EORTC-GU group expert opinion on metastatic renal cell cancer. European Journal of Cancer 45:5, 765-773
CrossRef798
Anthony J Polcari, Alex Gorbonos, John E Milner, Robert C Flanigan. (2009) The role of cytoreductive nephrectomy in the era of molecular targeted therapy. International Journal of Urology 16:3, 227-233
CrossRef799
Alvin S. Wong, Kian-Tai Chong, Chin-Tiong Heng, David T. Consigliere, Kesavan Esuvaranathan, Khai-Lee Toh, Benjamin Chuah, Robert Lim, James Tan. (2009) Debulking nephrectomy followed by a “watch and wait” approach in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 27:2, 149-154
CrossRef800
Satish K. Tickoo, Stephen M. Rohan. (2009) Pathologic Features of Adult Renal Cortical Tumors. Surgical Pathology Clinics 2:1, 1-25
CrossRef801
C. Lance Cowey, W. Kimryn Rathmell. (2009) VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy. Current Oncology Reports 11:2, 94-101
CrossRef802
Robin J. Prestwich, Karen J. Scott, Joanne Brown, Patricia Harnden, Peter Whelan, Jon Cartledge, Dearbhaile O’Donnell, Hardev S. Pandha, Peter J. Selby, Rosamund E. Banks, Alison E. Merrick, Alan A. Melcher. (2009) The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. BJU International 103:6, 740-746
CrossRef803
Guido Fechner. (2009) Reply. Urology 73:3, 669
CrossRef804
S. Joseph Sirintrapun, Anil V. Parwani. (2009) Molecular Pathology of the Genitourinary Tract: Molecular Pathology of Kidney and Testes. Surgical Pathology Clinics 2:1, 199-223
CrossRef805
Ronald M. Bukowski. (2009) Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer. Current Oncology Reports 11:2, 81-83
CrossRef806
Joaquim Bellmunt, Emiliano Calvo, Daniel Castellano, Miguel Ángel Climent, Emilio Esteban, Xavier García del Muro, José Luis González-Larriba, Pablo Maroto, José Manuel Trigo. (2009) Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemotherapy and Pharmacology 63:S1, 1-13
CrossRef807
Guido Fechner, Katarina Claßen, Doris Schmidt, Stefan Hauser, Stefan C. Müller. (2009) Rapamycin Inhibits In Vitro Growth and Release of Angiogenetic Factors in Human Bladder Cancer. Urology 73:3, 665-668
CrossRef808
Francesca Elice, Francesco Rodeghiero, Anna Falanga, Frederick R. Rickles. (2009) Thrombosis associated with angiogenesis inhibitors. Best Practice & Research Clinical Haematology 22:1, 115-128
CrossRef809
Laura Vroling, Astrid A. M. Veldt, Richard R. Haas, John B. A. G. Haanen, Gerrit Jan Schuurhuis, Dirk J. Kuik, Hester Cruijsen, Henk M. W. Verheul, Alfons J. M. den Eertwegh, Klaas Hoekman, Epie Boven, Victor W. M. Hinsbergh, Henk J. Broxterman. (2009) Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 12:1, 69-79
CrossRef810
Christian Britschgi, Martin F Fey. (2009) Tumor suppressor genes in myeloid differentiation and leukemogenesis. Future Oncology 5:2, 245-257
CrossRef811
Joaquim Bellmunt, Marta Guix. (2009) The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU International 103:5, 572-577
CrossRef812
Glenwood Goss, Frances A. Shepherd, Scott Laurie, Isabelle Gauthier, N. Leighl, Eric Chen, Ronald Feld, Jean Powers, Lesley Seymour. (2009) A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer 45:5, 782-788
CrossRef813
Cora N. Sternberg. (2009) A medical oncologist's perspective on the treatment of patients with genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations 27:2, 122-125
CrossRef814
Brian I Rini, Steven C Campbell, Bernard Escudier. (2009) Renal cell carcinoma. The Lancet 373:9669, 1119-1132
CrossRef815
Dietmar W. Siemann, W.D. Brazelle, Juliane M. Jürgensmeier. (2009) The Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor Cediranib (Recentin; AZD2171) Inhibits Endothelial Cell Function and Growth of Human Renal Tumor Xenografts. International Journal of Radiation Oncology*Biology*Physics 73:3, 897-903
CrossRef816
Inger Rosner, Gennady Bratslavsky, Peter A. Pinto, W. Marston Linehan. (2009) The clinical implications of the genetics of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 27:2, 131-136
CrossRef817
Simon Chowdhury, Toni K Choueiri. (2009) Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Review of Anticancer Therapy 9:3, 373-379
CrossRef818
Peter Hulick, Michael Zimmer, Vitaly Margulis, Steven Skates, Maureen Hamel, Douglas M. Dahl, Dror M. Michaelson, Towia Liebermann, Sabina Signoretti, Walter Carney, Christopher Wood, Othon Iliopoulos. (2009) Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. Clinical Proteomics 5:1, 37-45
CrossRef819
Daniel Y. C. Heng, Kim N Chi, Nevin Murray, Tao Jin, Jorge A Garcia, Ronald M Bukowski, Brian I Rini, Christian Kollmannsberger. (2009) A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 115:4, 776-783
CrossRef820
Bach, Peter B., . (2009) Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs. New England Journal of Medicine 360:6, 626-633
Full Text821
Risto Kerkela, Kathleen C. Woulfe, Jean-Bernard Durand, Ronald Vagnozzi, David Kramer, Tammy F. Chu, Cara Beahm, Ming Hui Chen, Thomas Force. (2009) Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase. Clinical and Translational Science 2:1, 15-25
CrossRef822
K. Oechsle, C. Bokemeyer. (2009) Kardiotoxizitäten bei Chemo- und Radiotherapie. Der Onkologe 15:2, 157-162
CrossRef823
Laurent Zini, Umberto Capitanio, Paul Perrotte, Claudio Jeldres, Shahrokh F. Shariat, Philippe Arjane, Hugues Widmer, Francesco Montorsi, Jean-Jacques Patard, Pierre I. Karakiewicz. (2009) Population-based Assessment of Survival After Cytoreductive Nephrectomy Versus No Surgery in Patients With Metastatic Renal Cell Carcinoma. Urology 73:2, 342-346
CrossRef824
Anil A. Thomas, Brian I. Rini, Brian R. Lane, Jorge Garcia, Robert Dreicer, Eric A. Klein, Andrew C. Novick, Steven C. Campbell. (2009) Response of the Primary Tumor to Neoadjuvant Sunitinib in Patients With Advanced Renal Cell Carcinoma. The Journal of Urology 181:2, 518-523
CrossRef825
Vishnu Chintalgattu, Shalin S. Patel, Aarif Y. Khakoo. (2009) Cardiovascular Effects of Tyrosine Kinase Inhibitors Used for Gastrointestinal Stromal Tumors. Hematology/Oncology Clinics of North America 23:1, 97-107
CrossRef826
David Diaz, Luis Chara, Julio Chevarria, Joaquin Carballido, Emilio Esteban, Victor Navas, Jorge Monserrat, Alfredo Prieto, Antonio la Hera, Melchor Alvarez-Mon. (2009) Inhaled IL-2 induces systemic immunomodulation in patients with renal cell carcinoma and lung metastasis. Cancer Immunology, Immunotherapy 58:2, 235-245
CrossRef827
Daniel C. Cho, Igor Puzanov, Meredith M. Regan, Talya Schwarzberg, Virginia Seery, Mee-Young Lee, Vivian Liu, Rupal Bhatt, Henry Koon, James W. Mier, Jeffrey A. Sosman, Michael B. Atkins, David F. McDermott. (2009) Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy 32:2, 181-185
CrossRef828
JONATHAN M GLEADLE. (2009) Review article: How cells sense oxygen: Lessons from and for the kidney. Nephrology 14:1, 86-93
CrossRef829
Jonathan Silberstein, Julia Grabowski, Sidney L. Saltzstein, Christopher J. Kane. (2009) Renal cell carcinoma in the pediatric population: Results from the California Cancer Registry. Pediatric Blood & Cancer 52:2, 237-241
CrossRef830
Joshua J. Meeks, Kathrine A. Kasper, Ximing Yang, Timothy M. Kuzel, Norm D. Smith. (2009) Metastatic Renal Cell Carcinoma With Partial Response to Sunitinib Complicated by Ureteral Obstruction From Necrotic Tumor. Urology 73:2, 444.e11-444.e12
CrossRef831
F.C.S. Eng, A.M. Easson, E. Szentgyorgyi, J.J. Knox. (2009) Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. European Journal of Surgical Oncology (EJSO) 35:2, 219-221
CrossRef832
Laetitia Vercellino, Guilhem Bousquet, Georges Baillet, Emmanuelle Barré, Olivier Mathieu, Pierre-Alexandre Just, François Desgrandchamps, Jean-Louis Misset, Elif Hindié, Jean-Luc Moretti. (2009) 18 F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study. Cancer Biotherapy & Radiopharmaceuticals 24:1, 137-144
CrossRef833
Amir T Fathi, Mark Levis. (2009) Lestaurtinib: a multi-targeted FLT3 inhibitor. Expert Review of Hematology 2:1, 17-26
CrossRef834
Risto Kerkela, Kathleen C. Woulfe, Jean-Bernard Durand, Ronald Vagnozzi, David Kramer, Tammy F. Chu, Cara Beahm, Ming Hui Chen, Thomas Force. (2009) Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase. Clinical and Translational Science
CrossRef835
Piotr Rutkowski, Włodzimierz Ruka. (2009) Emergency surgery in the era of molecular treatment of solid tumours. The Lancet Oncology 10:2, 157-163
CrossRef836
Christopher P. Evans. (2009) Identification of molecular targets in urologic oncology. World Journal of Urology 27:1, 3-8
CrossRef837
Thomas W. Flaig, Fernando J. Kim, Francisco G. Rosa, Kathryn Breaker, Jonathan Schoen, Paul D. Russ. (2009) Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Investigational New Drugs 27:1, 83-87
CrossRef838
T Kojima, T Shimazui, S Hinotsu, A Joraku, T Oikawa, K Kawai, R Horie, H Suzuki, R Nagashima, K Yoshikawa, T Michiue, M Asashima, H Akaza, K Uchida. (2009) Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene 28:2, 297-305
CrossRef839
Ronald M. Bukowski. (2009) Tyrosine Kinase Inhibitors in Advanced Renal Cell Carcinoma: The Evolving Treatment Paradigm. Clinical Genitourinary Cancer 7:1, 9-10
CrossRef840
Andrew Stone. (2009) The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials. Pharmaceutical Statisticsn/a-n/a
CrossRef841
Robert J. Motzer, Gary Hudes, George Wilding, Lawrence H. Schwartz, Subramanian Hariharan, Susan Kempin, Rana Fayyad, Robert A. Figlin. (2009) Phase I Trial of Sunitinib Malate plus Interferon-α for Patients with Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 7:1, 28-33
CrossRef842
Shailender Bhatia, John A. Thompson. (2009) Temsirolimus in patients with advanced renal cell carcinoma: an overview. Advances in Therapy 26:1, 55-67
CrossRef843
James M. G. Larkin, Rosemary E. J. Clarke, Lisa M. Pickering. (2009) Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: biology and pathways. Medical Oncology 26:S1, 40-45
CrossRef844
David F. McDermott. (2009) The application of high-dose interleukin-2 for metastatic renal cell carcinoma. Medical Oncology 26:S1, 13-17
CrossRef845
Yuan Xue, Natasa Petrovic, Renhai Cao, Ola Larsson, Sharon Lim, Shaohua Chen, Helena M. Feldmann, Zicai Liang, Zhenping Zhu, Jan Nedergaard, Barbara Cannon, Yihai Cao. (2009) Hypoxia-Independent Angiogenesis in Adipose Tissues during Cold Acclimation. Cell Metabolism 9:1, 99-109
CrossRef846
Aza Mohammed, Iqbal Shergill, Brian Little. (2009) Management of metastatic renal cell carcinoma: current trends. Expert Review of Molecular Diagnostics 9:1, 75-83
CrossRef847
Andrew X Zhu, Eric Raymond. (2009) Early development of sunitinib in hepatocellular carcinoma. Expert Review of Anticancer Therapy 9:1, 143-150
CrossRef848
Joaquim Bellmunt, Sylvie Négrier, Bernard Escudier, Ahmad Awada, Matti Aapro. (2009) The medical treatment of metastatic renal cell cancer in the elderly: Position paper of a SIOG Taskforce. Critical Reviews in Oncology/Hematology 69:1, 64-72
CrossRef849
Guru Sonpavde, Thomas E. Hutson. (2009) Everolimus for renal cell carcinoma: predictive factors for response and future directions. Medical Oncology 26:S1, 46-53
CrossRef850
Vitaly Margulis, Christopher G. Wood. (2009) Pre-surgical targeted molecular therapy in renal cell carcinoma. BJU International 103:2, 150-153
CrossRef851
Lisa M Pickering, Linda Pyle, James MG Larkin. (2009) Sunitinib is superior to interferon α with respect to quality of life for patients with renal cell carcinoma. Nature Clinical Practice Oncology 6:1, 6-7
CrossRef852
Min Hee Hong, Hyo Song Kim, Chan Kim, Jung Ryun Ahn, Hong Jae Chon, Sang-Joon Shin, Joong-Bae Ahn, Hyun Cheol Chung, Sun Young Rha. (2009) Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea. Cancer Research and Treatment 41:2, 67
CrossRef853
Arkadiusz Z. Dudek, Jakub Zolnierek, Anu Dham, Bruce R. Lindgren, Cezary Szczylik. (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115:1, 61-67
CrossRef854
Makoto Tahara, Atsushi Shibata, Shizuyo Yamaguchi, Yoshimasa Hamada. (2009) Pharmacology profile of sunitinib malate (Sutent® Capsules) and clinical findings on this drug. Folia Pharmacologica Japonica 133:4, 215-226
CrossRef855
Kenji Tamura. (2009) EGFR and VEGF-targeted drugs: clinical evidence for their effects from evaluation of biomarkers. Folia Pharmacologica Japonica 133:2, 69-72
CrossRef856
Michelle Lockley, Tim Eisen. (2009) Sorafenib: a multitargeted oral agent for the treatment of advanced renal cell cancer. Therapy 6:1, 111-124
CrossRef857
Michael B. Atkins. (2009) Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. Medical Oncology 26:S1, 18-22
CrossRef858
David Chu, Mario E. Lacouture, Elizabeth Weiner, Shenhong Wu. (2009) Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis. Clinical Genitourinary Cancer 7:1, 11-19
CrossRef859
Kojun OKAMOTO, Isamu KOYAMA, Mitsuo MIYAZAWA, Masayasu AIKAWA, Katsuya OKADA, Yasuko TOSHIMITSU, Satoshi TABUCHI, Toshimasa ISHII, Utaroh MOTOSUGI. (2009) Hepatic Metastasis 12 Years after Nephrectomy for Renal Cell Carcinoma. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 34:4, 642-645
CrossRef860
Bernard Escudier, John A. Thompson. (2009) Mechanism of action of everolimus in renal cell carcinoma. Medical Oncology 26:S1, 32-39
CrossRef861
Premal H. Patel, Peggy L. Senico, Rafael E. Curiel, Robert J. Motzer. (2009) Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer 7:1, 24-27
CrossRef862
Yong Hyun Park, Min Yong Kang, In Sik Hwang, Chan Soo Park, Sung Han Kim, Ja Hyun Ku, Cheol Kwak, Hyeon Hoe Kim. (2009) Targeted Therapy in Metastatic Renal Cell Carcinoma. Korean Journal of Urology 50:1, 1
CrossRef863
Yongping Crawford, Napoleone Ferrara. (2009) VEGF inhibition: insights from preclinical and clinical studies. Cell and Tissue Research 335:1, 261-269
CrossRef864
Amir Harandi, Aisha S. Zaidi, Abigail M. Stocker, Damian A. Laber. (2009) Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology 2009, 1-14
CrossRef865
Keith T. Flaherty. (2009) Where does the combination of sorafenib and interferon in renal cell carcinoma stand?. CancerNA-NA
CrossRef866
Mototsugu Oya. (2009) Renal Cell Carcinoma: Biological Features and Rationale for Molecular-targeted Therapy. The Keio Journal of Medicine 58:1, 1-11
CrossRef867
Hans Prenen, Thierry Gil, Ahmad Awada. (2009) New therapeutic developments in renal cell cancer. Critical Reviews in Oncology/Hematology 69:1, 56-63
CrossRef868
T. Gauler, M. Schuler. (2009) Hat die Systemtherapie von Lymphknotenmetastasen einen kurativen Wert?. Der Urologe 48:1, 62-65
CrossRef869
Anil A. Thomas, Brian I. Rini, Steven C. Campbell. (2009) Integration of surgery and systemic therapy in the management of metastatic renal cancer. Current Urology Reports 10:1, 35-41
CrossRef870
Harley King. (2009) Essentials of pharmacoeconomics. Journal of Commercial Biotechnology 15:1, 92-94
CrossRef871
Jean-Jacques Patard, Rodolphe Thuret, Avakian Raffi, Brigitte Laguerre, Karim Bensalah, Stéphane Culine. (2009) Treatment with Sunitinib Enabled Complete Resection of Massive Lymphadenopathy not Previously Amenable to Excision in a Patient with Renal Cell Carcinoma. European Urology 55:1, 237-239
CrossRef872
J.-O. Lee, K.-W. Lee, C.-J. Kim, Y. J. Kim, H. E. Lee, H. Kim, J. H. Kim, S.-M. Bang, J.-S. Kim, J. S. Lee. (2008) Metastatic Adrenocortical Carcinoma Treated with Sunitinib: A Case Report. Japanese Journal of Clinical Oncology 39:3, 183-185
CrossRef873
Christian Eichelberg, Roman Heuer, Felix K. Chun, Kristin Hinrichs, Mario Zacharias, Hartwig Huland, Hans Heinzer. (2008) Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis. European Urology 54:6, 1373-1378
CrossRef874
Christoph Eimer, Holger Gerullis, Thomas Otto. (2008) „Targeted therapy“ des metastasierten Nierenzellkarzinoms (mRCC). Onkopipeline 1:3, 82-90
CrossRef875
Christian Bolenz, Yair Lotan. (2008) Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nature Clinical Practice Urology 5:12, 676-685
CrossRef876
Axel Haferkamp, Jens Bedke, Caroline Vetter, Maria Pritsch, Nina Wagener, Stephan Buse, Irena Crnkovic-Mertens, Karin Hoppe-Seyler, Stephan Macher-Goeppinger, Felix Hoppe-Seyler, Frank Autschbach, Markus Hohenfellner. (2008) High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma. BJU International 102:11, 1700-1706
CrossRef877
Simon Chowdhury, Peter G Harper, Toni K Choueiri. (2008) The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy. Nature Clinical Practice Oncology 5:12, 698-699
CrossRef878
Albrecht Reichle, Thomas Vogt. (2008) Systems Biology: A Therapeutic Target for Tumor Therapy. Cancer Microenvironment 1:1, 159-170
CrossRef879
Tim Eisen. (2008) THE NATIONAL INSTITUTE OF HEALTH AND CLINICAL EXCELLENCE REJECTS NEW TREATMENTS FOR RENAL CELL CANCER: CINDERELLA'S INVITATION IS CANCELLED. BJU International 102:11, 1491-1492
CrossRef880
Marianna Aita, Gianpiero Fasola, Carlotta Defferrari, Annalisa Brianti, Maria Giovanna Dal Bello, Alessandro Follador, Graziella Sinaccio, Paolo Pronzato, Francesco Grossi. (2008) Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology 68:3, 183-196
CrossRef881
Naveen S. Vasudev, Roisean E. Ferguson, David A. Cairns, Anthea J. Stanley, Peter J. Selby, Rosamonde E. Banks. (2008) Serum biomarker discovery in renal cancer using 2-DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same?. PROTEOMICS 8:23-24, 5074-5085
CrossRef882
Fernando Cotait Maluf, Gustavo dos Santos Fernandes, Ariel Galapo Kann, José Luis Aguilar-Ponce, Jaime de la Garza, Antonio Carlos Buzaid. (2008) Exploring the role of novel agents in the treatment of renal cell carcinoma. Cancer Treatment Reviews 34:8, 750-760
CrossRef883
Y. Xue, P. Religa, R. Cao, A. J. Hansen, F. Lucchini, B. Jones, Y. Wu, Z. Zhu, B. Pytowski, Y. Liang, W. Zhong, P. Vezzoni, B. Rozell, Y. Cao. (2008) Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proceedings of the National Academy of Sciences 105:47, 18513-18518
CrossRef884
S. K. Winn, S. Ellis, P. Savage, S. Sampson, J. E. Marsh. (2008) Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?. Nephrology Dialysis Transplantation 24:2, 673-675
CrossRef885
B Billemont, J Medioni, L Taillade, D Helley, J B Meric, O Rixe, S Oudard. (2008) Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. British Journal of Cancer 99:9, 1380-1382
CrossRef886
D Strumberg, B Schultheis, I A Adamietz, O Christensen, M Buechert, J Kraetzschmar, P Rajagopalan, M Ludwig, A Frost, S Steinbild, M E Scheulen, K Mross. (2008) Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. British Journal of Cancer 99:10, 1579-1585
CrossRef887
Ferry ALM Eskens, Stefan Sleijfer. (2008) The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?. European Journal of Cancer 44:16, 2350-2356
CrossRef888
Sandrine Faivre, Eric Raymond. (2008) Mechanism of action of rapalogues: the antiangiogenic hypothesis. Expert Opinion on Investigational Drugs 17:11, 1619-1621
CrossRef889
Alonso V. Pacheco, Kanwaldeep Rasila, Sang-Joon Lee, Ian Rabinowitz, Laurence Elias, Fa Chyi Lee, Claire F. Verschraegen. (2008) Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. Urologic Oncology: Seminars and Original Investigations 26:6, 610-615
CrossRef890
Thomas E Hutson. (2008) Sunitinib (SUTENT ® ) for the treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 8:11, 1723-1731
CrossRef891
Francesca Elice, Jack Jacoub, Frederick R. Rickles, Anna Falanga, Francesco Rodeghiero. (2008) Hemostatic complications of angiogenesis inhibitors in cancer patients. American Journal of Hematology 83:11, 862-870
CrossRef892
Anne Schlesinger-Raab, Uwe Treiber, Dirk Zaak, Dieter Hölzel, Jutta Engel. (2008) Metastatic renal cell carcinoma: Results of a population-based study with 25 years follow-up. European Journal of Cancer 44:16, 2485-2495
CrossRef893
William G. Kaelin Jr. (2008) The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer. Nature Reviews Cancer 8:11, 865-873
CrossRef894
H. Moch. (2008) Molekulare Basis der zielgerichteten Therapien bei metastasierenden Nierenzellkarzinomen. Der Pathologe 29:S2, 184-186
CrossRef895
Brian R. Lane, Michael W. Kattan. (2008) Prognostic Models and Algorithms in Renal Cell Carcinoma. Urologic Clinics of North America 35:4, 613-625
CrossRef896
Satish K. Tickoo, Anuradha Gopalan. (2008) Pathologic Features of Renal Cortical Tumors. Urologic Clinics of North America 35:4, 551-561
CrossRef897
A. Ravaud, J. -C. Bernhard, J. -M. Ferrière. (2008) Bévacizumab et temsirolimus: quel apport dans la stratégie de prise en charge du cancer du rein métastatique ?. Oncologie 10:11, 653-656
CrossRef898
Brian I Rini. (2008) Lapatinib therapy for patients with advanced renal cell carcinoma. Nature Clinical Practice Oncology 5:11, 626-627
CrossRef899
Steven J. Harper, David O. Bates. (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nature Reviews Cancer 8:11, 880-887
CrossRef900
Glenn S. Kroog, Robert J. Motzer. (2008) Systemic Therapy for Metastatic Renal Cell Carcinoma. Urologic Clinics of North America 35:4, 687-701
CrossRef901
Jens Bedke, Alexandre E. Pelzer. (2008) Re: Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. European Urology 54:5, 1200-1201
CrossRef902
Tobias Klatte, Allan J. Pantuck. (2008) Molecular Biology of Renal Cortical Tumors. Urologic Clinics of North America 35:4, 573-580
CrossRef903
Jaafar Bennouna, Emmanuelle Bompas, Eve Marie Neidhardt, Frédéric Rolland, Irène Philip, Céline Galéa, Samuel Salot, Soraya Saiagh, Marie Audrain, Marie Rimbert, Sylvie Lafaye-de Micheaux, Jérôme Tiollier, Sylvie Négrier. (2008) Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy 57:11, 1599-1609
CrossRef904
Arie S. Belldegrun, Tobias Klatte, Brian Shuch, Jeffrey C. LaRochelle, David C. Miller, Jonathan W. Said, Stephen B. Riggs, Nazy Zomorodian, Fairooz F. Kabbinavar, Jean B. deKernion, Allan J. Pantuck. (2008) Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005). Cancer 113:9, 2457-2463
CrossRef905
Antonio Lopez–Beltran, Ziya Kirkali, Liang Cheng, Lars Egevad, Juan C. Regueiro, Ana Blanca, Rodolfo Montironi. (2008) Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. Seminars in Diagnostic Pathology 25:4, 232-244
CrossRef906
Thomas E Hutson, Robert A Figlin. (2008) Experimental therapy for advanced renal cell carcinoma. Expert Opinion on Investigational Drugs 17:11, 1693-1702
CrossRef907
C Le Tourneau, S Faivre, M Serova, E Raymond. (2008) mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?. British Journal of Cancer 99:8, 1197-1203
CrossRef908
Thomas E Hutson. (2008) Sunitinib (SUTENT ® ) for the treatment of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 0:0, 081017084851099
CrossRef909
M. Reckova, M. Kakalejcik, J. Beniak. (2008) Treatment of hemodialyzed patient with sunitinib. Annals of Oncology 20:2, 392-393
CrossRef910
A.S. Merseburger, M.A. Kuczyk. (2008) Der Stellenwert der Targeted-Therapie beim Nierenzellkarzinom. Der Urologe 47:10, 1303-1310
CrossRef911
Peter E. Clark, Michael S. Cookson. (2008) The von Hippel-Lindau gene. Cancer 113:S7, 1768-1778
CrossRef912
Bhanu K Vakkalanka, Ronald M Bukowski. (2008) Novel drugs for renal cell carcinoma. Expert Opinion on Investigational Drugs 17:10, 1501-1516
CrossRef913
Simon Chowdhury, James M.G. Larkin, Martin E. Gore. (2008) Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. European Journal of Cancer 44:15, 2152-2161
CrossRef914
Fernando J. Kim, Adriano Campagna, Lakshmipathi Khandrika, Sweaty Koul, Seok-Soo Byun, Adrie van Bokhoven, Ernest E. Moore, Hari Koul. (2008) Individualized Medicine for Renal Cell Carcinoma: Establishment of Primary Cell Line Culture from Surgical Specimens. Journal of Endourology 22:10, 2361-2366
CrossRef915
Emanuele Naglieri. (2008) Management of toxicity in patients treated with tyrosine kinase inhibitors (TKI). European Journal of Cancer Supplements 6:14, 42-45
CrossRef916
Josep M. Llovet, Jordi Bruix. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:4, 1312-1327
CrossRef917
G. Cartenì, A.M. Grimaldi, T. Guida, F. Riccardi, M. Biglietto, E. Perrotta, M. Otero, P. De Rosa, G. Nicolella, G. Esposito, R. Fiorentino, B. Chiurazzi, C. Battista, N. Panza. (2008) Target therapy in metastatic renal cell carcinoma. European Journal of Cancer Supplements 6:14, 38-41
CrossRef918
Ziya Kirkali. (2008) Will We Be Able to “Cure” Metastatic Renal Cell Carcinoma Like We Cure Testicular Tumours?. European Urology 54:4, 712-714
CrossRef919
A. Heidenreich, D. Thüer, D. Pfister. (2008) Der Stellenwert der Tageted-Therapie beim Peniskarzinom. Der Urologe 47:10, 1320-1327
CrossRef920
Camillo Porta, Ilaria Imarisio, Chiara Paglino, Elisa Ferraris, Mario Mensi, Bruno Rovereto. (2008) Prognostic factors in advanced renal cell cancer. European Journal of Cancer Supplements 6:14, 35-37
CrossRef921
Shahrokh F. Shariat, Christian Bolenz, Pierre I. Karakiewicz. (2008) Re: Bevacizumab plus Interferon alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial. European Urology 54:4, 948-949
CrossRef922
Chirag Amin, Eric Wallen, Raj S. Pruthi, Benjamin F. Calvo, Paul A. Godley, W. Kimryn Rathmell. (2008) Preoperative Tyrosine Kinase Inhibition as an Adjunct to Debulking Nephrectomy. Urology 72:4, 864-868
CrossRef923
Grace K. Dy, Alex A. Adjei. (2008) Systemic cancer therapy: Evolution over the last 60 years. Cancer 113:S7, 1857-1887
CrossRef924
Fernando Coz. (2008) Editorial Comment. Urology 72:4, 776
CrossRef925
Annika Berntsen, Redas Trepiakas, Lynn Wenandy, Poul F. Geertsen, Per thor Straten, Mads H. Andersen, Anders E. Pedersen, Mogens H. Claesson, Torben Lorentzen, Julia S. Johansen, Inge Marie Svane. (2008) Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma. Journal of Immunotherapy 31:8, 771-780
CrossRef926
Michael Staehler. (2008) Re: Pierre I. Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent Induction Therapy May Effectively Down-Stage Renal Cell Carcinoma Atrial Thrombi. Eur Urol 2008;53:845–8. European Urology 54:4, 950-951
CrossRef927
Robert J. Motzer, Ronald M. Bukowski, Robert A. Figlin, Thomas E. Hutson, M. Dror Michaelson, Sindy T. Kim, Charles M. Baum, Michael W. Kattan. (2008) Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113:7, 1552-1558
CrossRef928
Astrid A.M. van der Veldt, Merian van Wouwe, Alfons J.M. van den Eertwegh, R. Jeroen A. van Moorselaar, Herman P. van Geijn. (2008) Reply. Urology 72:4, 776-777
CrossRef929
R. Kath. (2008) Molekulare Therapie beim Nierenzellkarzinom. Der Onkologe 14:10, 1055-1064
CrossRef930
Shanthi Marur, James Eliason, Lance K. Heilbrun, Brenda Dickow, Daryn W. Smith, Karen Baranowski, Samir Alhasan, Ulka Vaishampayan. (2008) Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma. Urology 72:4, 898-902
CrossRef931
Brian Shuch, Jeff C. La Rochelle, Tobias Klatte, Stephen B. Riggs, Weiqing Liu, Fairooz F. Kabbinavar, Allan J. Pantuck, Arie S. Belldegrun. (2008) Brain metastasis from renal cell carcinoma. Cancer 113:7, 1641-1648
CrossRef932
Robert A Figlin. (2008) Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Nature Clinical Practice Oncology 5:10, 601-609
CrossRef933
M. Staehler, N. Haseke, K. Zilinberg, T. Stadler, A. Karl, C.G. Stief. (2008) Systemische Therapie des metastasierten Nierenzellkarzinoms. Der Urologe 47:10, 1357-1367
CrossRef934
Paul Wheatley-Price, Frances A. Shepherd. (2008) Targeting Angiogenesis in the Treatment of Lung Cancer. Journal of Thoracic Oncology 3:10, 1173-1184
CrossRef935
B W Hancock. (2008) Survival from kidney cancer in England and Wales up to 2001. British Journal of Cancer 99, S96-S97
CrossRef936
Ann H. Rosendahl, Jeff M.P. Holly, Mona Celander, Göran Forsberg. (2008) Systemic IGF‐I administration stimulates the in vivo growth of early, but not advanced, renal cell carcinoma. International Journal of Cancer 123:6, 1286-1291
CrossRef937
Brian Shuch, Jeff C. La Rochelle, Jon Wu, Tobias Klatte, Stephen B. Riggs, Fairooz Kabbinavar, Arie S. Belldegrun, Allan J. Pantuck. (2008) Performance status and cytoreductive nephrectomy. Cancer 113:6, 1324-1331
CrossRef938
Brian I. Rini, Toni K. Choueiri, Paul Elson, Mohamad K. Khasawneh, Claudiu Cotta, Jaya Unnithan, Laura Wood, Tarek Mekhail, Jorge Garcia, Robert Dreicer, Ronald M. Bukowski. (2008) Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 113:6, 1309-1314
CrossRef939
S.A. Wedel, A. Mickuckyte, E. Juengel, J. Jones, L. Hudak, D. Jonas, R.A. Blaheta. (2008) Präklinische Studien zum Einfluss des Tyrosinkinaseinhibitors AEE788 auf die Malignität des Nierenzellkarzinoms. Der Urologe 47:9, 1175-1181
CrossRef940
Harriet M Kluger, Summar F Siddiqui, Cesar Angeletti, Mario Sznol, William K Kelly, Annette M Molinaro, Robert L Camp. (2008) Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Laboratory Investigation 88:9, 962-972
CrossRef941
Vitaly Margulis, Christopher G. Wood. (2008) The Role of Lymph Node Dissection in Renal Cell Carcinoma: The Pendulum Swings Back. The Cancer Journal 14:5, 308-314
CrossRef942
Eric Jonasch, Nizar M. Tannir. (2008) Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma. The Cancer Journal 14:5, 315-319
CrossRef943
C.G. Hammerschmied, B. Walter, A. Hartmann. (2008) Nierenzellkarzinom 2008. Der Pathologe 29:5, 354-363
CrossRef944
Bernard Escudier. (2008) Signaling Inhibitors in Metastatic Renal Cell Carcinoma. The Cancer Journal 14:5, 325-329
CrossRef945
Masahiro Yao, Ying Huang, Koichi Shioi, Keiko Hattori, Takayuki Murakami, Futoshi Sano, Masaya Baba, Keiichi Kondo, Noboru Nakaigawa, Takeshi Kishida, Yoji Nagashima, Hisafumi Yamada-Okabe, Yoshinobu Kubota. (2008) A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. International Journal of Cancer 123:5, 1126-1132
CrossRef946
Peter Mulders. (2008) Continued Progress in the Treatment of Advanced Renal Cell Carcinoma: An Update on the Role of Sunitinib. European Urology Supplements 7:9, 579-584
CrossRef947
Aaron P. Brown, Deborah E. Citrin, Kevin A. Camphausen. (2008) Clinical biomarkers of angiogenesis inhibition. Cancer and Metastasis Reviews 27:3, 415-434
CrossRef948
J.A. RAUH-HAIN, R.T. PENSON. (2008) Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. International Journal of Gynecological Cancer 18:5, 934-936
CrossRef949
A. P. Berger, A. Hobisch. (2008) Treatment options in localised and metastatic renal cell carcinoma. memo - Magazine of European Medical Oncology 1:3, 167-170
CrossRef950
Nizar M. Tannir, Peter F. Thall, Chaan S. Ng, Xuemei Wang, Leiko Wooten, Arlene Siefker-Radtke, Paul Mathew, Lance Pagliaro, Christopher Wood, Eric Jonasch. (2008) A Phase II Trial of Gemcitabine Plus Capecitabine for Metastatic Renal Cell Cancer Previously Treated With Immunotherapy and Targeted Agents. The Journal of Urology 180:3, 867-872
CrossRef951
Jean-Jacques Patard. (2008) Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection. European Urology Supplements 7:9, 601-609
CrossRef952
Toni K. Choueiri, Susan A.J. Vaziri, Erich Jaeger, Paul Elson, Laura Wood, Ish Prasad Bhalla, Eric J. Small, Vivian Weinberg, Nancy Sein, Jeff Simko, Ali-Reza Golshayan, Linda Sercia, Ming Zhou, Frederic M. Waldman, Brian I. Rini, Ronald M. Bukowski, Ram Ganapathi. (2008) von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma. The Journal of Urology 180:3, 860-866
CrossRef953
Jan Roigas. (2008) Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma. European Urology Supplements 7:9, 593-600
CrossRef954
Bhanu K Vakkalanka, Brian I Rini. (2008) Targeted therapy in renal cell carcinoma. Current Opinion in Urology 18:5, 481-487
CrossRef955
A. Heidenreich, F. Finke. (2008) Klinische Netzwerkstrukturen in der Uroonkologie. Der Urologe 47:9, 1128-1132
CrossRef956
Klaus Mross. (2008) Inhibition des VEGF- Rezeptorsystems mit Tyrosinkinase-Inhibitoren. Angiogenese-Inhibition in der Onkologie. Pharmazie in unserer Zeit 37:5, 404-415
CrossRef957
Erin Grothey, Tara Gibson, Oliver Sartor, Ronald Bukowski. (2008) Highlights from: The 2008 Meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL. Clinical Genitourinary Cancer 6:2, 65-72
CrossRef958
David J Andorsky, John M Timmerman. (2008) Interleukin-21: biology and application to cancer therapy. Expert Opinion on Biological Therapy 8:9, 1295-1307
CrossRef959
Joaquim Bellmunt. (2008) Sunitinib in Advanced Renal Cell Carcinoma: Clinical Evidence. European Urology Supplements 7:9, 585-592
CrossRef960
A. Graser, C.R. Becker, M.F. Reiser, C. Stief, M. Staehler. (2008) Volumetrie von Metastasen beim Nierenzellkarzinom. Der Radiologe 48:9, 850-856
CrossRef961
Vitaly Margulis, Christopher G. Wood. (2008) Cytoreductive Nephrectomy in the Era of Targeted Molecular Agents: Is It Time to Consider Presurgical Systemic Therapy?. European Urology 54:3, 489-492
CrossRef962
Thomas Force, Risto Kerkelä. (2008) Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problem. Drug Discovery Today 13:17-18, 778-784
CrossRef963
David F. McDermott, Michael B. Atkins. (2008) Immunotherapy of Metastatic Renal Cell Carcinoma. The Cancer Journal 14:5, 320-324
CrossRef964
Vitaly Margulis, Surena F Matin, Christopher G Wood. (2008) Cytoreductive nephrectomy in metastatic renal cell carcinoma. Current Opinion in Urology 18:5, 474-480
CrossRef965
(2008) Scrotal Cutaneous Side Effects of Sunitinib. New England Journal of Medicine 359:9, 975-976
Full Text966
Robert L. Coleman, Elise C. Kohn. (2008) Rationale for combination use of targeted agents in ovarian cancer. Cancer 113:4, 665-667
CrossRef967
Ho-Yin Ngai, Lap-Yin Ho, Tung-Fei Chan, Hing-Shing So, Venu Velayudhan, Siu-Ho Lam. (2008) Rare presentation of renal cell carcinoma: Solitary sternal metastasis. Surgical Practice 12:3, 99-101
CrossRef968
Richard T. Lee, Francesca Fallarino, Andrew Ashikari, Thomas F. Gajewski. (2008) Melanoma presenting as circulating tumor cells associated with failed angiogenesis. Melanoma Research 18:4, 289-294
CrossRef969
J. Bellmunt, C. Szczylik, J. Feingold, A. Strahs, A. Berkenblit. (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology 19:8, 1387-1392
CrossRef970
K.K.H. Aben, T.K. Luth, M.L.G. Janssen-Heijnen, P.F. Mulders, L.A. Kiemeney, D.J. van Spronsen. (2008) No improvement in renal cell carcinoma survival: A population-based study in the Netherlands. European Journal of Cancer 44:12, 1701-1709
CrossRef971
Paul L. Crispen, Stephen A. Boorjian, Christine M. Lohse, Bradley C. Leibovich, Eugene D. Kwon. (2008) Predicting disease progression after nephrectomy for localized renal cell carcinoma: The utility of prognostic models and molecular biomarkers. Cancer 113:3, 450-460
CrossRef972
Justin Stebbing. (2008) FLEX data, KRAS and ERCC1 testing in oncology. Future Oncology 4:4, 471-473
CrossRef973
Robert J Motzer, Bernard Escudier, Stéphane Oudard, Thomas E Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A Thompson, Robert A Figlin, Norbert Hollaender, Gladys Urbanowitz, William J Berg, Andrea Kay, David Lebwohl, Alain Ravaud. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet 372:9637, 449-456
CrossRef974
Cora N Sternberg. (2008) Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. Nature Clinical Practice Urology 5:8, 422-423
CrossRef975
Vincenzo Ficarra, Giacomo Novara. (2008) The New Medical Treatment of Metastatic Renal Cell Carcinoma: A Good Debut, A Lot of Open Questions. European Urology 54:2, 252-255
CrossRef976
Alain Ravaud, Hervé Wallerand, Stéphane Culine, Jean-Christophe Bernhard, Patricia Fergelot, Karim Bensalah, Jean-Jacques Patard. (2008) Update on the Medical Treatment of Metastatic Renal Cell Carcinoma. European Urology 54:2, 315-325
CrossRef977
Shaoqi Wang, Shaoxiang Wang, Juan Wang. (2008) Current status of studies on targeted therapy for renal cell carcinoma. Chinese Journal of Clinical Oncology 5:4, 294-298
CrossRef978
Lee M. Ellis, Daniel J. Hicklin. (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer 8:8, 579-591
CrossRef979
Przemyslaw Twardowski, Robert A Figlin. (2008) Bevacizumab plus interferon α in patients with metastatic renal cell carcinoma. Nature Clinical Practice Oncology 5:8, 436-437
CrossRef980
Jennifer J Knox. (2008) Progression-free survival as endpoint in metastatic RCC?. The Lancet 372:9637, 427-429
CrossRef981
H. Izzedine, M. C. Etienne-Grimaldi, N. Renee, S. Vignot, G. Milano. (2008) Pharmacokinetics of sunitinib in hemodialysis. Annals of Oncology 20:1, 190-192
CrossRef982
A A M van der Veldt, E Boven, H H Helgason, M van Wouwe, J Berkhof, G de Gast, H Mallo, C N Tillier, A J M van den Eertwegh, J B A G Haanen. (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. British Journal of Cancer 99:2, 259-265
CrossRef983
Jacob A. Klapper, Stephanie G. Downey, Franz O. Smith, James C. Yang, Marybeth S. Hughes, Udai S. Kammula, Richard M. Sherry, Richard E. Royal, Seth M. Steinberg, Steven Rosenberg. (2008) High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma. Cancer 113:2, 293-301
CrossRef984
Jean-Jacques Patard, Patricia Fergelot, Pierre I. Karakiewicz, Tobias Klatte, Quoc-Dien Trinh, Nathalie Rioux-Leclercq, Jonathan W. Said, Arie S. Belldegrun, Allan J. Pantuck. (2008) Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. International Journal of Cancer 123:2, 395-400
CrossRef985
Mischel G. Neill, Michael A.S. Jewett. (2008) The once and future role of cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations 26:4, 346-352
CrossRef986
Cristiana Sessa, Aymeric Guibal, Gianluca Del Conte, Curzio Rüegg. (2008) Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. Nature Clinical Practice Oncology 5:7, 378-391
CrossRef987
Michael S. OʼReilly. (2008) The Interaction of Radiation Therapy and Antiangiogenic Therapy. The Cancer Journal 14:4, 207-213
CrossRef988
Stephen A. Boorjian, Paul L. Crispen, Christine M. Lohse, Bradley C. Leibovich, Michael L. Blute. (2008) Surgical Resection of Isolated Retroperitoneal Lymph Node Recurrence of Renal Cell Carcinoma Following Nephrectomy. The Journal of Urology 180:1, 99-103
CrossRef989
Thomas E. Hutson. (2008) RENAL CELL CARCINOMA: WHAT DOES THE FUTURE HOLD?. BJU International 102:1, 5-6
CrossRef990
Wolfram E. Samlowski, Bryan Wong, Nicholas J. Vogelzang. (2008) Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on. BJU International 102:2, 162-165
CrossRef991
Luca Cindolo, Paolo Chiodini, Ciro Gallo, Vincenzo Ficarra, Luigi Schips, Jacques Tostain, Alexandre de La Taille, Walter Artibani, Jean Jacques Patard. (2008) Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 113:1, 65-71
CrossRef992
Eric Jonasch, Walter M. Stadler, Ronald M. Bukowski, Teresa G. Hayes, Atul Varadhachary, Rajesh Malik, Robert A. Figlin, Sandy Srinivas. (2008) Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer 113:1, 72-77
CrossRef993
John M. Maris, Joshua Courtright, Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard Lock, Mayamin Tajbakhsh, C. Patrick Reynolds, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith. (2008) Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatric Blood & Cancer 51:1, 42-48
CrossRef994
Saby George, Thomas E. Hutson, Tarek Mekhail, Laura Wood, James Finke, Paul Elson, Robert Dreicer, Ronald M. Bukowski. (2008) Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology 62:2, 347-354
CrossRef995
M. E. Lacouture, L. M. Reilly, P. Gerami, J. Guitart. (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Annals of Oncology 19:11, 1955-1961
CrossRef996
Y. Loriot, P. Boudou-Rouquette, B. Billemont, S. Ropert, F. Goldwasser. (2008) Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Annals of Oncology 19:11, 1975-1975
CrossRef997
Zhong Jiang, Christine M. Lohse, Peigou G. Chu, Chin-Lee Wu, Bruce A. Woda, Kenneth L. Rock, Eugene D. Kwon. (2008) Oncofetal protein IMP3. Cancer 112:12, 2676-2682
CrossRef998
M. M. Hipp, N. Hilf, S. Walter, D. Werth, K. M. Brauer, M. P. Radsak, T. Weinschenk, H. Singh-Jasuja, P. Brossart. (2008) Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111:12, 5610-5620
CrossRef999
M H Strijbos, J W Gratama, J Kraan, C H Lamers, MA den Bakker, S Sleijfer. (2008) Circulating endothelial cells in oncology: pitfalls and promises. British Journal of Cancer 98:11, 1731-1735
CrossRef1000
Sigrun Langbein, Wilma M. Frederiks, Axel zur Hausen, Juljane Popa, Jan Lehmann, Christel Weiss, Peter Alken, Johannes F. Coy. (2008) Metastasis is promoted by a bioenergetic switch: New targets for progressive renal cell cancer. International Journal of Cancer 122:11, 2422-2428
CrossRef1001
Donna E Hansel, Brian I Rini. (2008) Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. Expert Review of Anticancer Therapy 8:6, 895-905
CrossRef1002
Aarif Y. Khakoo, Christos M. Kassiotis, Nizar Tannir, Juan Carlos Plana, Marc Halushka, Courtney Bickford, Jon Trent, J. Chris Champion, Jean-Bernard Durand, Daniel J. Lenihan. (2008) Heart failure associated with sunitinib malate. Cancer 112:11, 2500-2508
CrossRef1003
Robert J. Amato, Rahul Malya, Anish Rawat. (2008) Phase II Study of Combination Thalidomide/Interleukin-2 Therapy Plus Granulocyte Macrophage-Colony Stimulating Factor in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology 31:3, 237-243
CrossRef1004
S. E. Rosenbaum, S. Wu, M. A. Newman, D. P. West, T. Kuzel, M. E. Lacouture. (2008) Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Supportive Care in Cancer 16:6, 557-566
CrossRef1005
Klaus Strebhardt, Axel Ullrich. (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews Cancer 8:6, 473-480
CrossRef1006
Haiching Ma, Sean Deacon, Kurumi Horiuchi. (2008) The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opinion on Drug Discovery 3:6, 607-621
CrossRef1007
Premal H. Patel, G. Varuni Kondagunta, Lawrence Schwartz, Nicole Ishill, Jennifer Bacik, John DeLuca, Paul Russo, Robert J. Motzer. (2008) Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Investigational New Drugs 26:3, 273-276
CrossRef1008
Matthew F. O’Brien, Paul Russo, Robert J. Motzer. (2008) Sunitinib therapy in renal cell carcinoma. BJU International 101:11, 1339-1342
CrossRef1009
Shaker A. Mousa, Joel J. Bergh, Emie Dier, Abdelhadi Rebbaa, Laura J. O’Connor, Murat Yalcin, Ahmad Aljada, Evgeny Dyskin, Faith B. Davis, Hung-Yung Lin, Paul J. Davis. (2008) Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11:2, 183-190
CrossRef1010
Shireen Kassam, Silvia Montoto. (2008) Oncologic, Endocrine & Metabolic Emerging drugs in B-cell non-Hodgkin's lymphoma. Expert Opinion on Emerging Drugs 13:2, 323-343
CrossRef1011
Sabina Signoretti, Meredith Regan, Michael Atkins. (2008) Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. BJU International 101:s4, 31-35
CrossRef1012
S. Oudard, A. Cassar, A. Mejean, F. Thibault, D. Pouessel, S. Culine, A. Ravaud. (2008) Création d’une unité de coordination de la prise en charge des tumeurs rares du rein de l’adulte. Oncologie 10:6, 437-442
CrossRef1013
Karen L Reckamp, Robert M Strieter, Robert A Figlin. (2008) Chemokines as therapeutic targets in renal cell carcinoma. Expert Review of Anticancer Therapy 8:6, 887-893
CrossRef1014
Chris Coppin. (2008) Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Review of Anticancer Therapy 8:6, 907-919
CrossRef1015
Minoru Kobayashi, Hitoshi Ikeda, Akinori Nukui, Kazumi Suzuki, Yasuhiro Sugaya, Masayuki Yuzawa, Tatsuo Morita. (2008) Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: a single-institution experience. International Journal of Clinical Oncology 13:3, 257-262
CrossRef1016
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Michaelson, M. Dror, Iliopoulos, Othon, McDermott, David F., McGovern, Francis J., Harisinghani, Mukesh G., Oliva, Esther, . (2008) Case 17-2008. New England Journal of Medicine 358:22, 2389-2396
Full Text1017
M. L. Telli, R. M. Witteles, G. A. Fisher, S. Srinivas. (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Annals of Oncology 19:9, 1613-1618
CrossRef1018
Michael K. K. Wong. (2008) The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics. Current Oncology Reports 10:3, 259-263
CrossRef1019
Guru Sonpavde, Thomas E Hutson, Brian I Rini. (2008) Axitinib for renal cell carcinoma. Expert Opinion on Investigational Drugs 17:5, 741-748
CrossRef1020
C.N.A.M. Oldenhuis, S.F. Oosting, J.A. Gietema, E.G.E. de Vries. (2008) Prognostic versus predictive value of biomarkers in oncology. European Journal of Cancer 44:7, 946-953
CrossRef1021
Wai T Wong, Emily Y Chew. (2008) Ocular von Hippel???Lindau disease: clinical update and emerging treatments. Current Opinion in Ophthalmology 19:3, 213-217
CrossRef1022
I. Judson, J. Barriuso. (2008) Molecularly targeted therapy and cancer surgery. British Journal of Surgery 95:5, 537-538
CrossRef1023
Taner Demirer, Lisbeth Barkholt, Didier Blaise, Paolo Pedrazzoli, Massimo Aglietta, Angelo Michele Carella, Jacques-Olivier Bay, Fikret Arpaci, Giovanni Rosti, Gunhan Gurman, Dietger Niederwieser, Marco Bregni. (2008) Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nature Clinical Practice Oncology 5:5, 256-267
CrossRef1024
Naomi B. Haas, Robert Uzzo. (2008) Adjuvant therapy for renal cell carcinoma. Current Oncology Reports 10:3, 245-252
CrossRef1025
M. Jafri, A. Protheroe. (2008) An Update on a Case of Regression of Lung Metastases after Radiotherapy for Bone Metastasis in Renal Cell Carcinoma. Clinical Oncology 20:4, 316
CrossRef1026
M. Sommerauer, C. Doehn. (2008) Bevacizumab plus Interferon alfa-2a in der Therapie des metastasierten Nierenzellkarzinoms. Der Onkologe 14:5, 535-538
CrossRef1027
Naeem Bhojani, Claudio Jeldres, Jean-Jacques Patard, Paul Perrotte, Nazareno Suardi, Georg Hutterer, François Patenaude, Stéphane Oudard, Pierre I. Karakiewicz. (2008) Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma. European Urology 53:5, 917-930
CrossRef1028
Vitaly Margulis, Christopher G. Wood, Eric Jonasch, Surena F. Matin. (2008) Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Current Oncology Reports 10:3, 253-258
CrossRef1029
C. Wilhelm, A. Neubauer. (2008) Molekulare Tumortherapie. Der Internist 49:5, 581-592
CrossRef1030
Martin E. Gore, Pieter De Mulder. (2008) Establishing the role of cytokine therapy in advanced renal cell carcinoma. BJU International 101:9, 1063-1070
CrossRef1031
Kiran Gupta, Jeffrey D. Miller, Jim Z. Li, Mason W. Russell, Claudie Charbonneau. (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treatment Reviews 34:3, 193-205
CrossRef1032
Brian I Rini, W Kimryn Rathmell, Paul Godley. (2008) Renal cell carcinoma. Current Opinion in Oncology 20:3, 300-306
CrossRef1033
P.S. Hall, K. Kancherla, P.S.R.K. Sastry, J.E. Brown. (2008) Severe Epistaxis with Tyrosine Kinase Inhibitors. Clinical Oncology 20:4, 318-319
CrossRef1034
Chris Coppin, Lyly Le, Timothy J Wilt, Christian Kollmannsberger, Chris Coppin. 2008. Targeted therapy for advanced renal cell carcinoma. .
CrossRef1035
E Jonasch, C Wood, P Tamboli, L C Pagliaro, S M Tu, J Kim, P Srivastava, C Perez, L Isakov, N Tannir. (2008) Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. British Journal of Cancer 98:8, 1336-1341
CrossRef1036
Á. Sanz Rubiales, M. Luisa Del Valle. (2008) Disillusionment Bias in Clinical Trials Testing New Drugs. Clinical Oncology 20:3, 267
CrossRef1037
Roy Vergis, Catherine M Corbishley, Andrew R Norman, Jaclyn Bartlett, Sameer Jhavar, Michael Borre, Sara Heeboll, Alan Horwich, Robert Huddart, Vincent Khoo, Ros Eeles, Colin Cooper, Matthew Sydes, David Dearnaley, Chris Parker. (2008) Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. The Lancet Oncology 9:4, 342-351
CrossRef1038
Jean-Jacques Patard, Damien Pouessel, Karim Bensalah, Stéphane Culine. (2008) Targeted therapy in renal cell carcinoma. World Journal of Urology 26:2, 135-140
CrossRef1039
Subramanian Hariharan, Simon Lowry. (2008) Cardiotoxicity associated with sunitinib. The Lancet 371:9620, 1244-1245
CrossRef1040
Rakesh K. Jain. (2008) Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nature Reviews Cancer 8:4, 309-316
CrossRef1041
Walter M. Stadler, Apurva A. Desai, David I. Quinn, Ronald Bukowski, Bernard Poiesz, Carl G. Kardinal, Nancy Lewis, Alex Makalinao, Peter Murray, Frank M. Torti. (2008) A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemotherapy and Pharmacology 61:4, 689-694
CrossRef1042
Jean-Jacques Patard. (2008) New Treatment Options for Renal Cell Cancer—Critical Evaluation. European Urology Supplements 7:5, 443-446
CrossRef1043
Damien Pouessel, Stéphane Culine, Gregory Verhoest, Jean-Jacques Patard. (2008) Antiangiogenèse et cancer du rein. La Presse Médicale 37:4, 628-633
CrossRef1044
Rachel P. Riechelmann, Soo Chin, Lisa Wang, Ian F. Tannock, Domink R. Berthold, Malcolm J. Moore, Jennifer J. Knox. (2008) Sorafenib for Metastatic Renal Cancer. American Journal of Clinical Oncology 31:2, 182-187
CrossRef1045
Camillo Porta. (2008) Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunotherapy and the pathogenetic role of endogenous retroviruses. Oncology Reviews 2:1, 1-3
CrossRef1046
Amer H. Zureikat, Mark D. McKee. (2008) Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America 17:2, 279-301
CrossRef1047
Martin H Fenner, Gernot Beutel, Viktor Grünwald. (2008) Targeted therapies for patients with germ cell tumors. Expert Opinion on Investigational Drugs 17:4, 511-522
CrossRef1048
Hirotsugu Uemura, Marco A. Velasco. (2008) Tumor vaccines in renal cell carcinoma. World Journal of Urology 26:2, 147-154
CrossRef1049
Jean-Jacques Patard, Toni K. Choueiri, Eric Lechevallier, Nicolas Mottet. (2008) Recent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007. European Urology Supplements 7:6, 494-507
CrossRef1050
Jair Bar, Amir Onn. (2008) Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opinion on Pharmacotherapy 9:5, 701-715
CrossRef1051
Yoshiro Fujiwara, Katsuyuki Kiura, Masahiro Tabata, Nagio Takigawa, Katsuyuki Hotta, Shigeki Umemura, Masako Omori, Kenichi Gemba, Hiroshi Ueoka, Mitsune Tanimoto. (2008) Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anti-Cancer Drugs 19:4, 431-433
CrossRef1052
Vincenzo Ficarra, Antonio Galfano, Giacomo Novara, Massimo Iafrate, Matteo Brunelli, Silvia Secco, Stefano Cavalleri, Guido Martignoni, Walter Artibani. (2008) Risk stratification and prognostication of renal cell carcinoma. World Journal of Urology 26:2, 115-125
CrossRef1053
Edith M. Marom, Carlos H. Martinez, Mylene T. Truong, Xiudong Lei, Bradley S. Sabloff, Reginald F. Munden, Gregory W. Gladish, Roy S. Herbst, Rodolfo C. Morice, David J. Stewart, Carlos A. Jimenez, George R. Blumenschein, Amir Onn. (2008) Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. Journal of Thoracic Oncology 3:4, 351-357
CrossRef1054
Marcella M.L. Baldewijns, Iris J.H. van Vlodrop, Leo J. Schouten, Patricia M.M.B. Soetekouw, Adriaan P. de Bruïne, Manon van Engeland. (2008) Genetics and epigenetics of renal cell cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1785:2, 133-155
CrossRef1055
J B Tuynman, S M Lagarde, F J W ten Kate, D J Richel, J J B van Lanschot. (2008) Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. British Journal of Cancer 98:6, 1102-1108
CrossRef1056
F. Trotta, G. Apolone, S. Garattini, G. Tafuri. (2008) Stopping a trial early in oncology: for patients or for industry?. Annals of Oncology 19:7, 1347-1353
CrossRef1057
Christian Jackisch. (2008) Challenges in the treatment of ErbB2 (HER2)-positive breast cancer. European Journal of Cancer Supplements 6:5, 7-14
CrossRef1058
Claire Louise Cole, Gordon C Jayson. (2008) Oligosaccharides as anti-angiogenic agents. Expert Opinion on Biological Therapy 8:3, 351-362
CrossRef1059
Jeffrey A Sosman. (2008) Improving outcomes in patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy 8:3, 481-490
CrossRef1060
C Lance Cowey, W Kimryn Rathmell. (2008) Using molecular biology to develop drugs for renal cell carcinoma. Expert Opinion on Drug Discovery 3:3, 311-327
CrossRef1061
Carolyn D. Britten, Fairooz Kabbinavar, J. Randolph Hecht, Carlo L. Bello, Jim Li, Charles Baum, Dennis Slamon. (2008) A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemotherapy and Pharmacology 61:3, 515-524
CrossRef1062
Erin Grothey, Oliver Sartor, Ronald Bukowski. (2008) Highlights from: The 2008 Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CA. Clinical Genitourinary Cancer 6:1, 9-14
CrossRef1063
Brian I Rini. (2008) Is sorafenib plus interferon α2b safe and effective in patients with renal cell carcinoma?. Nature Clinical Practice Urology 5:3, 132-133
CrossRef1064
Andres Jan Schrader, Rainer Hofmann. (2008) Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anti-Cancer Drugs 19:3, 235-245
CrossRef1065
José Manuel Trigo, Joaquim Bellmunt. (2008) Estrategias actuales en el tratamiento del carcinoma de células renales: fármacos dirigidos a dianas moleculares. Medicina Clínica 130:10, 380-392
CrossRef1066
A. R. John, S. R. Bramhall, M. C. Eggo. (2008) Antiangiogenic therapy and surgical practice. British Journal of Surgery 95:3, 281-293
CrossRef1067
C. Le Tourneau, S. Faivre, E. Raymond. (2008) New developments in multitargeted therapy for patients with solid tumours. Cancer Treatment Reviews 34:1, 37-48
CrossRef1068
Timo Purmonen, Janne A. Martikainen, Erkki J.O. Soini, Vesa Kataja, Riikka-Liisa Vuorinen, Pirkko-Liisa Kellokumpu-Lehtinen. (2008) Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clinical Therapeutics 30:2, 382-392
CrossRef1069
Ali-Reza Golshayan, Ashley J Brick, Toni K Choueiri. (2008) Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncology 4:1, 85-92
CrossRef1070
Jon Jones, Hasan H. Otu, Franck Grall, Dimitrios Spentzos, Handan Can, Manuel Aivado, Arie S. Belldegrun, Allan J. Pantuck, Towia A. Libermann. (2008) Proteomic Identification of Interleukin-2 Therapy Response in Metastatic Renal Cell Cancer. The Journal of Urology 179:2, 730-736
CrossRef1071
Damien Pouessel, Stéphane Culine. (2008) High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor. European Urology 53:2, 376-381
CrossRef1072
Guru Sonpavde, Thomas E Hutson, Cora N Sternberg. (2008) Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opinion on Investigational Drugs 17:2, 253-261
CrossRef1073
Peter Albers. (2008) Treatment Approaches in Renal Cell Carcinoma: Past, Present, and Future Perspectives. European Urology Supplements 7:2, 36-45
CrossRef1074
H. Kirchner, H. Heinzer, J. Roigas, F. Overkamp. (2008) Differenzialtherapie beim metastasierenden Nierenzellkarzinom. Der Onkologe 14:2, 191-197
CrossRef1075
Daniela D. Rosa, Gustavo Ismael, Lissandra Dal Lago, Ahmad Awada. (2008) Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treatment Reviews 34:1, 61-80
CrossRef1076
Jean-Jacques Patard. (2008) European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why?. European Urology Supplements 7:2, 46-54
CrossRef1077
MJ Duffy, PM McGowan, WM Gallagher. (2008) Cancer invasion and metastasis: changing views. The Journal of Pathology 214:3, 283-293
CrossRef1078
Jan Roigas. (2008) The Role of Multitargeted Therapies in the Adjuvant Setting in Renal Cell Carcinoma. European Urology Supplements 7:2, 63-70
CrossRef1079
Joaquim Bellmunt. (2008) The Oncologist's View: Targeted Therapies in Advanced Renal Cell Carcinoma. European Urology Supplements 7:2, 55-62
CrossRef1080
J. Autier, C. Mateus, J. Wechsler, A. Spatz, C. Robert. (2008) Effets secondaires cutanés du sorafenib et du sunitinib. Annales de Dermatologie et de Vénéréologie 135:2, 148-153
CrossRef1081
Azizi, Michel, Chedid, Antoine, Oudard, Stéphane, . (2008) Home Blood-Pressure Monitoring in Patients Receiving Sunitinib. New England Journal of Medicine 358:1, 95-97
Full Text1082
Jonas Sjölund, Martin Johansson, Sugata Manna, Carl Norin, Alexander Pietras, Siv Beckman, Elise Nilsson, Börje Ljungberg, Håkan Axelson. (2008) Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. Journal of Clinical Investigation 118:1, 217-228
CrossRef1083
Rishi Sawhney, Fairooz Kabbinavar. (2008) Angiogenesis and angiogenic inhibitors in renal cell carcinoma. Current Urology Reports 9:1, 26-33
CrossRef1084
Ila Tamaskar, Jorge A. Garcia, Paul Elson, Laura Wood, Tarek Mekhail, Robert Dreicer, Brian I. Rini, Ronald M. Bukowski. (2008) Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy. The Journal of Urology 179:1, 81-86
CrossRef1085
Jon Jones, Allan J. Pantuck. (2008) Genomics and proteomics in renal cell carcinoma: Diagnosis, prognosis, and treatment selection. Current Urology Reports 9:1, 9-14
CrossRef1086
David Murdoch, Jason Sager. (2008) Will targeted therapy hold its promise? An evidence-based review. Current Opinion in Oncology 20:1, 104-111
CrossRef1087
Rachel E. Sanborn, David A. Sauer. (2008) Cutaneous Reactions to Chemotherapy: Commonly Seen, Less Described, Little Understood. Dermatologic Clinics 26:1, 103-119
CrossRef1088
W Kimryn Rathmell, Shufen Chen. (2008) VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Review of Anticancer Therapy 8:1, 63-73
CrossRef1089
Frédéric Thibault, Bertrand Billemont, Olivier Rixe. (2008) Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. Journal of Neuro-Oncology 86:2, 243-244
CrossRef1090
Katsuyuki Kiura, Nagio Takigawa, Isao Oze, Masayuki Yasugi, Nobuaki Ochi, Daijiro Harada, Mitsune Tanimoto. (2008) Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 119:3, 285-292
CrossRef1091
Georg Bartsch, Katharina Eggert, Shay Soker, Carsten Bokemeyer, Richard Hautmann, Gunter Schuch. (2008) Combined Antiangiogenic Therapy is Superior to Single Inhibitors in a Model of Renal Cell Carcinoma. The Journal of Urology 179:1, 326-332
CrossRef1092
P.M. Patel, S. Sim, D.O. O’Donnell, A. Protheroe, D. Beirne, A. Stanley, J.M. Tourani, D. Khayat, B. Hancock, P. Vasey, A. Dalgleish, C. Johnston, R.E. Banks, P.J. Selby. (2008) An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. European Journal of Cancer 44:2, 216-223
CrossRef1093
Marc B. Garnick. 2008. Primary Neoplasms of the Kidney. , 455-460.
CrossRef1094
M.S. Gordon. (2008) Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. Yearbook of Medicine 2008, 167-168
CrossRef1095
Guru Sonpavde, Kim N. Chi, Thomas Powles, Christopher J. Sweeney, Noah Hahn, Thomas E. Hutson, Matthew D. Galsky, William R. Berry, Dov Kadmon. (2007) Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer 110:12, 2628-2639
CrossRef1096
C. Porta, C. Paglino, I. Imarisio, L. Bonomi. (2007) Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clinical and Experimental Medicine 7:4, 127-134
CrossRef1097
Saby George, Ronald M Bukowski. (2007) Biomarkers in clear cell renal cell carcinoma. Expert Review of Anticancer Therapy 7:12, 1737-1747
CrossRef1098
Lauren C Harshman, Sandy Srinivas. (2007) Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 7:12, 1749-1761
CrossRef1099
Deborah A. Bradley, Bruce G. Redman. (2007) The times they are a-changin' (Bob Dylan, 1964). Cancer 110:11, 2366-2369
CrossRef1100
Daniel Y. C. Heng, Ronald M. Bukowski. (2007) Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma. Oncology Reviews 1:3, 170-176
CrossRef1101
Evangelos Zacharakis, Mahmoud Monem, Jean V Joseph, Hiten RH Patel. (2007) Molecular therapeutic targets for bladder cancer. Expert Review of Anticancer Therapy 7:12, 1691-1693
CrossRef1102
Enrichetta Corgna, Maura Betti, Gemma Gatta, Fausto Roila, Pieter H.M. De Mulder. (2007) Renal cancer. Critical Reviews in Oncology/Hematology 64:3, 247-262
CrossRef1103
Shigetaka Suekane, Masaaki Nishitani, Masanori Noguchi, Yoshihiro Komohara, Takako Kokubu, Masayasu Naitoh, Shigenori Honma, Akira Yamada, Kyogo Itoh, Kei Matsuoka, Hiroomi Kanayama. (2007) Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Science 98:12, 1965-1968
CrossRef1104
Heikki Joensuu. (2007) Cardiac toxicity of sunitinib. The Lancet 370:9604, 1978-1980
CrossRef1105
Michelle L Gervais, Pauline C Henry, Arthy Saravanan, T Nadine Burry, Brenda L Gallie, Michael A S Jewett, Richard P Hill, Andrew J Evans, Michael Ohh. (2007) Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. Laboratory Investigation 87:12, 1252-1264
CrossRef1106
Bernard Escudier, Anna Pluzanska, Piotr Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, Marek Filipek, Bohuslav Melichar, Emilio Bajetta, Vera Gorbunova, Jacques-Olivier Bay, Istvan Bodrogi, Agnieszka Jagiello-Gruszfeld, Nicola Moore. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet 370:9605, 2103-2111
CrossRef1107
Guilhem Bousquet, Chantal Dreyer, Sandrine Faivre, Eric Raymond. (2007) TOR (target of rapamycin) as an anti-cancer target. Drug Discovery Today: Therapeutic Strategies 4:4, 211-217
CrossRef1108
Jayesh DESAI, Howard GURNEY, Nick PAVLAKIS, Grant A McARTHUR, Ian D DAVIS. (2007) Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management*. Asia-Pacific Journal of Clinical Oncology 3:4, 167-176
CrossRef1109
Tammy F Chu, Maria A Rupnick, Risto Kerkela, Susan M Dallabrida, David Zurakowski, Lisa Nguyen, Kathleen Woulfe, Elke Pravda, Flavia Cassiola, Jayesh Desai, Suzanne George, Jeffrey A Morgan, David M Harris, Nesreen S Ismail, Jey-Hsin Chen, Frederick J Schoen, Annick D Van den Abbeele, George D Demetri, Thomas Force, Ming Hui Chen. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet 370:9604, 2011-2019
CrossRef1110
Da-Tong Chu. (2007) Learning management better to help kill two birds with one stone. Asia-Pacific Journal of Clinical Oncology 3:4, 165-166
CrossRef1111
Robert J Motzer, Ethan Basch. (2007) Targeted drugs for metastatic renal cell carcinoma. The Lancet 370:9605, 2071-2073
CrossRef1112
Rosamonde E. Banks, Rachel A. Craven, Patricia Harnden, Sanjeev Madaan, Adrian Joyce, Peter J. Selby. (2007) Key clinical issues in renal cancer: a challenge for proteomics. World Journal of Urology 25:6, 537-556
CrossRef1113
Johannes Theodor Wessels, Ann-Christin Busse, Margret Rave-Fränk, Stephan Zänker, Robert Hermann, Eckhardt Grabbe, Gerhard-Anton Müller. (2007) Photosensitizing and Radiosensitizing Effects of Hypericin on Human Renal Carcinoma Cells in Vitro. Photochemistry and Photobiology 0:0, 071107064500010-???
CrossRef1114
Bernard Escudier, Toni K. Choueiri, Stéphane Oudard, Cezary Szczylik, Sylvie Négrier, Alain Ravaud, Christine Chevreau, Peter Venner, Pierre Champagne, Daniel Croteau, Eric Dupont, Claude Hariton, Ronald M. Bukowski. (2007) Prognostic Factors of Metastatic Renal Cell Carcinoma After Failure of Immunotherapy: New Paradigm From a Large Phase III Trial With Shark Cartilage Extract AE 941. The Journal of Urology 178:5, 1901-1905
CrossRef1115
Robert J. Motzer, M. Dror Michaelson, Jonathan Rosenberg, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, Kim A. Margolin, George Wilding. (2007) Sunitinib Efficacy Against Advanced Renal Cell Carcinoma. The Journal of Urology 178:5, 1883-1887
CrossRef1116
W Marston Linehan. (2007) Targeting VEGF receptors in kidney cancer. The Lancet Oncology 8:11, 956-957
CrossRef1117
Christopher J. Farrell, Scott R. Plotkin. (2007) Genetic Causes of Brain Tumors: Neurofibromatosis, Tuberous Sclerosis, von Hippel-Lindau, and Other Syndromes. Neurologic Clinics 25:4, 925-946
CrossRef1118
Wolfram E Samlowski, Nicholas J Vogelzang. (2007) Emerging drugs for the treatment of metastatic renal cancer. Expert Opinion on Emerging Drugs 12:4, 605-618
CrossRef1119
Andrew Chi, Andrew D Norden, Patrick Y Wen. (2007) Inhibition of angiogenesis and invasion in malignant gliomas. Expert Review of Anticancer Therapy 7:11, 1537-1560
CrossRef1120
H. Labrosse, B. Favier, J. Fayette. (2007) Pharmacologie des thérapeutiques ciblées. Oncologie 9:11, 773-777
CrossRef1121
Renee N. Salas, James H. Finke, Brian I. Rini. (2007) The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma: implications for future therapeutics. Targeted Oncology 2:4, 225-234
CrossRef1122
Farbod Shojaei, Napoleone Ferrara. (2007) Antiangiogenic Therapy for Cancer: An Update. The Cancer Journal 13:6, 345-348
CrossRef1123
Olivier Rixe, Ronald M Bukowski, M Dror Michaelson, George Wilding, Gary R Hudes, Oliver Bolte, Robert J Motzer, Paul Bycott, Katherine F Liau, James Freddo, Peter C Trask, Sinil Kim, Brian I Rini. (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet Oncology 8:11, 975-984
CrossRef1124
Naomi B. Haas, Robert G. Uzzo. (2007) Tyrosine Kinase Inhibitors and Anti-Angiogenic Therapies in Kidney Cancer. Current Treatment Options in Oncology 8:3, 211-226
CrossRef1125
N Zantl, G Weirich, H Zall, B M Seiffert, S F Fischer, S Kirschnek, C Hartmann, R M Fritsch, B Gillissen, P T Daniel, G Häcker. (2007) Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 26:49, 7038-7048
CrossRef1126
Anders Lidgren, Anders Bergh, Kjell Grankvist, Torgny Rasmuson, Börje Ljungberg. (2007) Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1α. BJU International 0:0, 071008070648007-???
CrossRef1127
Jean-Jacques Patard, Damien Pouessel, Stéphane Culine. (2007) New therapies in renal cell carcinoma. Current Opinion in Supportive and Palliative Care 1:3, 174-179
CrossRef1128
F. Dorp, S. Krege, H. Rübben. (2007) Induktive Systemtherapie mit kurativer Zielsetzung urologischer Tumoren. Der Urologe 46:10, 1400-1403
CrossRef1129
C.-C. Lin, K. P. Papadopoulos. (2007) Novel targeted therapies for advanced esophageal cancer. Diseases of the Esophagus 20:5, 365-371
CrossRef1130
Brian I Rini. (2007) Sunitinib. Expert Opinion on Pharmacotherapy 8:14, 2359-2369
CrossRef1131
Lars Johan Nissen, Renhai Cao, Eva-Maria Hedlund, Zongwei Wang, Xing Zhao, Daniel Wetterskog, Keiko Funa, Ebba Bråkenhielm, Yihai Cao. (2007) Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. Journal of Clinical Investigation 117:10, 2766-2777
CrossRef1132
Rama Krishna Kancha, Rebekka Grundler, Christian Peschel, Justus Duyster. (2007) Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Experimental Hematology 35:10, 1522-1526
CrossRef1133
(2007) Temsirolimus for Advanced Renal-Cell Carcinoma. New England Journal of Medicine 357:10, 1050-1051
Full Text1134
Sylvie Négrier, Alain Ravaud. (2007) Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. European Journal of Cancer Supplements 5:7, 12-19
CrossRef1135
A. Buchner, M. Castro, A. Hennig, T. Popp, G. Assmann, A. Hofstetter, C. Stief, W. Zimmermann. (2007) Transkriptomanalysen beim Nierenzellkarzinom. Der Urologe 46:9, 1170-1175
CrossRef1136
Alain Ravaud. (2007) Current options for the treatment of locally advanced and metastatic renal cell carcinoma: focus on sunitinib. European Journal of Cancer Supplements 5:7, 4-11
CrossRef1137
Ziad Thotathil, Michael B Jameson. (2007) Early experience with novel immunomodulators for cancer treatment. Expert Opinion on Investigational Drugs 16:9, 1391-1403
CrossRef1138
Anna Kanerva, Mari Raki, Akseli Hemminki. (2007) Gene therapy of gynaecological diseases. Expert Opinion on Biological Therapy 7:9, 1347-1361
CrossRef1139
Arindel S.R. Maharaj, Patricia A. D'Amore. (2007) Roles for VEGF in the adult. Microvascular Research 74:2-3, 100-113
CrossRef1140
Thottathil Gopan, Steven A. Toms, Richard A. Prayson, John H. Suh, Amir H. Hamrahian, Robert J. Weil. (2007) Symptomatic pituitary metastases from renal cell carcinoma. Pituitary 10:3, 251-259
CrossRef1141
Stephen A. Boorjian, Matthew I. Milowsky, Jodi Kaplan, Martin Albert, Marta Vallee Cobham, Deirdre M. Coll, Nigel P. Mongan, Gary Shelton, Daniel Petrylak, Lorraine J. Gudas, David M. Nanus. (2007) Phase 1/2 Clinical Trial of Interferon ??2b and Weekly Liposome-encapsulated All-trans Retinoic Acid in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy 30:6, 655-662
CrossRef1142
Camillo Porta. (2007) ASCO 2007: “Translating Research into Practice”. Report from the 34th annual meeting of the American Society of Clinical Oncology. Oncology Reviews 1:2, 65-72
CrossRef1143
Peter E Clark. (2007) Recent advances in targeted therapy for renal cell carcinoma. Current Opinion in Urology 17:5, 331-336
CrossRef1144
Alain Ravaud. (2007) Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma. European Journal of Cancer Supplements 5:7, 20-27
CrossRef1145
Robert J Amato. (2007) 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opinion on Biological Therapy 7:9, 1463-1469
CrossRef1146
Giuseppe Di Lorenzo. (2007) Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal Cell Cacinoma Guideline. Eur Urol 2007;51:1502–10. European Urology 52:3, 926-928
CrossRef1147
Sandrine Faivre, George Demetri, William Sargent, Eric Raymond. (2007) Molecular basis for sunitinib efficacy and future clinical development. Nature Reviews Drug Discovery 6:9, 734-745
CrossRef1148
B??rje Ljungberg. (2007) Prognostic markers in renal cell carcinoma. Current Opinion in Urology 17:5, 303-308
CrossRef1149
Michael B. Atkins, David Carbone, George Coukos, Madhav Dhodapkar, Marc S. Ernstoff, James Finke, Thomas F. Gajewski, Jared Gollob, Michael T. Lotze, Walter Storkus, Louis M. Weiner. (2007) Report on the ISBTC Mini-symposium on Biologic Effects of Targeted Therapeutics. Journal of Immunotherapy 30:6, 577-590
CrossRef1150
Thomas E. Hutson, Robert A. Figlin. (2007) Renal Cell Cancer. The Cancer Journal 13:5, 282-286
CrossRef1151
Bernard J. Escudier. (2007) Temisorlimus in the treatment of advanced renal cell carcinoma. Oncology Reviews 1:2, 73-80
CrossRef1152
Aristotle Bamias. (2007) Case Report 1. Sunitinib malate in patients with pre-existing haematological abnormalities. European Journal of Cancer Supplements 5:7, 28-29
CrossRef1153
Alain Ravaud. (2007) Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse-event management and key considerations. European Journal of Cancer Supplements 5:7, 1-3
CrossRef1154
Cora N Sternberg. (2007) Molecular pathways and the hope of targeting angiogenesis. Nature Clinical Practice Urology 4:9, 470-471
CrossRef1155
Manisha Gupta, Erin Grothey, Ronald Bukowski, Oliver Sartor. (2007) Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL. Clinical Genitourinary Cancer 5:6, 362-370
CrossRef1156
Thomas E Hutson. (2007) Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview. Expert Review of Anticancer Therapy 7:9, 1193-1202
CrossRef1157
Sylvie Négrier. (2007) Case Report 3. Sunitinib malate in patients with cerebellar metastases. European Journal of Cancer Supplements 5:7, 32-34
CrossRef1158
James MG Larkin, Simon Chowdhury, Martin E Gore. (2007) Drug Insight: advances in renal cell carcinoma and the role of targeted therapies. Nature Clinical Practice Oncology 4:8, 470-479
CrossRef1159
Brian Rini, Santwana Kar, Peter Kirkpatrick. (2007) Temsirolimus. Nature Reviews Drug Discovery 6:8, 599-600
CrossRef1160
Toni K. Choueiri, Jorge A. Garcia, Paul Elson, Mohamad Khasawneh, Saif Usman, Ali Reza Golshayan, Rachid C. Baz, Laura Wood, Brian I. Rini, Ronald M. Bukowski. (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:3, 543-550
CrossRef1161
Roberto Petrioli, Loretta Paolelli, Edoardo Francini, Stefania Marsili, Alessandra Pascucci, Angela Sciandivasci, Giovanni de Rubertis, Gabriele Barbanti, Antonio Manganelli, Francesco Salvestrini, Guido Francini. (2007) Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. Anti-Cancer Drugs 18:7, 817-820
CrossRef1162
Cheryl A Grandinetti, Barry R Goldspiel. (2007) Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer. Pharmacotherapy 27:8, 1125-1144
CrossRef1163
Przemyslaw Twardowski, Robert Alan Figlin. (2007) What are the indications for sorafenib treatment in patients with renal cell carcinoma?. Nature Clinical Practice Oncology 4:8, 456-457
CrossRef1164
Georgios Giamas, Justin Stebbing, Constantinos E Vorgias, Uwe Knippschild. (2007) Protein kinases as targets for cancer treatment. Pharmacogenomics 8:8, 1005-1016
CrossRef1165
Kazutaka Nakayama, Nizar M. Tannir, Ping Liu, Jay K. Wathen, Yee Chung Cheng, Richard E. Champlin, Naoto T. Ueno. (2007) Natural History of Metastatic Renal Cell Carcinoma in Patients Who Underwent Consultation for Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 13:8, 975-985
CrossRef1166
C. Kratochwil. (2007) Wertigkeit bildgebender Verfahren bei ossären Metastasen. Der Urologe 46:8, 891-896
CrossRef1167
Walter M Stadler, Russell Z Szmulewitz. (2007) Sunitinib—a new standard of care for metastatic renal cell carcinoma. Nature Clinical Practice Oncology 4:8, 458-459
CrossRef1168
H. Lu, X. Xu, M. Zhang, R. Cao, E. Brakenhielm, C. Li, H. Lin, G. Yao, H. Sun, L. Qi, M. Tang, H. Dai, Y. Zhang, R. Su, Y. Bi, Y. Zhang, Y. Cao. (2007) Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proceedings of the National Academy of Sciences 104:29, 12140-12145
CrossRef1169
Gérard Tobelem. (2007) VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. Targeted Oncology 2:3, 153-164
CrossRef1170
J. Tol, C. J. A. Punt. (2007) Targeted therapy in advanced colorectal cancer, an update. Targeted Oncology 2:3, 165-172
CrossRef1171
Daniel Rayson, Paul McIntyre. (2007) Transitions to palliation: Two solitudes or inevitable integration?. Current Oncology Reports 9:4, 285-289
CrossRef1172
Quoc T. Ho, Calvin J. Kuo. (2007) Vascular endothelial growth factor: Biology and therapeutic applications. The International Journal of Biochemistry & Cell Biology 39:7-8, 1349-1357
CrossRef1173
S. Krege, M. Schenck. (2007) Urologische Aspekte in der Palliativmedizin. Der Onkologe 13:7, 602-608
CrossRef1174
Francesco Montorsi. (2007) Kidney Cancer: Highlights from 2006. European Urology Supplements 6:12, 745-753
CrossRef1175
Val R. Adams, Markos Leggas. (2007) Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors. Clinical Therapeutics 29:7, 1338-1353
CrossRef1176
Pierre I. Karakiewicz, Georg Hutterer. (2007) Re: Sorafenib in Advanced Clear-Cell Renal Cell Carcinoma. European Urology 52:1, 279-280
CrossRef1177
B. Alt-Epping, W. Jung, F. Nauck. (2007) Symptomkontrollierende Effekte der Chemotherapie. Der Onkologe 13:7, 619-624
CrossRef1178
D. R. Feldman, A. J. Martorella, R. J. Robbins, R. J. Motzer. (2007) Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. JNCI Journal of the National Cancer Institute 99:12, 974-975
CrossRef1179
Alberto Breda, Ramdev Konijeti, John S Lam. (2007) Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Review of Anticancer Therapy 7:6, 847-862
CrossRef1180
Theo Nicholaou, Rachel Wong, Ian D Davis. (2007) Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. The Lancet 369:9577, 1923-1924
CrossRef1181
J.-Y. Blay. (2007) Thérapeutiques antiangiogéniques des tumeurs solides. La Revue de Médecine Interne 28, S7-S8
CrossRef1182
Dan G. Duda, Tracy T. Batchelor, Christopher G. Willett, Rakesh K. Jain. (2007) VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends in Molecular Medicine 13:6, 223-230
CrossRef1183
Allan J. Pantuck, David B. Seligson, Tobias Klatte, Hong Yu, John T. Leppert, Laurence Moore, Timothy O'Toole, Jay Gibbons, Arie S. Belldegrun, Robert A. Figlin. (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 109:11, 2257-2267
CrossRef1184
Matthew D Galsky, Nicholas J Vogelzang. (2007) Outcomes and prognosis in advanced renal cell carcinoma. Expert Review of Anticancer Therapy 7:6, 839-845
CrossRef1185
Henk. M. W. Verheul, Herbert M. Pinedo. (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer 7:6, 475-485
CrossRef1186
Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jacques Patard, Ioanel C. Sinescu. (2007) Renal Cell Carcinoma Guideline. European Urology 51:6, 1502-1510
CrossRef1187
Paul Russo. (2007) Editorial Comment. The Journal of Urology 177:6, 2018-2019
CrossRef1188
Jin-Young Park, Pei-yin Lin, Robert H Weiss. (2007) Targeting the PI3K–Akt pathway in kidney cancer. Expert Review of Anticancer Therapy 7:6, 863-870
CrossRef1189
M. Dror Michaelson. (2007) ASCO 2006 highlights: Targeted therapy for renal cell carcinoma. Cancer Treatment Reviews 33:4, 381-390
CrossRef1190
Fred Saad. (2007) Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma. European Urology Supplements 6:11, 683-688
CrossRef1191
Hudes, Gary, Carducci, Michael, Tomczak, Piotr, Dutcher, Janice, Figlin, Robert, Kapoor, Anil, Staroslawska, Elzbieta, Sosman, Jeffrey, McDermott, David, Bodrogi, István, Kovacevic, Zoran, Lesovoy, Vladimir, Schmidt-Wolf, Ingo G.H., Barbarash, Olga, Gokmen, Erhan, O'Toole, Timothy, Lustgarten, Stephanie, Moore, Laurence, Motzer, Robert J., . (2007) Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. New England Journal of Medicine 356:22, 2271-2281
Full Text1192
Pieter H.M. De Mulder, Jean-Jaques Patard, Cezary Szczylik, Thomas Otto, Tim Eisen. (2007) Current Status of Targeted Therapy in Metastatic Renal Cell Carcinoma. European Urology Supplements 6:10, 665-671
CrossRef1193
P J Wysocki, J Zolnierek, C Szczylik, A Mackiewicz. (2007) Recent developments in renal cell cancer immunotherapy. Expert Opinion on Biological Therapy 7:5, 727-737
CrossRef1194
Nicholas J. Vogelzang, Cora N. Sternberg. (2007) Signal-transduction inhibitors in renal cell carcinoma. BJU International 99:5b, 1289-1295
CrossRef1195
Zhong Jiang. (2007) Prognostic biomarkers in renal cell carcinoma. Expert Review of Molecular Diagnostics 7:3, 293-307
CrossRef1196
Thomas Force, Daniela S. Krause, Richard A. Van Etten. (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer 7:5, 332-344
CrossRef1197
M. Kuczyk, S. Kruck, A.S. Merseburger. (2007) Wirksamkeit von Multikinaseinhibitoren in der Therapie des fortgeschrittenen Nierenzellkarzinoms. Der Urologe 46:5, 504-510
CrossRef1198
Manfred Johannsen, Olaf A. Brinkmann, Lothar Bergmann, Hans Heinzer, Thomas Steiner, Martin Ringsdorf, Andreas Römer, Jan Roigas. (2007) The Role of Cytokine Therapy in Metastatic Renal Cell Cancer. European Urology Supplements 6:10, 658-664
CrossRef1199
Jeffrey C Cilley, Keren Barfi, Al B Benson, Mary F Mulcahy. (2007) Bevacizumab in the treatment of colorectal cancer. Expert Opinion on Biological Therapy 7:5, 739-749
CrossRef1200
Andrew C. Novick. (2007) Kidney cancer: Past, present, and future. Urologic Oncology: Seminars and Original Investigations 25:3, 188-195
CrossRef1201
P Hinnen, F A L M Eskens. (2007) Vascular disrupting agents in clinical development. British Journal of Cancer 96:8, 1159-1165
CrossRef1202
(2007) Sunitinib and Hypothyroidism. New England Journal of Medicine 356:15, 1580-1581
Full Text1203
(2007) Sunitinib improves response and survival rates in metastatic RCC. Nature Clinical Practice Urology 4:4, 181-181
CrossRef1204
Christoph W. M. Reuter, Michael A. Morgan, Viktor Grünwald, Thomas R. W. Herrmann, Martin Burchardt, Arnold Ganser. (2007) Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. World Journal of Urology 25:1, 59-72
CrossRef1205
(2007) Trial watch. Nature Reviews Cancer 7:2, 74-74
CrossRef1206
Drazen, Jeffrey M., Zarin, Deborah A., . (2007) Salvation by Registration. New England Journal of Medicine 356:2, 184-185
Full Text1207
Brugarolas, James, . (2007) Renal-Cell Carcinoma — Molecular Pathways and Therapies. New England Journal of Medicine 356:2, 185-187
Full Text1208
Michael Froehner, Oliver W. Hakenberg, Manfred P. Wirth. (2007) Molecular Therapy in Urologic Oncology. Urologia Internationalis 79:1, 1-7
CrossRef1209
Sasja F. Mulder, Dick Johan van Spronsen, Pieter H.M. De Mulder. (2007) Do the Results of the New Trials Change the Standard Treatment of Metastatic Renal Cell Cancer?. Onkologie 30:5, 260-264
CrossRef1210
Viktor Grünwald, Hans Heinzer, Walter Fiedler. (2007) Managing Side Effects of Angiogenesis Inhibitors in Renal Cell Carcinoma. Onkologie 30:10, 519-524
CrossRef
- Letters
